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Abstract 
The endoplasmic reticulum (ER), within eukaryotic cells, is a hub for protein folding 
and assembly. Misfolded proteins and unassembled subunits of protein complexes 
are retained in the ER and degraded by a process termed endoplasmic reticulum 
associated degradation (ERAD). Frizzled class receptor 4 (FZD4) and muscle, 
skeletal, receptor tyrosine kinase (MuSK) are Wnt receptors. These proteins contain 
the frizzled cysteine-rich domain (Fz-CRD) required for dimerization in the ER. 
Mutations in FZD4 and MuSK genes are known to cause familial exudative 
vitreoretinopathy (FEVR, an autosomal dominant disease) and congenital 
myasthenic syndrome (CMS, an autosomal recessive disease), respectively. It was 
hypothesized that missense mutations within Fz-CRD lead to misfolding of FZD4 
and MuSK proteins and consequent ER-retention. Investigating the molecular 
mechanism of these mutations is important since misfolded protein and ER-targeted 
therapies are in development being developed. Wild-type and mutants of FZD4 and 
MuSK were expressed at 37 °C in HeLa, COS-7, and HEK293 cells and their 
subcellular localizations were investigated using confocal microscopy imaging and 
glycosidase treatments. Abnormal trafficking was demonstrated in 10 of 21 mutants 
studied; nine mutants were within Fz-CRD and one was distant from Fz-CRD. These 
ER-retained mutants were improperly N-glycosylated confirming ER-localization. 
They were tagged with polyubiquitin chains confirming targeting for proteasomal 
degradation. The half-lives of wild-type MuSK and P344R-MuSK were 45 and 37 
minutes, respectively; the latter half-life improved on incubation with proteasomal 
inhibitor MG132. The P344R-MuSK kinase mutant showed around 50% of its in vivo 
autophosphorylation activity. Trafficking defects in three of the 10 mutants (M105T-
FZD4, C204Y-FZD4, and P344R-MuSK) were rescued by expression at 27 °C and 
by chemical chaperones (2.5-7.5% glycerol, 0.1-1% dimethyl sulfoxide, 10 µM 
thapsigargin, or 1 µM curcumin). Trafficking of wild-type FZD4 was not affected by 
vii 
 
 
co-expression with any of the nine ER-retained mutants, suggesting 
haploinsufficiency as the mechanism of disease. Thus, all nine Fz-CRD mutants of 
FEVR and CMS studied resulted in misfolded proteins. In contrast, only one of the 
12 mutants outside Fz-CRD resulted in ER-retention. These findings demonstrate a 
common mechanism for diseases associated with Fz-CRD missense mutations. 
Disorders of Fz-CRD may be receptive to novel therapies that alleviate protein 
misfolding. 
Keywords: Familial exudative vitreoretinopathy; congenital myasthenic syndrome; 
endoplasmic reticulum associated degradation; frizzled class receptor 4; muscle, 
skeletal, receptor tyrosine kinase; frizzled cysteine-rich domain.  
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 cibarA ni tcartsbA dna eltiT
الآلية الخلوية والجزيئية للطفرات المغلطة المرتبطة بإعتلال الشبكية توضيح 
 )SMC( ) ومتلازمة الوهن العضلي الخلقيةRVEFالوراثي ( الزجاجي
 الملخص
محور لطي البروتين  في الخلايا حقيقية النواة )RE( muluciter cimsalpodneالشبكة الإندوبلازمية تعتبر 
تستقر في الشبكة  وكذلك الوحدات الجزئية غير المجمعة من مجمعات البروتين الخاطئ يالبروتينات ذات الطه. وتجميع
 خلال عملية تسمى التدهور المترابط في الشبكة الإندوبلازمية من  تتدهورو  )RE(الإندوبلازمية 
 )4DZF( البروتين المستقبل فريزلد  .)DARE( noitadarged detaicossa muluciter cimsalpodnE
). تحتوي هذه البروتينات على السستين tnWيعتبران من مستقبلات وينت (  )KSuM(والبروتين المستقبل مسك
الضروري لعمليات ربط جزيئات البروتينات  )DRC-zF( niamod hcir-enietsyc delzzirf
) هي KSuM( ) وجين مسك4DZF). الطفرات في جين فرزلد (RE) في الشبكة الإندوبلازمية (noitaziremid(
 cinehtsaym latinegnoc مرضلو  )RVEF( yhtaponiteroertiv evitaduxe lailimafمرضالمسببة ل
السستين  -على التوالي. لقد تم الإفتراض بأن الطفرات المغلطة في المجالات الغنية بفرزلد )SMC( emordnys
وإلى الإستبقاء في الشبكة  )KSuM) ومسك (4DZF) تؤدي إلى الطي الخاطئ في بروتينات فرزلد (DRC-zF(
والعلاجات المستهدفة للطي الخاطئ للبروتين و  ). البحث في الآلية الجزيئية لهذه الطفرات مهم كونREالإندوبلازمية (
) عند KSuM) و مسك (4DZFللشبكة الإندوبلازمية في تطور. تم إختبارالبروتين السليم والطفرات لكل من فرزلد (
) كما تم البحث في التمركز التحت خلوي 392KEHو  7- SOCو aLeHفي خلايا ( وسسلسي 73درجة حرارة 
 )ypocsorcim lacofnoc(التصوير المجهري متحد البؤر) لهما بواسطة noitazilacol ralullecbus(
). ظهرت عمليات نقل غير طبيعية في عشرة طفرات  من stnemtaert esadisocylg( غليكوزيداز علاجاتو
الإحدى والعشرين التي تمت دراستها، حيث  كانت تسع من هذة الطفرات  ضمن المجالات الغنية بفرزلد الطفرات 
) كانت غير صحيحة RE) وواحدة بعيدة عنها. هذة الطفرات المستقرة في الشبكة الإندوبلازمية (DRC-zFالسستين (
 الإندوبلازمية و كانت موسومة بسلسلة مما يؤكد تمركزها في الشبكة )detalysocylg-Nي (لغليكوزيلالإرتباط ا
 البروتيزوملي ) مما جعلها هدف للتدهور sniahc nitiuqibuylop( يوبيكويتينالبول
النوع المطفرن  و )KSuM( مسكالطبيعي  من لنوع لكانت أعمار النصف  .)noitadarged lamosaetorp(
عمر الأخير خلال فترة الحضانة بواسطة  ، وقد تحسن نصفدقيقة على التوالي 73و  54هي  )KSuM -R443P(
) KSuM-R443P). أظهرت الطفرة مسك (231GM rotibihni lamosaetorp( البروتيزوملياستخدام المانع 
لقد تم تصحيح عيوب ). noitalyrohpsohpotua oviv ni% من نشاط الفسفرة الآلي في الجسم الحي (05نحو 
) من KSuM-R443Pو 4DZF-Y402C و  4DZF-T501M(هي و من العشر طفراتثلاث عملية النقل  في 
 lacimehC( الكيميائية المواد واستخدام سلسيوس 72خلال زراعة الخلايا المختبرة عند درجة حرارة 
 %5.7-5.2(الكركمين  ميكرومتر الثابسيجارجن وو سلفوكسيد الثنائي ميثيل  الجلسرين و )senorepahc
). لم تتأثر عملية nimucruc Mµ 1 ,nigragispaht Mµ 01 ,edixoflus lyhtemid %1-1.0 ,lorecylg
) التسع عندما تم احتضانها بشكل ثنائي مع كل 4DZF) بأي من طفرات فرزلد (4DZFنقل البروتين السليم فرزلد (
إن كافة هي الآلية المسببة لهذا المرض. لذا ف )ycneiciffusniolpah(عدم كفاية الهابلو منها مما يدل على أن 
تنتج عن الطي الخاطئ   )SMC(ولمرض  )RVEF() والمسببة لمرض DRC -ZFالطفرات التسع الموجودة في (
) أدت الى DRC -ZFللبروتين. وعلى العكس من ذلك فإن واحدة فقط من الطفرات الإثنا عشر الموجودة خارج (
آلية مشتركة للأمراض المرتبطة بالطفرات  ). أظهرت هذه النتائج وجودREالإستقرار في الشبكة الإندوبلازمية (
) بإستخدام DRC -ZF) مما يدل على امكانية علاج الإظطرابات الموجودة في (DRC -ZFالمغلطة الموجودة في (
  علاجات جديدة وغير مسبوقة تخفف من الطي الخاطئ للبروتين.
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Chapter 1: Introduction 
1.1 Problem statement and motivation  
 Folding and processing of proteins destined for the secretory pathway takes 
place within the endoplasmic reticulum (ER) as a specialized series of events 
resulting in the expression of bona fide proteins. The primary amino acid sequence 
inherent in the polypeptide backbone and multiple post-translational modifications 
indicate the folding status of polypeptides in the ER [1-3]. The fidelity of protein 
folding and assembly is mediated by cellular proteins that are collectively referred to 
as molecular chaperones which function together as “quality control monitors” [4]. 
The chaperones are capable of distinguishing between native and non-native states 
of the polypeptide.  
 Glycoproteins incapable of reaching their native states, either due to a mutation 
or an error in the folding, trigger a signal to the glycoprotein quality control (GQC) 
system [5, 6] which utilizes protein N-glycosylation and N-glycan trimming [7] to 
dislocate nascent glycopolypeptide substrates from the ER via extremely complex 
ER-machinery. The mechanism of ER-misfolded protein recognition, targeting, 
retrotranslocation and cytosolic degradation by the ubiquitin-proteasome has been 
collectively termed endoplasmic reticulum-associated degradation (ERAD) [8-13]. 
 Over the past 30 years, the cellular pathogenesis of multiple genetic disorders 
caused by single amino acid substitutions (missense mutations) has been directly 
linked to altered protein folding and/or abnormal protein maturation [1, 8, 14, 15]. 
These ER-retained proteins are either susceptible to aggregation [16] or up-
regulation of the unfolded protein response (UPR) within the cell resulting in cell 
death [17] or elimination of the protein by ERAD.  
 ER-retained misfolded proteins caused by missense mutations are not well 
represented in extant literature. Bioinformatic tools have predicted that proteins, in 
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the human genome, with ER-targeting signals that enter the secretory pathway en 
route to their final destinations, are more than stated in the literature (45 versus 
30%) [18]. The extant literature appreciates that 85% of proteins harboring signal 
peptides come from known disease-associated genes and have been shown to be 
authentic ERAD substrates. Therefore, the pathological cellular and molecular 
mechanism of many human genetic diseases where ERAD is the cause of the loss-
of-function of the protein remains to be elucidated.  
 More importantly, little is known about inherited missense mutations located 
within the conserved frizzled cysteine-rich domain (Fz-CRD) of proteins. The  
Fz-CRD is a mobile evolutionary unit that has been found mainly in Wnt (wingless-
type mouse mammary tumor virus integration site family) receptors. Fz-CRD 
families are named so because they possess 10 conserved cysteine motifs. Fz-CRD 
attains a correct fold in the ER alongside homo-and/or hetero-dimerization [19-23]. 
The major cell surface receptors for Wnts are the seven-transmembrane frizzled 
proteins [24], certain receptor tyrosine kinases such as muscle, skeletal, receptor 
tyrosine kinase (MuSK) [19, 21] and receptor tyrosine kinase-like orphan receptor 2 
(ROR2) [25]. Missense mutations in frizzled class receptor 4 (FZD4) and MuSK 
genes are known to cause familial exudative vitreoretinopathy (FEVR, an autosomal 
dominant disease) and congenital myasthenic syndrome (CMS, an autosomal 
recessive disease), respectively. It was hypothesized that missense mutations within 
Fz-CRD lead to misfolding of FZD4 and MuSK and their retention in the ER. They 
would consequently be degraded by ERAD leading to loss-of-function at the cell 
surface.  
 Cystic fibrosis (CF) is a well-known hereditary disorder that affects 1 in 2500-
4000 newborns [26] of Caucasian descent. Patients mainly suffer from thick mucous 
secretions in both the lung and the intestine which leads to repeated lung infections. 
Fifty years ago, the life expectancy of CF patients was about six months but they 
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can now live up to 37 years [27]. Correction of the molecular defect offers the 
maximum potential for improving CF patients’ quality of life and life expectancy [27]. 
Observations were made that the deletion of phenylalanine at position 508 (ΔF508) 
in the cystic fibrosis conductance regulator protein (CFTR) causing CF appears to 
reach the native state, move out of the ER to the plasma membrane and function as 
a cyclic adenosine monophosphate (cAMP)-stimulated chloride channel [28, 29].  
 Therefore, knowledge of the cellular and molecular mechanisms underpinning a 
disease is vital and serves to facilitate understanding of both the pathology of the 
disease and the selection and development of appropriate therapeutic targets. 
Lower-temperature incubation has been shown to slow down cellular processes 
assisting folding. These temperature-sensitive misfolded proteins are salvageable 
and can be further manipulated using chemical compounds referred to as chemical 
chaperones. Chemical chaperones work in different ways to assist the folding, 
stabilization and/or exit of mutant proteins out of the ER [28, 30-32]. Some misfolded 
proteins targeted by the ERAD machinery have been shown to be biologically 
functional if allowed to exit from the ER and pass further on in the secretory pathway 
to their final destinations [33-35].  
 This raised the possibility that strategies that influence the protein folding 
environment inside cells might prove to have therapeutic value [8, 29, 31]. 
Manipulation by silencing of the messenger RNA (mRNA), siRNA of prominent 
ERAD machinery components responsible for the ubiquitination or handling of the 
misfolded protein before it is dislodged out of the ER and transferred to the 
proteasome system, could also correct and rescue the misfolded protein. This has 
encouraged researchers to manipulate the ER folding and GQC machinery in ways 
that offer novel therapeutic approaches in some diseased states.  
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1.2 Objectives  
 Some disease-causing missense mutations in selected Wnt genes namely: FZD4 
and MUSK were potential candidates for retention in the ER and handling by ERAD. 
Another gene, TEK tyrosine kinase endothelial (TEK), was also a potential 
candidate. These candidates can be examined by analyzing the effect of the 
mutations on the protein structure using bioinformatics tools and evaluated 
experimentally using cell line model systems. These proteins are functionally diverse 
and each possesses a unique tertiary structure with different interacting partners.  
The specific objectives that I set out to seek in my dissertation research are 
highlighted below: 
Firstly, to characterize the cellular, biochemical and molecular mechanisms 
underlying disease-causing mutations in the following genes: 
1. Muscle, Skeletal, Receptor Tyrosine Kinase (MuSK) gene causing 
Congenital Myasthenic Syndrome (CMS) 
2. Frizzled Class Receptor 4 (FZD4) gene causing Familial Exudative 
Vitreoretinopathy (FEVR) 
3. TEK Tyrosine Kinase, Endothelial (TEK) gene causing Multiple Cutaneous 
and Mucosal Venous Malformations  (VMCM) 
Secondly, to evaluate the effects of manipulating the ER cellular environment to 
assist correct folding of ER-retained mutant proteins. The effect of varying culturing 
temperatures and incubation with different chemical chaperones on the selected 
mutants was evaluated by confocal microscopy and protein expression studies. 
Changes in the trafficking, judged by confocal imaging, deglycosylation assays and 
cell-surface protein biotinylation, were evaluated by immunofluorescence, 
immunoprecipitation and western blotting [18].  
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Initially, transient transfection allowed for screening of a larger number of 
mutants. These preliminary results showed which mutants were thermosensitive, 
hence, can be manipulated to traffic normally to the cell surface. Chemical 
chaperones reported in the literature and found to affect the folding of ∆F508-CFTR 
and other ER-retained proteins were evaluated.  
Thirdly, to generate stably transfected cell lines of a model ERAD substrate. The 
aim was to generate stably expressing cells for a thermosenstive mutant, its wild-
type and an empty vector. A kill curve was generated to determine the lowest 
concentration of antibiotic necessary to maintain the stable cell lines. Stable cell 
lines allowed for more consistent reproducible results and therefore were also used 
to look at N-glycosylation profiles, chemical chaperone treatment and siRNA 
knockdown treatment.  
Finally, to assess the knockdown of some ERAD machinery components using 
siRNA. RNAi and siRNA technologies have emerged in recent years to be the 
methods of choice for downregulation/knock out of specific genes expressed in 
cultured cells, tissues and even whole animals [36]. This project aimed to 
downregulate a set of proteins involved in the degradation of ERAD substrates. 
Based on work carried out in this area, prominent ERAD machinery components 
were chosen for siRNA knockdown.  
1.3 Dissertation structure 
This dissertation is divided into five chapters. Chapter 2 contains the background 
biology and literature about the GQC system and ERAD as a disease causing 
mechanism for numerous human diseases. It also contains research that is being 
adapted to help misfolded proteins exit from the ER mimicking the chemical 
chaperones in this regard, as well as offering misfolded protein and ER-targeted 
therapy. Silencing has emerged as a useful tool to observe the knockout effect of 
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ERAD machinery components and their effect on proteins. A brief description shows 
how silencing can be used as a target to promote the rescue of misfolded proteins.  
Chapter 3 outlines the materials and research methods used in the dissertation. 
Chapter 4 presents and discusses the results and provides the bulk of the 
dissertation. A brief literature background on the genes and/or proteins utilized in 
this research. More importantly each section includes the results obtained together 
with brief discussion. Designing and making the mutant and wild-type constructs, 
expression of these constructs within mammalian cell lines and observing their 
effects in vitro allowed the mechanisms of disease to be elucidated. Further work 
such as chemical chaperone treatment carried out in vitro and observing the effects 
provide the groundwork for potential therapeutic interventions.  
Chapter 4, section 4.1 focuses on FZD4, the gene and protein that effects many 
missense mutations scattered throughout the protein studied. The subcellular 
localization of mutants within mammalian cell lines and FZD4’s pathological cellular 
and molecular mechanism in FEVR will be explained. Chapter 4, section 4.2 
discusses MuSK, the gene and protein will also be discussed. The localization of six 
reported missense mutations will be observed. One vital disease causing mutation, 
found within the Fz-CRD, will be studied in detail with biochemical and functional in 
vitro analysis showing the involvement of ubiquitin/proteasome in loss-of-function of 
the misfolded protein as the cause for CMS. Chapter 4, section 4.3 will briefly 
discuss TEK; the gene and protein. The results exclude TEK disease-causing 
inherited mutations from being ERAD substrates. Chapter 4; section 4.4 will discuss 
the effects of silencing the ERAD machinery components on stable cell lines 
expressing a selected ERAD substrate. Silencing of ERAD machinery components 
in vitro is to observe any rescue effect on the misfolded protein. Chapter 5 will briefly 
summarize the findings, provide a general disussion, highlight the conclusions, 
outlook and perspectives for future directions.  
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Chapter ‎2: Literature Review 
2.1 The ER as a hub for protein folding  
2.1.1 History of the endoplasmic reticulum and disease 
 Thymus lymphocyte (T-cell) receptor was seen to be rapidly degraded in cells 
independent of lysosomal proteases. This observation by Lippincott-Schwartz in 
1988 led to the proposal that the ER organelle had some uncharacterized proteolytic 
activity towards misfolded proteins. In yeast Saccharomyces cerevisiae  
(S. cerevisiae), a component of the ubiquitin conjugation machinery [37] further 
confirmed this observation when a short-lived misfolded ER membrane protein’s 
degradation was blocked in Ubc6 deficient yeast cells. Ubc6, a component of the 
ubiquitin conjugation machinery [37] is involved in the covalent attachment of the 76 
amino acid ubiquitin (Ub) protein acting as a degradation signal and targeting them 
to ubiquitin activating (E1), ubiquitin conjugating (E2) and ubiquitin ligase (E3) 
enzymes [38]. These ubiquitin tagged proteins are then targeted for proteasomal 
degradation [39].  
 The ubiquitin-proteasome systems’ involvement in CFTR degradation was shown 
when proteasome inhibition resulted in the accumulated polyubiquitinated CFTR [40, 
41]. In addition, luminal misfolded proteins such as carboxypeptidase Y (CPY*) 
yeast mutants [39] defective in the breakdown of a mutated soluble vacuolar protein, 
[38, 39] were also studied as a prototype ERAD substrate. Collectively, these 
studies resulted in the understanding that aberrant misfolded proteins were 
disposed of by an ubiquitin-proteasome system in the cytosol.  
2.1.2 ERAD regulates and maintains homeostasis of the cell  
 ERAD has been shown to be involved in the regulation of metabolic pathways in 
the presence of a specific signal. The key enzyme in sterol biosynthesis, 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase, was found to be tightly 
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regulated through ERAD degradation when the level of cholesterol in the cell is 
adequate i.e. intracellular cholesterol homeostasis, thereby preventing 
atherosclerosis [42]. Yet another enzyme of the sterol biosynthetic pathway, 
squalene monooxygenase (SQLE), also an ERAD substrate, orchestrated through a 
feedback inhibition system to prevent the accumulation of toxic intermediate sterol 
metabolites [43]. Synthesis of sterols and other sterol-derived metabolites is 
regulated by ERAD in mammals, yeasts and plants [44] indicating a role for the 
evolutionary conservation of this mechanism.  
 Viral and bacterial toxins such as the human cytomegalovirus and cholera toxin, 
hijack the ERAD machinery to degrade host defense proteins such as the major 
immunohistocompatibility complex class I (MHC I) or CD4 complexes and, as a 
result, they escape surveillance mechanisms and consequently gain access to the 
cell [45]. Several soluble and cytoplasmic proteins have also been subjected to 
protein turnover by ERAD machinery [43]. 
Subsequent genetic and biochemical studies in both mammalian cells and 
budding yeast identified many ERAD components and the organization of the ERAD 
machinery. Taxis et. al., [46] identified distinct specificity for different classes of 
misfolded proteins and the differentiated substrate approach taken by ERAD 
machinery leading to multiple branches of this pathway [47].  
2.1.3 Protein translocation and folding in the endoplasmic 
reticulum 
 The ER is an essential cellular organelle which maintains lipid biosynthesis, 
redox and calcium homeostasis and more importantly protein folding and secretion. 
Approximately one third of all open reading frames code for proteins which enter the 
ER [48]. The folding of proteins is very complex yet intriguing and is discussed in the 
next few sections. 
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 Nascent secretory pathway targeted polypeptides translated on ribosomes in the 
cytoplasm are co-translationally translocated into the ER lumen via a translocon [49] 
(Figure ‎2.1.1). When the polypeptide sequence emerges from the ribosome exit 
tunnel, an N-terminal hydrophobic signal peptide (SP) sequence of 20-30 amino 
acids exposes itself to the cytoplasm. This SP targets the polypeptide to the ER for 
further processing and the nature of the SP is vital for further processing of the 
polypeptide [50]. 
 Polypeptides destined to the ER harboring this signal peptide are recognized and 
captured by a ribonucleoprotein complex, the signal recognition particle (SRP) [51] 
using guanosine-5'-triphosphate (GTP) as energy. This complex of translating 
ribosomes and SRP causes translational arrest, and concomitantly targets the 
complex to a translocon channel via SRP receptor located on the cytosolic face of 
the ER. Binding of the complex to the SRP receptor stimulates GTP hydrolysis and 
the release of SRP, allowing translation to resume and the polypeptide to enter the 
ER lumen [48].  
 Protein folding always starts during translation [52], but the vast majority of 
folding takes place when the polypeptides enter the ER lumen where the signal 
peptide is cleaved by a signal sequence peptidase complex. Timing of signal 
peptide cleavage is not the same for different proteins. For example, tyrosinase’s SP 
is cleaved when the polypeptide chain reaches ~ 120 aminoacids [53] and the 
human immunodeficiency virus (HIV) envelope glycoprotein has its SP cleaved post-
translationally after initial folding has started [54]. Inefficient cleavage also results in 
proteins with different features from a single transcript. When the ER protein, ER 
degradation-enhancing alpha-mannosidases-like protein 1 (EDEM1) undergoes an 
inefficient SP cleavage, a soluble EDEM1 is formed. When the SP is not cleaved, a 
type II membrane ER anchored protein is formed. Inherited mutations in the insulin 
10 
 
SP result in ER-localization and as a consequence, early-onset diabetes in patients 
[55].  
 Therefore, the SP targets the polypeptide, influences folding and the features of a 
protein, further modifications and localization. Other major post-translational ER 
modifications include N-linked glycosylation, O-glycosylation, disulfide-bond 
formation and glycosylphosphatidylinositol (GPI)-anchoring [56, 57]. Both covalent 
linked N-glycosylation and disulfide-bond formation play crucial roles in the folding of 
numerous secretory and membrane proteins. In addition, assembly of multi-subunit 
complexes takes place within the ER. 
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Figure ‎2.1.1. Polypeptides enter the endoplasmic reticulum en route through the 
secretory pathway. Appearance of the signal sequence found on a nascent 
polypeptide (shown in orange) prompts the signal recognition particle (SRP) 
portrayed as a red oval. Binding of SRP to the signal sequence initiates two 
signals. First it slows down translation of the mRNA found within the ribosome and 
second it binds the signal sequence to the dimeric SRP co-receptor and in doing 
so, escorts the nascent polypeptide to the ER membrane. The SRP is then 
released for recycling and translation ensues and a nascent soluble polypeptide 
enters the ER lumen via a translocon. An integral membrane protein is 
incorporated into the membrane also by the translocon complex. Once settled, the 
soluble proteins and some membrane proteins have their signal sequences 
cleaved by the ER localized signal peptidase complex portrayed as a blue 
snipping tool. Redrawn from reference [8]. 
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2.1.4 The ER lumen 
 Protein folding is dependent on the internal chemical environment of the ER 
lumen. Folding chaperones are the gatekeepers for protein folding and quality 
control [58, 59]. The ER lumen is relatively oxidative in nature and contains 
millimolar calcium (Ca2+) concentrations and lipophilic content compared to the 
cytoplasm and plasma membrane, respectively [60]. This calcium content is 
required for cellular signaling and as a cofactor for chaperone function. Folding 
chaperones residing in the ER lumen are numerous reaching up to 0.1-1.0 mM 
concentrations.  
 Proteins destined for secretion or insertion into the membrane enter the ER in an 
unfolded form and generally leave only after they have reached their native folded 
states. Protein concentration can reach up to >100 mg/ml in the ER lumen [2] and 
as a result, folding in the ER is often slow and inefficient, with a substantial fraction 
of polypeptides failing to reach their native states as the protein concentration has 
been seen to reach 300-400 g/L [61]. Quality control occurs at every stage of protein 
biosynthesis in the ER. These include co-translational translocation, post-
translational modification, chaperone-assisted folding, assembly of multi-subunit 
complexes, trafficking and export. Protein folding rates are altered for different 
proteins ranging from a few minutes to hours. Some proteins fold quickly however, 
linger inside the ER lumen before moving on through the secretory pathway [2].  
 Within the ER, the folding cascade of the polypeptide is challenged and 
dependent on the kinetic and thermodynamic stability of polypeptides in the 
oxidizing and relatively calcium rich environment of the ER. However, it is the rich 
ER lumen milieu, alongside chaperones, that assist the newly synthesized proteins 
to form disulfide bonds and fold into their native three-dimensional structure based 
on the primary structure inherent in their amino acid sequence. These nascent 
polypeptides fold and assemble into proteins and undergo modification within the 
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ER lumen and are then targeted for expression at the plasma membrane, directed to 
intracellular organelles or destined for secretion. 
 The cell must continuously assess the pool of folding proteins and remove 
polypeptides that are terminally misfolded. This process of culling is critical to 
protect the cell from the toxic effects of misfolded proteins. As a consequence, 
misfolded proteins and orphaned subunits of protein complexes are targeted for 
degradation [7]. 
2.1.5 Folding chaperones 
 ER-folding chaperones form networks and complexes that collaborate and 
propagate folding. Chaperones residing in the ER lumen include but are not limited 
to protein disulfide isomerase (PDI) enzymes, heat shock protein like HSP70 
(HSPA5/BiP), heat shock protein like HSP90, HSP70/HSP110 and the lectin 
chaperones, calnexin (CXN) and calreticulin (CRTN), UDP-Glc:glycoprotein 
glucosyltransferase 1 (UGGT1) and the peptidyl prolyl isomerases (PPIs) such as 
cyclophilin B (CypB) [2, 8].  
 These chaperones exist in complexes in the ER-lumen when assisting the folding 
of proteins. For example, the thyroglobulin protein complexes with the HSPA5/BiP, 
heat shock protein 90kDa beta (Grp94), member 1 (HSP90B1), hypoxia up-
regulated 1 (HYOU1/Grp 170) and the PDIs and protein disulfide isomerase family 
A, member 4 (PDIA4/ERp72) forms a mutimeric complex in the ER lumen [62]. 
Characteristics of the folding protein determine which chaperone complex is 
recruited to the nascent chains. For example immunoglobulins bind to HSPA5/BiP 
then CNX or CRT [2].  
 Chaperones promote efficient folding by supporting polypeptide native folding. 
Chaperones prevent the aggregation of exposed hydrophobic residues. They survey 
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the ER-lumen for immature, abberant or aggregation-prone proteins and promote 
their disposal to maintain proteostasis.  
2.1.6 Post-translational modification in the ER 
 Glycosylation of asparagine (Asn) residues is an essential protein modification 
reaction that occurs in 90% of proteins that enter the secretory pathway in 
eukaryotic cells [63]. A core unit of 14 saccharides (Glu(3)Man(9)GlcNAc(2)) 
(Figure ‎2.1.2) is synthesized as a dolichol pyrophosphate precursor by enzymes 
located in the ER membrane. Asparagine-linked N-glycans are transferred en bloc 
onto polypeptides in the lumen of the rough endoplasmic reticulum (RER) by the 
oligosaccharyltransferase (OST), found close to or on the translocon complex, using 
a dolichol pyrophosphate-linked oligosaccharide (OS-PP-Dol) as the donor 
substrate [64]. This addition occurs when the polypeptide is ~ 13 amino acids into 
the ER lumen and the Asn residue aligns correctly with OST [50]. OST’s subunit 
Ost3/6p has been found to contain an active thioredoxin-like domain possessing 
oxidoreductase activity. Oxidation of substrate proteins has been shown to 
negatively impact glycosylation efficiency [65], therefore covalent tethering of 
nascent chains to the Ost3/6p subunit can impact glycosylation transfer efficiency in 
polypeptides [64, 66].  
2.1.7 N-glycosylation 
 N-glycosylation is unique to the ER and marks the initiation of protein folding of 
glycoproteins. Congenital disorders of glycosylation represent a large number of 
diseases resulting from improper N-glycosylation [67]. This type of glycosylation 
involves the en bloc transfer of a glycan complex Glu(3)Man(9)GlcNAc(2) from the 
lipid-linked sugar donor Glu(3)Man(9)GlcNAc(2)-diphosphate dolichol by the OST 
complex to selected asparagines at canonical consensus tripeptide sequon motifs of 
Asn-Xxx-Ser/Thr or more rarely Asn-Xxx-Cys, Asn-Xxx-Val, or Asn-Gly sequons 
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within the sequence of the polypeptide (where X can be any amino acid except 
proline) [68-70].  
 
Figure ‎2.1.2. The composition of N- glycans attached to a tripeptide sequon motif. 
The 14-member carbohydrate is covalently linked to Asn residues of the 
consensus sequence Asn-Xxx-Ser/Thr as shown above. The glycan is comprised 
of three branches depicted as A, B and C corresponding to the 3 mannose 
branches. 3 glucoses (G) (green circles), 9 mannoses (M) (blue triangles), and 2 
N-acteylglucosamines (GlcNAc) (red squares). Saccharide units are labeled a-n. 
The orientation of the glycosidic linkages is shown as either α or β with the 
corresponding numbers each G, M or GlcNAc. The sites of cleavages of 
glucosidase I and II are indicated by arrows, the mannose K recognized by the 
glucosidase II mannose 6-phosphate receptor homology (MRH) domain is 
highlighted in light green and the region important for folding kinetics of the protein 
is indicated in shaded grey. N-glycans are crucial to the stability and conformation 
of proteins. Redrawn from reference [71].  
 Glycans are hydrophilic modifications added to the folding peptide, to protect and 
stabilize the unstructured polypeptides from hydrophobic aggregations [72] and 
increase their solubility and interaction with chaperones. N-glycans enhance the 
kinetics and thermodynamics of folding (Figure ‎2.1.2; highlighted in shaded grey). 
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This was seen with the human immune cell receptor cluster of differentiation 2 
(hCD2ad) folding energetics. It was observed that the first saccharide accounted for 
a 2/3 accelerated folding and stabilization of the polypeptide. The next two 
saccharides further potentiated and completed the stabilization effect. The core 
(ManGlcNAc(2) was shown to have intrinsic benefits to folding energetics [73].  
 Little is known about how chaperones in the ER are organized into complexes to 
assist in the proper folding of secreted proteins. However, it was established that 
glycans act as substrates for the lectin chaperones CNX and CRT [57, 74], which 
are part of the ER folding and quality control machinery.  
2.1.8 Trimming of the N-glycan 
 The A-branch or glucose-containing arm of N-linked glycans (Figure ‎2.1.2) 
recruits molecular chaperones that assist in the efficient folding of glycoproteins [72, 
75]. The terminal glucose residue (n) of the transferred triglucosylated glycan is 
rapidly removed by α-glucosidase I (GI), which is associated with the translocon 
complex. Malectin, a Glc2-binding protein, might then intervene to retain immature 
and/or misfolded polypeptides in the ER [76]. Trimming of the final glucose (m) by 
the α-glucosidase II (GII), a luminal heterodimeric enzyme, supports co- or post-
translational association of folding polypeptides with the ER lectins CNX and CRT. 
GII contains an MRH domain which requires the presence of mannose residue k on 
branch c. The MRH domain makes GII a key regulator of the QC mechanism of 
glycoprotein folding. It has been shown that a decrease in N-glycan mannose 
content results in lower GII enzymatic activity [77]. 
2.1.9 The calnexin cycle 
 Glycoprotein association with CNX or CRT marks the beginning of the ‘calnexin 
cycle’ [78]. CNX is a membrane-anchored protein and CRT is a luminal homolog 
(Figure ‎2.1.3). Both proteins consist of: (1) a globular domain that harbors both the 
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oligosaccharide- and calcium-binding sites; and (2) an elongated arm, also known 
as the P domain because of its proline-rich sequence motifs [79, 80]. The 
oligosaccharide-binding site in the globular domain of CRT has been well 
established [81]; yet, how polypeptides bind CNX and CRT is less clear. CNX and 
CRT are structurally similar with different preferences to substrates [82]. CRT forms 
complexes with HSPA5/BiP and Grp94 and the former two are close to the 
translocon pore on the luminal side of the ER [83].  
 Recent structural studies have identified possible peptide-binding sites in both 
the lectin and arm domains of CRT [84]. The P domain binds to a luminal thiol-
disulfide oxidoreductase, ERp57, an accessory protein (Figure ‎2.1.3) [85] and a PPI, 
CypB [86]. Together, CNX or CRT (CNX/CRT), protein disulfide isomerase family A, 
member 3 (ERp57) and CypB assist the nascent glycoproteins in achieving a native 
conformation with the correct disulfide bonds. Affiliated with PPIase CypB, CNX and 
CRT have been shown to promote proline isomerization [86]. The duo also retain 
misassembled or non-native protein conformations to allow more time for proper 
folding and prevent aggregation and turnover of non-native proteins allowing for 
proteostasis within the ER [50].  
 The ER enzymes, GI and GII, remove the two terminal glucose residues of the 
glycan moiety from the nascent polypeptides forming (Glu(1)Man(9)GlcNAc(2) 
(Figure ‎2.1.3). Then the lectin chaperones, membrane bound-CNX and its lumen 
soluble homolog CRT [72], both in complex with the glycan directed oxidoreductase 
PDIA3/ERp57, modulate enzymatic change to form disulfide bonds within the 
monoglucosylated glycan client (Glu(1)Man(9)GlcNAc(2). Interestingly, these lectin 
proteins slow down folding to allow more efficient folding to take place.  
  
18 
 
 
 
Figure ‎2.1.3. The glycoprotein folding cycle within the endoplasmic reticulum 
lumen. As the polypeptide enters the ER, an en bloc transfer of the core 
oligosaccharide (Glc(3)Man(9)GlcNAc(2)) where glucose is represented as green 
and mannose as red circles and N-acetylglucosamine is Y-shaped attached to the 
nascent polypeptide chain. Glucosidases I and II remove two of the three glucoses 
generating a monoglucosylated glycoprotein. This monoglucosylated protein is a 
signal for interacting with CNX and CRT, both lectins bound to thiol-disulphide 
oxidoreductase (ERp57). For simplicity and representation purposes; CRT is 
shown. CRT is the soluble form of CNX and they form interchain disulfide bonds 
(S-S) with the bound glycoproteins. Removal of the final glucose by glucosidase II 
allows the glycoprotein to be released from the chaperones and leave the ER 
through ER exit sites to the Golgi Apparatus. In the event that the protein has not 
been processed correctly, UDP-glucose-glucosyltransferase re-adds a single 
glucose on to the glycan and the cycle of protein folding is repeated. If the 
glycoprotein is permanently misfolded, the terminal mannose α1–2Man from the 
central arm of Man(9)GlcNAc(2), shown as a red circle, from the b branch of the 
oligosaccharide is removed by α-1,2-mannosidase I yielding a Man(8)GlcNAc(2) b-
isomer. A second ER resident α-mannosidase I–like protein which lacks enzyme 
activity known as ER degradation-enhancing α-mannosidase I–like protein 
(EDEM), recognizes misfolded glycoproteins and targets them for ERAD. Redrawn 
from reference [56]. 
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2.1.10 HSPA5/BiP chaperone 
 Being true chaperones to their polypeptides, the first ER-resident molecular 
chaperone (HSPA5/BiP), interacts with the hydrophobic stretches on the polypeptide 
with its substrate-binding pocket (SBP). HSPA5/BiP is the most abundant of ER 
chaperones. HSPA5/BiP is a peptide-dependent adenosine triphosphatase 
(ATPase) that can either increase or decrease the folding rate of protein ligands 
[87]. It binds with low ATPase activity and affinity. HSPA5/BiP has co-chaperone 
partners that regulate binding of the glycoprotein substrate to HSPA5/BiP. These 
regulatory proteins such as DnaJ (Hsp40) homolog, subfamily C, member 1-7 
(DNAJC/ERdj1-7) proteins which harbor thioredoxin domains [7], and the guanine 
nucleotide exchange factor BiP associated protein (BAP) [87] and glucose-regulated 
protein (GRP) GRP170 alongside HSP90-like chaperones (GRP94), stimulate ATP 
hydrolysis on BiP [10]. The resultant ADP-BiP binds to the polypeptide with high 
affinity resulting in a tight BiP-substrate complex that is locked into the SBP [8]. This 
allows BiP to hold the substrate while it interacts with other chaperones such as the 
protein disulfide isomerases and attains its native conformation. This ATP binding 
and hydrolysis regulates cyclic binding to glycoproteins thereby assisting their 
protein folding. 
2.1.11 Protein disulfide isomerase enzymes 
 Oxidized glutathione (GSSG) enters the ER from the cytosol and generates 
oxidizing and buffering conditions pertaining to the ER environment [88]. Proteins 
depend on their disulfide bonds for their stability, maturation and function. Disulfide-
linked folding has been reported to be slow due to its dependence on a redox 
reaction in the ER. Mispairing of cysteine residues can be detrimental by preventing 
proteins from attaining their native conformations consequently leading to misfolding 
[88].  
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 PDIs are enzymes which contain cysteines (CXXC) motifs and thioredoxin-like 
domains [89, 90]. PDIs are oxidoreducatase enzymes which have the J-domain and 
multiple thioredoxin domains necessary for disulfide exchanges. ERdj5 has been 
shown to be involved in reducing disulfide bonds for proteins destined for ERAD and 
in certain proteins it is needed for efficient folding of a protein [90]. These motifs and 
domains utilize paired cysteine residues to reduce (donate electrons) and oxidize 
free thiols (accept electrons) on cysteine residues of the proteins forming disulfide 
bridges. PDI protein can rearrange incorrect disulfides as well by breaking 
incorrectly formed disulfide bonds and remaking them [3, 8, 88]. The oxidative 
potential of the ER is largely generated by ER oxidase 1 (Ero1) to regulate the 
balance of oxidized and reduced PDIs by transfer of electrons to oxygen [1, 91, 92].  
 A novel oxidoreductase, ERp44 has been shown to act specifically on plasma 
cell protein folding such as the IgM J-chain, heavy chain and light chain proteins 
[93]. Substrate specificity and cell-type specificity of these oxidoreductases remains 
to be determined. ERp57 interacts with CNX and CRT and PDIs have a b’domain 
containing an inactive thioredoxin fold able to bind hydrophobic stretches of a 
polypeptide in complex with CRT and CNX [50, 94]. In this regard, PDIs are 
considered to possess both chaperone-like qualities and an oxidoreductase activity. 
Correct disulfide bond formation is crucial for proper folding and provides stability for 
the protein in the extracellular environment and proteins are then allowed to proceed 
along the ER-to-Golgi anterograde trafficking pathway. 
2.1.12 Peptidyl prolyl isomerases 
 Another set of ER catalyst enzymes, PPIs rotate the peptide [95], which is 
immobilized by the interaction of proline side chains within the peptide backbone. 
PDI’s and PPIs have been shown to catalyze proline cis-trans isomerization [50], the 
latter being a very important feature for proper and correct folding of polypeptides. 
Proline residues are found in trans conformations as the enter the ER-lumen. Trans-
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prolines are then converted to cis-prolines in the native protein. This is a rate-limiting 
step in protein folding and slows down folding [50, 96]. This substrate-chaperone 
interaction guides folding of the polypeptides within the ER. To terminate the folding 
process, GII can remove the remaining glucose residue and abolish the binding site 
for CNX and CRT to the glycoprotein. This prevents rebinding of the glycoprotein to 
the CNX/CRT-ERp57 complex [97].  
2.1.13 Glucosyltransferase  
 In the event that a polypeptide has been incompletely folded, the ER enzyme 
UGGT1 recognizes structured, hydrophobic patches in folding intermediates and re-
glucosylates the Man(7-9)GlcNAc(2) to restore the binding site for CXN and CRT to 
re-guide folding again (Figure ‎2.1.3). UGGT1 is a folding sensor and to re-
glucosylate, it has been shown that the glycoprotein substrates must have at a 
minimum the innermost GlcNAc residue of the N-glycan and hydrophobic amino 
acids exposed in denatured conformations. More disordered conformations, i.e. 
those exposing more hydrophobic amino acids, were found to have a higher glucose 
acceptor capacity [98].  
 UGGT1 has been found to reglucosylate N-glycans only on the misfolded half 
[99], suggesting that the N-glycans must be near the misfolded region of the 
substrate. UGGT1 has also been reported to reglucosylate N-glycans that were 
more distant (40 Å) from local hydrophobic regions [100]. Despite these substrate-
specific differences, it seems that UGGT1 can survey glycoprotein substrates for 
misfolded regions and reglucosylate attached N-glycans when appropriate. UGGT1 
was able to sense an unfolded dimer within a heterodimer of the ribonuclease, 
RNase B (RNAse B) and specifically reglucosylates it [99]. Reglucosylation 
mediated by UGGT1 can promote association with CNX/CRT-ERp57 and the thiol-
disulfide isomerase activity of ERp57 can promote proper disulfide bond formation 
[101]. 
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 It has been shown recently that proteins that linger in the ER undergo O-
mannosylation in yeast [102]. O-mannosylation involves the addition of a mannose 
residue to an oxygen atom on serine or threonine amino acids. This in turn acts as a 
cell timer to prevent further unproductive folding cycles for a non-glycosylated 
protein and targets it for ERAD. Two key players contribute to yeast O-
mannosylation; protein O-mannosyltransferases 1 and 2 (Pmt1 and Pmt 2). The 
importance of this finding is that this modification to the non-glycosylated protein 
renders it soluble for ER exit through the translocon. It has been proposed that it 
stimulates unfolding of the protein [103] and it may be the first step in the elimination 
process of misfolded or unassembled proteins. 
2.1.14 The mannosidases 
 Unfortunately, this cyclic quality control can be disrupted by the prolonged 
retention of the glycoprotein in the ER lumen so that the removal of mannose 
residues from the b and c branches of Man(9)GlcNAc(2) by ER mannosidases I and 
II form Man(7-8)GlcNAc(2), is not recognized by GII and UGGT1, hence this 
glycoprotein has a different fate. ER lectins of the ER degradation-enhancing alpha-
mannosidases-like protein (EDEM) family (EDEM1-3) also act as mannosidases and 
recognize the mannose trimmed N-glycans that have an energetically unstable 
conformation. Unfortunately, these partially folded proteins are targeted for ERAD. 
Interestingly, studies have shown that proteins that are kinetically stable and 
thermostable in the ER, but do not conform to a proper conformation, can still 
progress to the secretory pathway [57, 104].  
2.1.15 Glycoprotein export out of the ER 
 Following this close scrutiny, bona fide synthesized proteins may exit the ER to 
set off for their final destinations within the cell, or are secreted into the extracellular 
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environment [12, 13, 105]. Two different mechanisms have been proposed (1) bulk-
flow and (2) receptor-mediated transport [106].  
 Glycoproteins are sent to the Golgi complex where they are demannosylated by 
one or more of the resident mannosidases: alpha-mannosidases I and II (Golgi Man 
I-(A, B, C)) and (Golgi Man II) [107]. These Golgi mannosidases can remove 
mannoses from glycopeptides with a range of attachments to the N-glycans:  
Glc(0-3)Man(8-9)GlcNAc(2), allowing for their processing. Natively folded, 
demannosylated substrates are glycosylated and transported to their final 
destination. Like the ER, the Golgi complex may also make conformation-based 
sorting decisions leading to disposal of selected proteins. Misfolded glycoproteins 
scrutinized by Golgi complex quality-control systems are either sent back to the ER 
to be degraded by the proteasome or more often re-directed to lysosomes for 
degradation [108]. 
 The proteins that assume a stable conformation are recognized and sorted into 
secretory vesicles by the cytosolic coat protein complex II (COPII). The formation of 
the COPII coat on ER membranes drives vesicle budding [109]. This occurs due to 
sequential binding of at least five soluble components, including the small GTPase 
Sar1p and two cytosolic heterodimeric protein complexes, Sec23/24 homolog (S. 
cerevisiae) (Sec23/Sec24) and Sec13/31 homolog (S. cerevisiae) Sec13/Sec31. 
Budding from the ER involves activation of the SAR1 homolog A (S. cerevisiae) 
pseudogene 1 (SAR1AP1/Sar1) GTPase by the ER-resident protein Sec12, a Sar1-
specific guanine nucleotide exchange factor (GEF).   
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 The binding of Sec23 to GTP bound Sar1 recruits Sec23/24 to the membrane 
and these constitute the inner-layer membrane of the coat. The extended surface of 
this Sar1-Sec23/24 complex has binding pockets. Cargo proteins interact with these 
binding pockets directly via receptors or indirectly with low affinity and high 
specificity and enter the budding vesicles at ER exit sites. Sec13/31 subunits are 
recruited to the membrane through interactions of Sec31 with Sec23/24 and Sar1. A 
molecular cage is formed by the Sec13/31 subunits to form the outer coat. Soon 
after formation and trafficking, COPII vesicles shed their coat, and then fuse with the 
cis-Golgi compartment [56, 109]. On the other hand, the stringent quality control 
system of the ER detects misfolded proteins, unmodified or orphaned subunits of 
protein complexes from properly folded proteins and targets them for retention and 
degradation by ERAD [56, 105, 110-112]. 
2.2 Homeostasis of the proteome 
 The ER prevents retained misfolded proteins from forming aggregates in the ER 
lumen and thus reducing their deleterious effects on the cell. Accumulation of 
misfolded proteins can lead to an overwhelming ER which disrupts its function and 
is known as ER stress [113]. Proteome stability and functionality is maintained by 
constant homeostasis of the proteome (proteostasis network) (PN).  
 Besides, protein synthesis, the PN regulates the retention, folding and/or 
degradation of unfolded, misfolded and/or non-native proteins within the ER and 
protein ubiquitination and/or proteasomal degradation on the cytosolic side of the 
ER. It is vigilant for cell stress and adapts it’s mechanism to avoid it at all costs. It 
adjusts the expression and activity of molecular chaperones at both the 
transcriptional and post-translational level [114] ensuring cross-talk between 
mechanisms is tightly regulated. The main outcome of the PN is to detoxify cells 
from non-repairable proteins. 
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 The ER employs two main mechanisms in response to the presence of misfolded 
and/or unfolded proteins. One mechanism is an ER-adaptive stress response 
termed the unfolded protein response (UPR) outlined in Figure ‎2.2.1 [56, 57, 115]. 
The UPR acts to remodel the ER so that it increases its folding capacity. The other 
mechanism is ERAD, which eliminates misfolded proteins retained in the ER after 
surveillance systems scrutinize proteins by ER quality control mechanisms. ERAD is 
equally important to maintain the turnover of specific proteins to establish the PN 
within the cell [116]. ERAD tuning has also been defined as an ER-adaptive 
pathway regulated by misfolded protein loads [117]. Proteins may also aggregate in 
the ER and get cleared by cell apoptosis or lysosomal autophagy.  
2.2.1 The unfolded protein response 
 Misfolded or aggregated proteins are potentially cytotoxic and consequently the 
cell needs to remove these aberrant proteins as early as possible. Because aberrant 
proteins may expose hydrophobic regions as well as free cysteine residues, they 
have a tendency to aggregate and ER molecular chaperones play key roles in 
ERQC because they recognize misfolded and aggregation-prone proteins [118]. 
Accumulation of misfolded proteins elicits an apoptotic response, the unfolded 
protein response (UPR), by proapoptotic genes which lead to cell death. 
 The UPR shown in Figure ‎2.2.1 involves at least 3 signaling pathways stemming 
from the ER. The three integral ER membrane proteins acting as ER stress sensors 
are: inositol requiring transmembrane kinase/endoribonuclease 1 α (IRE1α), PKR-
activated protein kinase-like eukaryotic initiation factor 2 α kinase (PERK) and 
activating transcription factor 6 α (ATF6α). The activation of these proximal sensors 
is dependent on dissociation from ER chaperone HSPA5/BiP. When the proximal 
sensors are bound to HSPA5/BiP, their dimerization and activation is turned off 
[119]. As misfolded proteins accumulate in the ER, HSPA5/BiP is sequestered from 
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these sensors [120] unmasking their dimerization motifs thereby allowing their 
oligomerization, transphosphorylation and activation.  
 The UPR is activated by IRE1α, which when activated cleaves a 26-base 
fragment from the mRNA encoding X-box binding protein-1 (XBP1) [121]. Spliced 
Xbp1 mRNA is translated into potent transcription factor XBP1s which targets 
proteins involved in protein folding, protein secretion from the cell and ERAD. PERK 
is the second arm, which phosphorylates the α-subunit of eukaryotic translational 
initiation factor 2 α (eIF2 α). eIF2 α generally decreases protein influx into the ER 
lumen. The PERK-eIF2α-ATF4 pathway also induces CCAAT enhancer-binding 
protein (C/EBP) and homologous protein (CHOP/GADD153), a pro-apoptotic factor 
induced by ER stress [122]. During severe ER stress, CHOP up-regulates apoptosis 
related genes to promote cell death. Cell survival is the purpose of the UPR though 
prolonged or persistent stress results in the activation of pathways that ultimately 
lead to cell death [60, 115, 119]. 
 ATF6α, a transcription factor, is the third arm of the mammalian UPR. When 
ATF6 dissociates from HSPA5/BiP, it moves to the Golgi apparatus and undergoes 
regulated intramembrane proteolysis releasing its cytoplasmic domain. This in turn 
translocates to the nucleus and activates gene transcription [123]. Activated ATF6α 
transcribes unspliced XBP1. When Ire1α is dimerized and transphosphorylated, 
Ire1α’s endonuclease activity specifically splices XBP-1 mRNA and induces the 
translation of the active form of XBP-1 [115].  
 Multiple perturbations can cause accumulation of unfolded proteins in the ER and 
activate UPR. Other cellular conditions such as hypoxia, glucose deprivation, 
oxidative stress, viral infection, high fat or cholesterol also upregulate the UPR. All in 
all, the UPR regulates transcription and translation of genes such as ER chaperones 
and components of the ERAD pathway to restore ER homeostasis and prevents 
protein translation.  
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Figure ‎2.2.1. The three arms of the unfolded protein response (UPR) include 
IRE1α, PERK and ATF6α. When misfolded proteins accumulate in the ER, the 
three arms IRE1α, PERK and ATF6α are released from the HSPA5/BiP 
chaperones. This in turn is the signal for activation of the UPR. PERK 
phosphorylates eIF2α and the latter inhibits protein translation. PERK also 
activates ATF4 leading to the synthesis of protein phosphatase 1, regulatory 
subunit 15A (PPP1R15A) which then targets protein phosphatase I (PPI) to 
dephosphorylate eIF2α-P resuming protein translation. ATF6 is mobilized to the 
Golgi where it is activated producing an unspliced XBP1 which is then activated by 
IRE1 to further transcribe folding chaperones and ERAD machinery components. 
Redrawn from reference [115].  
2.2.2 Endoplasmic reticulum associated degradation (ERAD)  
 Proteins that fail the stringent ERQC checkpoints are initially retained in the ER. 
This retention-based ERQC system is made up of ER-resident chaperones such as 
HSPA5/BiP, Ero1, PDIs, and ER lectins and members of the EDEM family (EDEM 
1–3). Proteins of the Der1-like domain family, member 1 (DERL1-3) also interact 
with EDEM proteins that monitor the folding of N-glycoproteins [124]. A misfolded 
BACE457 substrate was found to interact with PDI and EDEM. It may be possible 
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that chaperones, co-chaperones and oxidoreducatases work together collectively on 
ERAD [2]. ERAD is a process in which misfolded retained proteins are consequently 
retrotranslocated back to the cytoplasm for degradation by the ubiquitin/proteasome 
systems [7, 12, 13, 18, 56, 125-127]. These interactions provide a direct link 
between the quality control system within the ER and cytosolic proteasomal 
degradation machinery. 
2.2.2.1 Mannose trimming 
 ER mannosidase I (ERMan I) catalyzes the removal of the terminal mannose of 
the B chain of the N-glycan residue (i) shown in Figure ‎2.1.2. This tags polypeptides 
for disposal [128]. This mannose removal also occurs for native polypeptides 
selected for secretion. This step is a pre-requisite for the intervention of EDEM, 
which removes mannose (k) displayed on misfolded polypeptides [129] 
(Figure ‎2.1.2). Removal of the mannose residue (g) prevents the substrate from 
UGGT1-mediated re-glucosylation and re-entry into the CNX cycle. Removal of the 
terminal mannose residues from the B and C chains, residues (i) and (k) 
respectively, allows binding of the N-glycan by the ERAD lectins osteosarcoma 
amplified 9, endoplasmic reticulum lectin (OS9/OS-9) and endoplasmic reticulum 
lectin 1 (ERLEC1/XTP3-B), promoting degradation [77]. OS-9 containing MRH 
domain binds Man7 oligosaccharides exposing the terminal α-1,6-bonded mannose 
(j). This now signals this glycoprotein as a substrate for ERAD retrotranslocation and 
degradation [130, 131] as outlined below. 
2.2.3 The main steps of ERAD  
 ERAD is primarily involved in protein QC, since most ERAD substrates are 
damaged, misfolded or orphan proteins. ERAD pathways involve the ubiquitin-
proteasome pathway to execute degradation marking the substrates by covalent 
addition of multiubiqutin chains, leading to destruction by the 26S proteasome. 
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There are four main steps in ERAD as depicted in Figure ‎2.3.1 [12, 13, 18, 56, 125, 
126].  
 ERAD starts with a recognition of ER-retained substrates known as “Step 1: 
substrate recognition”. Here proteins which have misfolded cytoplasmic, ER luminal 
or transmembrane domains are recognized by ER luminal or cytoplasmic 
chaperones, depending on the site of the lesion in the protein. As mentioned, these 
consist of the HSPA5/Bip, CXN, CRT and PDIs. The misfolded protein is now 
targeted to the dislocation/retrotranslocation machinery and/or to the E3 ligases [10]. 
The E3s have variable numbers of transmembrane domains and a cytosolic Really 
Interesting New Gene (RING) finger domain on their cytosolic C-terminus which 
catalyzes the transfer of ubiquitin (Ub) from the E2 directly on to the substrate [132]. 
They catalyze substrate ubiquitination [133] and organize the complexes that 
coordinate events on both sides of and within the ER membrane “Step 2: 
Ubiquitination”.  
 Ubiquitination is a post-translational modification taking place in both the cytosol 
and nucleoplasm of cells. It serves to add Ub moieties to the substrate for 
recognition by the proteasome as an ERAD substrate. An ubiquitin-activating 
enzyme (E1) transfers ubiquitin via ATP to an active site cysteine [134] in an 
ubiquitin-conjugating enzyme (E2). Ubiquitin ligase (E3) acts as a platform for Ub 
moieties and then transfers ubiquitin from E2 to a lysine residue on the misfolded 
protein. Substrates are first monoubiquitinated and then they are further modified by 
the addition of additional Ubs leading to the formation of polyubiquitin chains 
(PUCs). Polyubiquitination occurs at the ER membrane via cytoplasmic or ER-
localized E3 ligases [110].  
 E3 ligases are numerous in number and make up approximately 600 in 
mammalian cells probably due to specificity for one or a few particular substrate(s) 
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[135, 136]. Once substrates are polyubiquitinated, they become exposed to the 
cytosol where they are recognized for early retrotranslocation. 
 Self-ubiquitination of the E3 ubiquitin ligase is reversible. Ub moieties attached to 
substrates are not a permanent modification. They serve to promote the late steps 
of retrotranslocation by recruiting the ATPases associated with diverse cellular 
activities (AAA ATPase) via binding to its adapter protein [137]. Machinery involved 
in ubiquitination is recruited to the misfolded protein either within the membrane or 
by cytoplasmic chaperones.  
 Ubs can attach to one another in different ways forming PUCs with different chain 
conformations [135, 138]. The C-terminal glycine of the donor Ub can be attached to 
the α-amino group of the N-terminus of the acceptor Ub. Alternatively, the C-
terminal glycine of the donor Ub can attach to seven internal lysines of the acceptor 
Ub via a peptide bond. Prolonged substrate ER-retention of the low density 
lipoprotein 6 (LRP6) has been shown to lead to extension on mono-Ub by E3 
ligases forming PUCs and these PUCs are recognized by the ERAD system and 
connect it to the ERQC [135].  
 Retrotranslocation ensues as the third step of ERAD and is the most perplexing. 
ERAD substrates must be moved from the ER to the cytoplasm for ubiquitination 
and proteasomal destruction by a process called retrotranslocation. Many aspects of 
retrotranslocation are poorly understood, including its generality, the cellular 
components required, the energetics and the mechanism of transfer through the ER 
membrane [139-142]. Here, the protein can be removed through the retrotranslocon 
channel or by removal of the protein and the surrounding membrane by interaction 
with the small VCP/p97-interacting protein (SVIP) [8]. The latter is an AAA ATPase 
complex and uses ATP hydrolysis for possible mechanical removal of the misfolded 
protein especially since it is folded in the lumen or membrane spans in the lipid 
bilayer.  
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 The presence of six-ATP sites in the assembled complex may reflect an extreme 
energy requirement for this process [140]. The AAA ATPAse complex binds 
multiubiquitin chains and has also been implicated in the energy-dependent 
movement of polyubiquitined proteins from non-covalent complexes in a wide variety 
of circumstances [143]. An intriguing question remains as to whether the AAA 
ATPase pulls the substrates across the membrane or alternatively, mediates 
removal of ubiquitinated substrates bound to the ERAD complex after 
retrotranslocation. The proteasome itself has been proposed to actively participate 
in the retrotranslocation or extraction of proteins from the ER membrane because of 
its resemblance structurally and functionally to VCP/p97 [144]. The proteasome 
utilizes ATP hydrolysis to undergo large conformational changes of the unfolding 
and/or movement of substrates out of the ER membrane [110, 135, 144, 145]. 
 The last step of ERAD is “degradation”, as its name implies. Misfolded proteins 
are escorted to the 26S proteasome by a 19S cap. An enzyme named N-glycanase 
removes N-glycan residues and de-ubiquitinating enzymes remove ubiquitin tags 
within the cytosol or proteasome cap [146]. The 20S proteasome core contains 
enzymes with trypsin-like, chymotrypsin-like and caspase-like peptidases. These 
enzymes cleave the misfolded protein into short peptides for recycling back into the 
cell [6, 50, 110, 147].  
2.3 Human disease and the involvement of ERAD 
 Mutations as modest as a single amino acid substitutions have been directly 
linked to protein misfolding with ER retention of misfolded proteins and the 
pathogenesis of multiple human genetic disorders [4]. ERAD is the underlying cause 
of many highly debilitating disorders ranging from Alzheimer's disease to cystic 
fibrosis (CF) [1, 18, 148, 149]. Disease-associated mutations often jeopardize 
acquisition of the native folding conformation of the affected protein and/or 
destabilize the native structure. Proteins which are unable to fold into their native 
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conformations have either full or partial loss-of-function. In some instances, for 
example in neurodegenerative diseases, inefficient removal of misfolded proteins 
results in aggregations with cytotoxic effects perturbing essential cellular functions 
and integrity. 
 
Figure ‎2.3.1. The four main steps for endoplasmic reticulum protein associated 
degradation (ERAD). Step 1 is recognition where a misfolded region (red stars) are 
recognized by cytoplasmic, ER luminal or transmembrane recognition factors 
depending on the site of lesion and occurs during protein synthesis. Ubiquitination 
is step 2. Chaperones and co-chaperones direct the misfolded substrate to the 
dislocation machinery. An ubiquitin activating enzyme (E1) transfers ubiquitin (Ub) 
(grey circles) to a cysteine residue in an active site of an ubiquitin conjugating 
enzyme (E2) using ATP as energy. Ubiquitin ligase then transfers Ub to a lysine 
residue on the substrate protein. The latter process occurs on either the ER or 
cytoplasmic side of the membrane. Retrotranslocation is step 3. The substrate 
protein is removed either by passing through the translocon or by complete removal 
of the misfolded protein and surrounding membrane. This is mainly done by the 
VCP/P97 AAA ATPase which interacts with Ub on the substrate and 
deubiquitinates the mutant protein and sends it off to the 26S proteasome for 
degradation. Degradation step 4 is the final step. Here, the polyubiquitinated 
substrates are escorted to the 26S proteasome to degrade the faulty proteins 
maintaining homeostasis in the ER lumen. N-glycans are cleaved off by an N-
glycanase and Ub moieties are removed by de-ubuitinating enzymes found in the 
cytoplasm or in the proteasome cap to release small peptides shown in green. 
Redrawn from reference [8]. 
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2.3.1 The link between ERAD and disease 
 One of the first diseases linked to the ERAD pathway was cystic fibrosis (CF). CF 
is caused by defects in the CFTR. The classic ΔF508-CFTR mutant protein is the 
cause of disease in 80% of Caucasian patients with CF. This mutation causes the 
CFTR protein to misfold in the ER or prevents folding altogether and/or alters 
membrane spanning domain folding. This leads to protein instability and a defect in 
the presentation of an ER exit motif, causing the ΔF508-CFTR to be retained in the 
ER. This retention causes the CFTR to be eradicated by ERAD and thus its 
expression at cellular apical plasma membranes in ducts and airway epithelia is 
drastically reduced. The outcome is the loss-of-function of the CFTR protein as a 
chloride channel i.e. its function is compromised and hydration of the mucosal layer 
lining the lungs’ airways is reduced, leading to bacterial growth and lung fibrosis [1].  
 There are more than 100 diseased states currently identified in the literature, 
where ERAD is involved as the underlying cellular mechanism for disease [1, 8]. 
The retention and degradation of a mutant protein leads to the loss of its biological 
function which very often leads to a disease state [1, 18]. Given the high proportion 
(~30%) of cellular proteins that are targeted to the secretory pathway, it has been 
reasoned that ERAD is the cellular pathogenesis of more diseases relative to the 
ERAD-related diseases currently recognized in the literature [1, 14, 15]. These 
disorders include monogenic diseases, neurodegenerative disorders, metabolic 
diseases, serinopathies, viruses, toxins, ATP-binding cassette transporters and 
cancers among many others. A list of ER causative diseases can be accessed in the 
latest ERAD review by Guerriero and Brodsky (2012) alongside Aridor, et al. (2000, 
2002 and 2007).  
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2.4 Data mining for disease causing ERAD candidate 
genes 
2.4.1 Receptor tyrosine kinase-like orphan receptor 2 gene  
 Disease-associated alleles were sought after using bioinformatic algorithms and 
databases as previously described [18]. Candidates for initial analysis included the 
receptor tyrosine kinase-like orphan receptor 2 (ROR2) gene, an orphan receptor 
tyrosine kinase with alleles associated with Robinow and Brachydactyly type 1B 
syndromes [150]. Robinow syndrome is an autosomal recessive disorder. All but 
one of the missense mutations reported to traffic abnormally were found in the Fz-
CRD. One mutation was found in the kringle domain close to Fz-CRD. Interestingly, 
it was determined that such alleles were responsible for misfolding of the ROR2 
protein confirming ER-retention and therefore loss-of-function due to ERAD as the 
underlying mechanism in all Robinow syndrome-causing missense mutations [18, 
148].  
2.4.2 Natriuretic peptide receptor B 
 Hume et al., (2009) recently found that eleven out of the twelve known missense 
pathogenic mutations in the natriuretic peptide receptor B (NPR-B) gene found in 
Acromesomelic Dysplasia type Maroteaux (AMDM) patients resulted in the retention 
of the mutated proteins in the ER. Hence, this confirmed that loss-of-function in 
AMDM is indeed due to the trafficking defect of the receptor.  
2.4.3 Discoidin domain receptor tyrosine kinase 2 
 ERAD is also responsible for most of the mutations causing Sponydylo-meta-
epiphyseal Dysplasia with short limbs and abnormal calcifications caused by 
mutations in discoidin domain receptor tyrosine kinase 2 (DDR2) [149]. The finding 
that almost all the missense mutations in ROR2, NPR-B and DDR2 resulted in the 
retention of mutant proteins in the ER and their degradation by ERAD provided 
support for the bioinformatic approach [18].  
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2.4.4 Endoglin and activin receptor-like kinase 
 More recently, Osler-Rendu-Weber syndrome or hereditary hemorrhagic 
telangiectasia (HHT), a genetically heterogeneous autosomal dominant vascular 
disorder was studied. Endoglin (ENG) and activin receptor-like kinase (ACVRL1) 
encode endoglin and ALK1 proteins, respectively, that modulate transforming 
growth factor (TGF)-β superfamily signaling in vascular endothelial cells are 
commonly mutated in hereditary hemorrhagic telangiectasia 1 and 2 (HHT1 and 
HHT2), respectively. Mutations lead to the development of fragile telangiectatic 
vessels and arteriovenous malformations. In addition, they are characterized by 
multi-organ vascular dysplasia, recurrent epistaxis and mucocutaneous 
telangiectasia.  
 Endoglin is a disulfide-linked homodimer integral membrane glycoprotein. 
Randomly selected missense mutants within the orphan domain known to cause 
HTT were examined and demonstrated that eight of eleven mutations were retained 
in the ER [151]. 
 It has become evident that a large number of diseases with very different 
pathologies share a common framework of protein misfolding, accompanied by 
degradation and/or aggregation of these misfolded proteins. Inherited genetic 
diseases which harbor missense mutations affect the folding process and/or the 
stability of the folded structure of the proteins. By obstructing the folding process, 
increasing aggregation or de-stabilizing the native structure, disease-associated 
amino acid replacements may cause loss-of-function or gain-of-function pathologies.  
2.5 The importance of the cysteine rich domain 
 Frizzleds (Fz) and Wnts have been identified in all major groups of metazoans. 
Extracellular amino terminus Fz-CRD serves as the Wnt binding domain and Fz-
CRD is the key mediator [152] in the Wnt signalling pathway: considered vital during 
36 
 
embryogenesis. In adult tissue, disturbances in the Wnt pathway can lead to human 
degenerative disease and cancer.  
 A study on Wnt3-Fz 1 chimera was used as a model to look at canonical Wnt 
signaling [153]. A chimera of human Wnt3 and Fz1 receptor was developed that 
efficiently activated the T cell transcription factor (TCF)-luciferase reporter. As a 
result it was shown that the Fz-CRD was also critical for Wnt signaling, as a deletion 
of 29 amino acids in the 2nd cysteine loop resulted in the total loss of TCF-luciferase 
activation.  
 Wnt interacts with the soluble N-terminal CRD of frizzled, which relays signals to 
downstream effectors inside the cell to regulate a number of signaling events, e.g. 
β-catenin-dependent activation of target genes in the canonical Wnt pathway. 
Wnt11r binds MuSK through its Fz-CRD in vitro. In the embryo, wnt11r binds in a 
non-canonical dishevelled signaling manner in muscle fibers and this is required for 
MuSK function [154]. 
 Fz-CRD is a mobile evolutionary unit that has been found in members of the 
seven-pass transmembrane proteins (Fz1-Fz8), certain receptor tyrosine kinases 
such as MuSK [19, 21] and ROR [25]. The majority of the Fz-CRD domains are 
named so because they possess 10 conserved cysteines that exhibit a general 
pattern of “C*C*CX8CX6C*CX3CX6,7C*C*C” (C: conserved cysteine; *: a variable 
number of residues, Xn: n residues, and Xm,n: m to n residues). The number of 
residues between the seventh and eighth conserved cysteines is usually six, while 
receptor-tyrosine kinase-associated CRDs have seven residues between them [24]. 
Structural studies of three CRDs, in mouse FZD, mouse secreted Frizzled-related 
proteins (SFRPs), SFRP3 [19] and rat MuSK [21] revealed a common alpha-helical 
fold mainly consisting of four core alpha-helices. They also contain the same two N-
terminal beta strands (β1-β2). In all these structures, the disulfide connectivity 
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patterns among the 10 conserved cysteines are C1–C5 (between the first and fifth 
conserved cysteines), C2–C4, C3–C8, C6–C10, and C7–C9 [24, 155]. 
 FZD4 crystal structure has not been reported however, it is structurally similar to 
the FZD8 and MuSK crystal structures placed on the PDB website: 
http://www.rcsb.org/pdb/home/home.do. Xenopus Wnt8 (XWnt8) has been seen as 
a complex with several Fz-CRD and this XWnt8/Fz-CRD complex has been 
observed as oligomeric forms with molecular weights ranging from ~50 kDa to ~200 
kDa [22]. FZ-CRD has been shown to oligomerize in the ER [20] and the crystal 
structure of the Fz-CRD displays a conserved dimer interface that may be a feature 
of Wnt signalling [19]. MuSK’s Fz-CRD forms an asymmetric dimer [21]. The Fz-
CRD then goes on to form homo-and heterodimers in the ER and possible 
oligomerization [20-23]. Consequently, proteins harboring Fz-CRD must fold 
correctly and dimerize in the ER to function in the Wnt pathway. 
2.6 The clinical value of targeting ERAD for therapeutic 
purposes 
 As previously mentioned, ERAD has been implicated in the mechanism of 
numerous human diseases. ER retention of possibly functional proteins has resulted 
in research for drug-induced rescue of their cell surface expression (misfolded 
protein and ER-targeted therapy). Therefore, understanding the underlying 
mechanism is of clinical value. New therapeutic approaches are aimed at either 
correcting the basic protein folding defect “protein repair” or at overcoming the 
intracellular retention of the mutant protein through the manipulation of the key 
interacting players “protein rescue”. Targeting ERAD is complex as the proteostasis 
network for cell types is different and the folding properties of a variety of client 
proteins is regulated by cyclical interactions with a variety of different co-chaperones 
and/or chaperones.  
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 Potential therapeutic intervention and manipulation of ∆F508-CFTR has been 
sought after for many years and has been successful. The ∆F508-CFTR trafficking 
and therapeutic manipulation has been considered a model for this group of 
genetically inherited diseases. A group of 10 academic laboratories came together 
and unified a hypothesis that the biogenesis of ∆F508-CFTR can be manipulated by 
understanding the intra-molecular fold alongside the rate-limiting inter-molecular 
interactions in the ER as compared to the cell surface and manipulate these factors 
accordingly [27].  
2.6.1 Chemical compounds (chemical chaperones) 
 To alleviate misfolding or correct a mutant protein’s ER-retention, a lot of 
research has been dedicated to the protein folding environment. The ∆F508-CFTR 
protein was tested for its ability to fold in vivo at 37° C and at temperatures below 30 
°C and a comparison was made. It was observed that at higher temperatures, the 
synthesized protein was misfolded and consequently degraded by ERAD. In 
contrast, at lower temperatures the ∆F508-CFTR mutant protein was able to fold 
properly into its native state. These so called “thermosensitive” mutant proteins 
could then be manipulated or their environment modulated by chemical chaperones 
which may stabilize the mutant proteins or correct folding defects. These 
compounds have been collectively called “chemical chaperones” [30] and were 
named so because of their influence on protein conformation [156]. Brown et al. 
defined these chemical chaperones as “low molecular mass compounds known to 
stabilize protein conformation against thermal and chemical denaturation” [31].  
 Chemical chaperones have been observed to account for the rescue of several 
different classes of misfolded proteins. To name a few: CFTR [157], α1-antitrypsin 
[158], human Phenylalanine hydroxylase (hPAH), aquaporin-2 [159], vasopressin V2 
receptor [160], ATP-binding cassette transporter proteins [35], α-galactosidase A 
[161], Fukutin protein [162], the prion protein PrP [156], the temperature-sensitive 
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mutants of the tumor suppressor protein p53, viral oncogene protein pp60, the 
ubiquitin-activating enzyme E1 [163] and P-glycoprotein [164] among many others.  
 Interestingly, the variant ΔF508-CFTR is mainly retained in the ER as a result of 
misfolding yet, when a minute amount of the ΔF508-CFTR protein is expressed on 
the cell surface, it exhibited significant chloride-channel conductance activity [29, 
165]. Such results provide insight that the molecular machinery that directs folding 
and export could play an important role in both understanding the molecular basis 
for disease and achieving correction by promoting folding and transport of ΔF508-
CFTR to the cell surface [29].  
 Following these observations on CFTR, several approaches have been 
attempted to overcome the retention of mutated proteins in the ER by stabilizing 
mutant protein conformation or by inducing a stress response, leading to up-
regulation of molecular chaperones. Enhancing the cellular folding capacity by 
remodeling the proteostasis network promotes native folding. The approaches used 
consist of low temperature treatments.  
2.6.2 Low temperature incubation 
 In recent years, there have been a growing number of reports on the use of 
reduced temperature cultivation of mammalian cells for the enhanced production 
and improved product quality of trafficking proteins. Low temperature incubation of 
affected cells and/or tissues has never been a feasible therapeutic option. However; 
this data shows how modulating kinetic i.e. speed of folding and/or thermodynamic 
aspects of any protein may possibly suffice when targeting the protein for ERAD. 
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Figure ‎2.6.2. The effects of chemical chaperones. Glycerol increases the hydration 
layer, the strength of the intramolecular hydrophobic bonding of the protein, in the 
ER, which consequently allows the free movement of proteins, so as to prevent 
aggregation. Differing concentrations (0.1-1%) of DMSO probably act by increasing 
protein synthesis of the misfolded proteins or by overwhelming the quality control 
system [166]. Thapsigargin is an inhibitor of the ER sarco/endoplasmic reticulum 
Ca2+-ATPase (SERCA) calcium pump, and has been shown to increase cytosolic 
calcium, resulting in an enhanced rescue of mutant proteins [160]. Curcumin, a 
nontoxic natural constituent of turmeric spice affects the calcium ([Ca2+]ER) ATPases 
[167] found on the ER plasma membrane, by inhibiting their ability to maintain a high 
ER calcium level. This in turn, affects the ability of ER molecular chaperones to 
target the misfolded protein for ERAD, hence, allowing the mutant protein to exit the 
ER. 
 The sub-physiological culture of mammalian cells (28-34 ºC) results in changes in 
gene expression and culture longevity [168]. Moderate hypothermia (16-20 ºC) for 
24-48 hours has been used to enrich cultures. For example shifting HeLa cells from 
37 ºC to 33 ºC doubles their generation time. These temperature shifts have been 
41 
 
used to prolong the cell cycle by up to 7-fold. Temperatures of 25-33 ºC results in 
temporal dilation of the G1 and S phases with G2 being the least sensitive [169].  
 Cell membrane expression of functional ΔF508-CFTR has been achieved by 
growing the expressing cells at lower temperatures [30, 32]. Processing of ΔF508-
CFTR reverts towards that of wild-type as the incubation temperature is reduced. 
When the processing defect is corrected, cAMP-regulated chloride channels appear 
in the plasma membrane.  
 Recent studies show how a reduced temperature culture (e.g. 27 °C) treatment 
corrected the subcellular location of the Fukutin missense mutants in Fukuyama-
type congenital muscular dystrophy (FCMD) [170]. The cellular localization of a 
pathogenic mutant of human glucagon receptor causing Mahvash disease was 
restored by culturing at 27 °C [171].  
 Another recent example was a study involving the human cardiac Kv1.5 (hKv1.5). 
The amount of protein expressed at a lower temperature increased the immature 
protein and this was shown not to be due to inhibition of proteolysis. The low 
temperature treatment markedly shifted the subcellular distribution of the mature 
hKv1.5, which showed considerable overlap with the trans-Golgi component. N-
glycosylation of hKv1.5 was also shown to be more effective at 28 °C than at 37 °C. 
The hypothermic treatment also rescued the protein expression and current of 
trafficking-defective hKv1.5 mutants. These results indicate that low temperature 
exposure stabilizes the protein in the cellular organelles or on the plasma 
membrane, and modulates its maturation and trafficking, thus enhancing the current 
of hKv1.5 [172]. 
42 
 
2.6.3 Glycerol 
 Glycerol acts as an osmolyte increasing the hydration layer, the strength of the 
intramolecular hydrophobic bonding of the protein in the ER, which consequently 
allows the free movement of proteins, so as to prevent aggregation [28].  
 Glycerol has three hydroxyl groups which makes it soluble in water. Glycerol can 
decrease the relative hydration of the mutant polypeptide. This tighter packing has 
an increased hydrophobic effect allowing the polypeptide more stability in the 
cellular environment [31, 173, 174]. Glycerol is an example of a chemical chaperone 
which stabilizes mutant protein native conformation [160]. This chemical compound 
improves the yield of the soluble human phenylalanine hydroxylase enzymes 
(hPAH) by 2-3 times. It was also able to increase the specificity of chaperones 
towards the mutant enzyme  Glycerol’s effect has increased the rate of in vitro 
protein re-folding [175]. Another feature of glycerol is that it can improve the kinetics 
i.e. the rate of oligomeric assembly of proteins [176].  
 Others postulated that glycerol may rescue ER-retained mutants by increasing 
mutant expression or change the course of stress-sensitive molecular chaperones 
[177, 178]. Yeast ER membrane protein 3-hydroxy-3-methylglutaryl-CoA reductase 
(Hmg2p) [179] and the ∆F508 CFTR [28] temperature-sensitive trafficking mutant 
and a vasopressin mutant [160], among many others, were stabilized by the addition 
of glycerol to the expressing cells.  
 Addition of glycerol has been shown to affect the refolding parameters of 
recombinant human brain-type creatine kinase (rHBCK) [180]. It can affect refolding 
yield, reaction kinetics and aggregation. The results indicate that glycerol could 
alleviate the aggregation of rHBCK during refolding in both dilute solutions and 
macromolecular crowding systems, and increase refolding yields and reaction rates.  
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Figure 2.6.3. Glycerol is a simple polyol (sugar 
alcohol) compound. It is a colorless, odorless, 
viscous liquid that is widely used in 
pharmaceutical formulations. Glycerol has 
three hydroxyl groups that are responsible for 
its solubility in water and its hygroscopic 
nature. 
2.6.4 Dimethyl sulfoxide  
 
Figure 2.6.4. Dimethyl sulfoxide (DMSO) is 
an organosulfur compound with the formula 
(CH3)2SO. This colorless liquid is an 
important polar solvent that dissolves both 
polar and nonpolar compounds and is 
miscible in a wide range of organic solvents 
as well as water. DMSO is used as a mild 
oxidant. DMSO acts as a buffer in solution 
and has a structural effect on proteins.  
 
 Other chemical chaperones like dimethyl sulfoxide (DMSO) [181], trimethyl-
amine-N-oxide [182], calcium pump inhibitors [167] and curcumin [183] have been 
tested to shift the folding equilibrium of mutant secretory proteins towards their 
native states, thus releasing them from the ER retention state. DMSO has been 
postulated to have the same action as glycerol [31, 160, 177-179]. It’s solvation 
results in exposing the protein’s hydrophobic residues by methyl groups in DMSO 
[184]. DMSO also acts to expose the protein’s surface area: allowing chaperones to 
possibly interact with the protein to enhance protein processing. In vitro studies with 
DMSO show reduced cytotoxicity and cell death, therefore DMSO offers a possible 
therapeutic approach [185]. 
 Missense mutants of transmembrane protein E-cadherin were shown to be 
rescued from ERAD by treatment of cells with the proteasomal inhibitor, MG132, or 
2% dimethyl sulfoxide (DMSO) [186]. Retinol dehydrogenase 12 (RDH12) is a 
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microsomal enzyme that catalyzes the reduction of all-trans-retinaldehyde to all-
trans-retinol when expressed in cells. Mutations in RDH12 cause severe retinal 
degeneration, albeit some of the disease-associated RDH12 mutants retain 
significant catalytic activity. T49M and I51N variants of RDH12 undergo accelerated 
degradation through the ubiquitin-proteasome system, which results in reduced 
levels of these proteins in cells. However chemical chaperones, namely 2% DMSO, 
were able to restore the mutant localization to the cell surface [187].  
2.6.5 Curcumin 
 
Figure 2.6.5. Curcumin is a diarylheptanoid, C21H20O6. It is the principal 
curcuminoid of the popular South Asian spice turmeric, which is a member of the 
ginger family (Zingiberaceae). Curcumin appears to possess a spectrum of 
pharmacological properties, due primarily to its inhibitory effects on metabolic 
enzymes. It has been studied as a universal remedy for most diseases ranging 
from cancer and most inflammatory diseases. Image taken from 
http://pubchem.ncbi.nlm.nih.gov/ 
 This chemical chaperone affects the internal cellular proteostasis within the cell. 
By acting in this way, curcumin allows an enhanced favorable fold for the protein 
and/or affects its trafficking environment. Curcumin may still be able to treat CF as it 
can function at different steps of CFTR biogenesis and it has been shown to help 
other types of CFTR mutants [188]. Reproducing some of the results on CF mouse 
models with curcumin treatments has been disputed [189]. 
 Recent studies show that 10 µg/ml curcumin treatment at 37°C corrected the 
subcellular location of the Fukutin missense mutants in FCMD [170]. Curcumin 
affects the calcium ([Ca2+]ER) ATPases [167] found on the ER plasma membrane by 
inhibiting their ability to maintain a high ER calcium level. This in turn, affects the 
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ability of ER molecular chaperones to target the misfolded protein for ERAD, hence, 
allowing the mutant protein to exit the ER. Protective effects in two prominent 
diseases; Creutzfeldt-Jakob Disease [190] and Parkinson Disease [191] have been 
observed by a decrease in protein misfolding and therefore protein aggregation. 
Curcumin has therefore succeeded for treating misfolded proteins and their 
diseases.  
2.6.6 Thapsigargin 
 
Figure 2.6.6. Thapsigargin. Thapsigargin 
is a sesquiterpene lactone found in roots 
of Thapsia. It inhibits Ca2+-transporting-
ATPase mediated uptake of calcium into 
the sarcoplasmic reticulum. Image taken 
from http://pubchem.ncbi.nlm.nih.gov/ 
 Thapsigargin is the most widely used inhibitor of the ubiquitous sarco-
endoplasmic reticulum Ca2+-ATPases in mammalian cells. Over the past twenty 
years, this compound, of plant origin, has become a popular tool in a host of studies 
directed at elucidating the mechanisms of intracellular Ca2+ signaling. Its remarkable 
potency and selectivity have been instrumental in expanding our understanding of 
the function of intracellular Ca2+ stores to include such key aspects as store-
operated Ca2+ entry, or the involvement of the stores in protein synthesis and cell 
growth. 
2.6.7 Pharmacological chaperones 
 Pharmacological chaperones are a particular type of chemical chaperone that 
directly binds to the misfolded proteins [1]. They are more specific to the protein in 
that they support folding, counteract formation of toxic aggregates and/or stabilize 
the native structure of mutant proteins. By lowering the protein’s free energy state, 
they promote better protein folding [8]. Some pharmacological chaperones are 
46 
 
competitive inhibitors and have been used to help stabilize mutant proteins and 
rescue them from ER retention. 
 The F508 position is important for the folding and assembly of native CFTR. It 
participates in the formation of interdomain contacts that stabilize interactions 
between  the domains of the protein. Yu et al., 2011 [192] demonstrated the use of a 
pharmacological chaperone, VRT-325, which resulted in partial correction of the 
nucleotide binding domain (NBD) of ΔF508-CFTR. The combined application of 
another drug known as a potentiator, VX-770, had an additive effect that restores 
both the folding and trafficking defects associated with ΔF508-CFTR and potentiated 
its reduced channel activity. It has been shown that the CFTR corrector, VX-809, 
allows the cell surface expression of functional ΔF508-CFTR. This cell surface 
expression results in partial restoration of chloride transport in cultured human 
bronchial epithelial cells derived from people with CF who are homozygous for 
ΔF508-CFTR [193]. VX-809 was chosen from a National Cancer Institute diversity 
set I (NCIDS) database through molecular docking screening [194].  
 In vitro, chloride transport can be enhanced by combining VX-809 with Corr-4a  
[195] or VRT-325 [196], or with CFTR potentiators, for example, VX-770 (also 
known as Ivacaftor) [196]. In clinical trials, VX-809 in combination with VX-770 
improved clinical measures of CFTR function and lung function [196, 197].  
 Robben et al., [160] have shown how vasopressin V2 receptor mutants are 
rescued via pharmacological chaperones, and different chemical chaperones, such 
as osmolytes, namely 4% glycerol and 1% DMSO. Rescue of ER retained proteins 
is postulated to be due to an increased expression of changed functionality of 
stress-sensitive molecular chaperones. Calcium ([Ca2+]ER) ATPase inhibitors such 
as: 1 µM thapsigargin and 1 µM curcumin, showed an increase in cytosolic calcium, 
resulting in enhanced rescue of the receptor. They also show how the rescue 
activity of a pharmacological versus chemical chaperone is broader and stronger.  
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 A well-established example is the use of the pharmacological chaperone 1-
deoxygalactonojrimycin to rescue the trafficking of some missense α-galactosidase 
A (α-Gal A) mutants, from the ER to the lysosome, for the treatment of Fabry 
disease in patients. Fabry disease is a lysosomal storage disorder caused by α-Gal 
A enzyme deficiency. Fan et al., [198] have demonstrated the rescue of the enzyme 
activity in lymphoblasts for Fabry disease patients harbouring two missense 
mutations within the α-Gal A gene. This was achieved by cultivating the mutant 
expressing cell in a medium containing 1-deoxygalactonojrimycin, a potent 
competitive inhibitor of α-Gal A enzyme. The same group further confirmed that 
most of the disease-causing missense mutations are retained in the ER, albeit they 
are biologically functional and this loss-of-function trafficking defect can be corrected 
by the chemical chaperone approach [199].  
2.7 Silencing of ERAD machinery components by siRNA  
 ERAD encompasses a number of different pathways, each responsible for the 
degradation of subsets of proteins that share common physical properties [116, 139, 
145, 200]. A lot of research has gone into dismantling the components of the ERAD 
machinery [35].  
 siRNA has been used to dictate the difference between a deleterious mutation 
and a tolerated polymorphism as is seen with CF [201]. Partial silencing of the 
Hsp90 co-chaperone ATPase regulator (Aha1) [201] improved the trafficking of 
ΔF508-CFTR from the ER to the cell surface. In vitro [30] as well as in vivo [202] 
experiments have shown, however, that defective CFTR proteins are still 
functionally competent as chloride ion transporters [165].  
 The ability to control cell fate via the ER-folding, export and degradation 
pathways provides an exciting direction in future drug development within 
monogenic diseases. Identifying the cellular mechanism underlying genetic disease 
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has offered hope to CF and other patients. It remains to be determined if these 
disease causing mutations can be rescued, or if the ER milieu can be altered to 
allow these defective proteins to function as close as possible to their WT 
counterparts. This will provide the basis for designing specific drugs such as 
chemical and/or pharmacological chaperones that aid the transport of the diseased 
protein(s) to cellular membranes and eventually open up options for these patients. 
Likewise, tissue-specific chaperones can be therapeutic targets and have the 
capacity to be important tools in biotechnology.  
 One major hurdle for parsing mutated proteins by ER quality control is substrate 
recognition. Certain chaperones are shown to be substrate specific [158]. A detailed 
section on the silencing of ERAD components will be discussed in Chapter 4: 
Results; section 4: Gene silencing of ERAD components. The ERAD components 
chosen for this study were dependent on the substrate model chosen. 
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Chapter 3: Materials and Research Methods  
3.1 Resources 
3.1.1 Reagents and chemicals 
The following were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA): 
endoglycosidase H (Endo H) (A0810), protease inhibitors (S8830, SIGMAFAST 
protease inhibitor cocktail tablets), phosphatase inhibitor cocktail (P0044), 
phosphatase inhibitor cocktail 2 (P5726), β-mercaptoethanol (BME) (M7154), 
glycerol (G5516), thapsigargin (T9033), dimethyl sulfoxide (DMSO) (5879), 
curcumin (C7727), dithiothreitol (D9779), cycloheximide (C1988) and MG132 
(C2211). Turbo Pfu DNA polymerase was obtained from Stratagene (La Jolla, CA 
USA). A bicinchoninic acid protein (BCA) assay kit (No. 23227) and Sepharose A/G 
beads (No. 20421) were obtained from Pierce (Rockford, IL, USA). Immunofluor 
mounting media were purchased from Dako (Carpinteria, CA, USA). A cell surface 
biotinylation kit (EZ-Link sulfo-NHS-SS-biotin, 89881 from Pierce, Rockford, IL, USA.  
3.1.2 Antibodies 
Antibodies, their dilution, sources and usage for immunofluorescence (IF) and 
western blot (WB) are as follows: mouse FLAG octapeptide epitope tag 
(DYKDDDDK) (anti-FLAG) monoclonal antibody (1:1000, IF and WB; Sigma-Aldrich 
Corp.), rabbit anti-FLAG antibody (1–2 µg/mL immunoprecipitation [IP], F7425; 
Sigma-Aldrich Corp.), rabbit anti-calnexin polyclonal antibodies (1:50, IF; Santa 
Cruz, Dallas, TX,), mouse monoclonal anti–ubiquitin (Ub) antibody (1:1000, WB, 
U0508; Sigma-Aldrich Corp.), insulin-like growth factor 2 receptor (IGF2R) was a gift 
from Dr. Suhail Al-Salam (1:1000, WB, Sc-25462m Santa Cruz, Dallas, TX), 
AlexaFluor 568 goat anti-mouse IgG (1:200; Molecular Probes, Grand Island, NY, 
USA), and AlexaFluor 488 goat anti-rabbit IgG (1:2000; Molecular Probes). 
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Thermoscientific, UK: Anti-SYVN1/HRD1 (PA1-46121; 1:1000), Abcam, USA: anti-
SEL1L (ab78298; 1:400), anti-OS9 (ab19853; 1:400), anti-DER1 (ab93341: 1:500).  
Secondary antibodies for WB were anti-rabbit IgG (whole molecule)-peroxidase 
antibody produced in goat (A0545, 1:30,000; Sigma-Aldrich Corp.), anti-mouse IgG 
(whole molecule)-peroxidase antibody produced in rabbit (A9044, 1:50,000; Sigma-
Aldrich Corp.), and Pierce ECL plus WB substrate (32132; Thermo Scientific, 
Rockford, IL, USA).  
3.1.3 Cell culture  
 Human embryonic kidney (HEK 293T), HeLa, and COS-7 cells were obtained 
from ATCC (Manassas, VA, USA). HEK293 was a gift from Dr. Rajesh Mohanraj 
(Department of Pharmacology and Therapeutics, CMHS, UAEU). Bovine serum 
albumin was obtained from Fisher Scientific (Loughborough, UK). Dulbecco’s 
modified Eagle’s medium (DMEM) and PBS were obtained from Invitrogen (Grand 
Island, NY, USA). Fetal bovine serum (FBS), L-glutamine, and penicillin-
streptomycin were obtained from GIBCO (Grand Island, NY, USA). The liposomal 
transfection reagent FuGENE HD was purchased from Promega (Madison, WI, 
USA). 
3.1.4 cDNA clones 
TEK (NM_000459.1 ) Human cDNA open reading frame (ORF) clone construct 
was obtained from Origene (catalogue number SC119843, USA); Wild-type MUSK 
(NM_005592) Human cDNA ORF clone (Origene catalogue number: RC212253, 
USA). FZD4 construct was a gift from Dr. Jeremy Nathans (The John Hopkins 
University, Baltimore, Maryland, United States). 
3.1.5 Silencer select pre-designed siRNA 
 Silencer® Select Pre-designed siRNA (Life Technologies) were used for 
silencing. Three mers were chosen to cover the majority of transcriptional variants 
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for each gene in the study. Silencer® Select Negative controls (catalogue numbers 
4390843 and 4390846) were used as scrambled sequences for every experiment. 
Glyceraldehyde-3-phosphate dehydrogenase GAPDH (catalogue number 4390849) 
was used as a positive control for siRNA transfection efficiency.  
Table ‎3.1.1. The targeting sequences to knockdown SYVN1, SEL1L, OS9 and 
DER1. 
Gene Sense strand (5’-3’)  Antisense strand (3’-5’) 
SYVN1 
mer 1 
CCAGCAUCCCUAGCUCAGAtt UCUGAGCUAGGGAUGCUGGtg 
SYVN1 
mer 2 
CCUACUACCUCAAACACCAtt UGGUGUUUGAGGUAGUAGGcg 
SYVN1 
mer 3 
GCAUUGUCUCUCUUAUGUUtt AACAUAAGAGAGACAAUGCgg 
SEL1L 
mer 1 
GCACCGAUGUAGAUUAUGAtt UCAUAAUCUACAUCGGUGCca 
SEL1L 
mer 2 
GGAUAUUCACCUUGCGAAAtt UUUCGCAAGGUGAAUAUCCtg 
OS-9 
mer 1 
GUAUGGAGAUAAAAUCAUAtt UAUGAUUUUAUCUCCAUACtg 
OS-9 
mer 2 
GGAUGACAGUAAGGACUCAtt UGAGUCCUUACUGUCAUCCtt 
OS-9 
mer 3 
GGGAAAAUUGAGAUCAAAAtt UUUUGAUCUCAAUUUUCCCtg 
Der1  
mer 1 
GAGGCUCGGUAAUCAAUGAtt UCAUUGAUUACCGAGCCUCcg 
Der1  
mer 2 
GCUUAGCAAUGGAUAUGCAtt UGCAUAUCCAUUGCUAAGCca 
Der1  
mer 3 
GGGUUAUCCUUGGAUUCAAtt UUGAAUCCAAGGAUAACCCag 
3.2 Experimental Procedures 
3.2.1 Tagging of the cDNA construct 
In the first cycle four amino acids (DYKD) of the FLAG tag were introduced prior 
to the stop codon of the cDNA. In the second cycle, the resulting construct was used 
as a template and the remaining four amino acids (DDDK) were introduced. 
Similarly, the HA-tagged version of the wild-type FZD4 was generated by site-
directed mutagenesis to introduce the nine amino acids of the HA tag 
(YPYDVPDYA) in two cycles as shown below: 
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Table ‎3.2.1. Introduction of the HA and FLAG tags before the stop codon of FZD4 
cDNA gene. The sequences corresponding to the TAGs are highlighted in bold font.  
FZD4 Forward 5’-3’ Reverse 5’-3’ 
FZN4 HA 1    
GACTGTGGTATACCCATACGATG
TTTAAGGCTAGTCAGCCTCCATG 
CATGGAGGCTGACTAGCCTTAAAC
ATCGTATGGGTATACCACAGTC 
FZN4 HA 2   
TACGATGTTCCAGATTACGCTTA
AGGCTAGTCAGCCTCCATG   
CATGGAGGCTGACTAGCCTTAAGC
GTAATCTGGAACATCGTA 
FZN4 
FLAG 1 
GACTGTGGTAGATTACAAGGATT
AAGGCTAGTCAGCCTCCATG 
CATGGAGGCTGACTAGCCTTAATC
CTTGTAATCTACCACAGTC 
FZN4 
FLAG 2 
TACAAGGATGACGACGATAAGTA
AGGCTAGTCAGCCTCCATG   
CATGGAGGCTGACTAGCCTTACTT
ATCGTCGTCATCCTTGTA 
3.2.2 Molecular cloning of TEK 
TEK-WT cDNA; was amplified using primers which contain a C-terminal 
hemaglutinin (HA) tag and then restriction enzymes (RE), EcoRI and XhoI, were 
used to cut and clone into a pcDNA 3.1 /Zeo+ vector. The TEK cDNA-pcDNA 
3.1/zeo construct was subjected to site-directed mutagenesis for introduction of the 
RE and HA tag as shown below: 
Table ‎3.2.2. Molecular cloning of TEK. The sequences corresponding to the TAG 
and RE sites are highlighted in bold font.  
TEK HA Forward 5’-3’ 
 
TCGAATTCCCACCATGGACTCTTTAGCCAGCTTA 
TEK HA Reverse 5’-3’ 
 
AGCTCGAGCTAAGCGTAATCTGGAACATCGTATGG
GTAGGCCGCTTCTTCAGCAGAAC 
3.2.3 Generation of missense mutants 
All missense mutants were introduced by QuickChange site-directed 
mutagenesis with Turbo Pfu DNA polymerase (Stratagene) with wild-type Human 
cDNA as a template. Primers were generated using Primer X 
(http://www.bioinformatics.org/primerx/ [in the public domain]) and are shown: 
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Table ‎3.2.3. FZD4 missense primers used to generate the reported missense 
mutations used in this project. The mismatched nucleotides are highlighted in bold 
font.  
 Forward 5’-3’ Reverse 5’-3’ 
P33S 
(Pro33Ser) 
CTGCTGCTCCTGGGGTCGGCGC
GGGGCTTC 
GAAGCCCCGCGCCGACCCCAGGA
GCAGCAG 
G36D 
(Gly36Asp) 
CTGGGGCCGGCGCGGGACTTCG
GGGACGAG 
CTCGTCCCCGAAGTCCCGCGCCG
GCCCCAG 
H69Y 
(His69Tyr) 
CAACCTGGTTGGGTACGAGCTGC
AGAC 
GTCTGCAGCTCGTACCCAACCAG
GTTG 
C181R 
(Cys181Arg) 
AGCCTGGGGAAGAGCGTCACTCT
GTGGGAA 
TTCCCACAGAGTGACGCTCTTCCC
CAGGCT 
M105V 
(Met105Val) 
GTTCTGTTTATGTGCCAGTGTGC
ACAGAGAAGATC 
GATCTTCTCTGTGCACACTGGCAC
ATAAACAGAAC 
M105T  
(Met105Thr) 
CTGTTTATGTGCCAACGTGCACA
GAGAAGATC 
GATCTTCTCTGTGCACGTTGGCAC
ATAAACAG 
C204R 
(Cys204Arg) 
CTGTGTGCTCAAGCGTGGCTATG
ATGC 
GCATCATAGCCACGCTTGAGCACA
CAG 
C204Y  
(Cys204Tyr) 
CTGTGTGCTCAAGTATGGCTATG
ATGCTGG 
CCAGCATCATAGCCATACTTGAGC
ACACAG 
G488D 
(Gly488Asp) 
CTTTGTTGGTGGACATCACTTCA
GG 
CCTGAAGTGATGTCCACCAACAAA
G 
W335C 
(Trp335Cys) 
CAGCAGGACTCAAATGCGGTCAT
GAAGCCATTG 
CAATGGCTTCATGACCGCATTTGA
GTCCTGCTG 
R417P 
(Arg417Pro) 
GGCCTTGTTCAAAATTCCGTCAAA
TCTTCAAAAGG 
CCTTTTGAAGATTTGACGGAATTTT
GAACAAGGCC 
R417Q 
(Arg417Glu) 
GGTGGCCTTGTTCAAAATTCAGT
CAAATCTTCAAAAGGATGG 
CCATCCTTTTGAAGATTTGACTGA
ATTTTGAACAAGGCCACC 
T445P 
(Thr445Pro) 
CTCAGTACTGTACCCAGTTCCTG
CAACG 
CGTTGCAGGAACTGGGTACAGTA
CTGAG 
G492R 
(Gly492Arg) 
GGGCATCACTTCACGCATGTGGA
TTTGG 
CCAAATCCACATGCGTGAAGTGAT
GCCC 
S497P 
(Ser497Pro) 
GCATGTGGATTTGGTTTGCCAAA
ACTCTTCAC 
GTGAAGAGTTTTGGCAAACCAAAT
CCACATGC 
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Table ‎3.2.4. MuSK missense primers used to generate the reported missense 
mutations used in this project. The mismatched nucleotides are highlighted in bold 
font. 
Mutation Forward Primer 5’-3’ Reverse Primer 5’-3’ 
T114A 
(Asp38Glu) 
CTCTTGAAACAGTGGAAGCCT
TAGTTGAAGAAG  
CTTCTTCAACTAAGGCTTCCA
CTGTTTCAAGAG  
C1031G 
(Pro344Arg) 
CAACACCTCCTATGCGGACCG
AGAGGAGGCCCAAGAGCTAC 
GTAGCTCTTGGGCCTCCTCTC
GGTCCGCATAGGAGGTGTTG 
G1815A 
(Met605Ile) 
CTATGAACCTTTCACTATAGT
GGCAGTAAAGATGCTC 
GAGCATCTTTACTGCCACTAT
AGTGAAAGGTTCATAG 
C2180T 
(Ala727Val) 
CACCGAGATTTAGTCACCAGG
AACTGCC 
GGCAGTTCCTGGTGACTAAAT
CTCGGTG 
G2368A  
(Val790Met) 
GATGTGTGGGCCTATGGCAT
GGTCCTCTGGGAGATC 
GATCTCCCAGAGGACCATGCC
ATAGGCCCACACATC 
A2503G 
(Met835Val) 
GAGCTGTACAATCTCGTGCGT
CTATGTTGG 
CCAACATAGACGCACGAGATT
GTACAGCTC 
Dead kinase 
K609A 
(Lys609Arg) 
CACTATGGTGGCAGTAGCGAT
GCTCAAAGAAGAAG 
 
CTTCTTCTTTGAGCATCGCTA
CTGCCACCATAGTG 
 
 
Table ‎3.2.5. TEK missense primers used to generate the reported missense 
mutations used in this project. The mismatched nucleotides are highlighted in bold 
font. 
Mutation Forward Primer 5’-3’ Reverse Primer 5’-3’ 
R849W 
(C2545T) 
GAAGGATGGGTTATGGATGGA
TGCTGCC 
GGCAGCATCCATCCATAACCC
ATCCTTC 
Y897C 
(A2690G) 
GAACATCGAGGCTGCTTGTAC
CTGGC 
GCCAGGTACAAGCAGCCTCG
ATGTTC 
Y897S 
(A2690C) 
GAACATCGAGGCTCCTTGTAC
CTGGC  
GCCAGGTACAAGGAGCCTCG
ATGTTC  
R915H 
(G2744A) 
CTGGACTTCCTTCACAAGAGC
CGTGTG 
CACACGGCTCTTGTGAAGGAA
GTCCAG  
R918C 
(C2752T) 
CTTCGCAAGAGCTGTGTGCTG
GAGAC 
GTCTCCAGCACACAGCTCTTG
CGAAG 
A925S 
(G2773T) 
GGAGACGGACCCATCATTTGC
CATTGC 
GCAATGGCAAATGATGGGTCC
GTCTCC 
V919L 
(G2755T) 
CTTCGCAAGAGCCGTTTGCTG
GAGACGGAC 
GTCCGTCTCCAGCAAACGGCT
CTTGCGAAG 
K1100N 
(G3300C) 
 
GTTAGAGGAGCGAAACACCTA
CGTGAATAC 
GTATTCACGTAGGTGTTTCGC
TCCTCTAAC 
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3.2.4 DNA sequencing 
Deoxyribonucleic acid sequencing was performed using the dideoxy Sanger 
method with fluorescent automated sequencing on the ABI 3130xl Genetic Analyzer 
(Applied Biosystems, Foster City, CA, USA). Data were analyzed using sequencing 
analysis ABI software version 5.3 (Applied Biosystems). ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/ [in the public domain]) was used for 
sequence alignments.  
3.2.5 Cell culture and transfection  
HeLa, COS-7, and HEK293 cells were cultured in DMEM supplemented with 
10% FBS, 2 mM L-glutamine, and 100 U/mL penicillin-streptomycin at 37 °C with 
5% carbon dioxide. For immunofluorescence (IF), cells were grown on sterile 
coverslips in 24-well tissue culture plates. Transfection was performed after 24 
hours of seeding using the liposomal transfection reagent FuGENE HD (Promega) 
according to the manufacturer’s instructions. For each well, 1-2 µg of wild-type or 
mutant constructs were used. Forty-eight hours post transfection, the cells were 
fixed and processed for confocal fluorescence microscopy (CFM) as described in 
section ‎3.4.7. For WB, 1 day before transfection cells were seeded on six multiwells 
(35 mm in diameter) and grown to about 70% confluency. Transfection was 
performed using the FuGENE HD transfection reagent (Promega) according to the 
manufacturer’s instructions.  
3.2.6 siRNA transfection  
Stable HEK293 cell lines of MuSK-WT, P344R-MuSK were cultured in reduced 
serum-free media (OptiMEM) at 37 °C with 5% carbon dioxide. Transfection was 
performed using the FuGENE HD transfection reagent according to the 
manufacturer’s instructions. The cells were transfected with siRNA for 72 hours. 
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3.2.7 Immunofluorescence and confocal fluorescence 
microscopy  
For immunofluorescence (IF), cover slips-grown HeLa, HEK293 or COS-7 cells 
were washed with PBS, fixed with cold methanol at -20 ˚C for 7 minutes. Then fixed 
cells were then washed in PBS three times and incubated in blocking solution (10% 
BSA in PBS) for 1 hour at room temperature. The fixed cells were then incubated for 
1 hour at room temperature with the primary monoclonal antibodies (anti-FLAG) 
alone or co-incubated with anti-calnexin polyclonal antibodies. After washing with 
PBS, the cells were incubated with the appropriate fluorescently-labelled secondary 
antibodies for 1 hour at room temperature then washed several times with PBS and 
mounted in immunofluor medium. We used enhanced green fluorescent protein-
Harvey rat sarcoma viral oncogene homolog (EGFP HRAS) as a marker for the 
plasma membrane [203]. In this case, the EGFP HRAS construct was co-
transfected with MUSK constructs. Data were acquired using a Nikon confocal 
microscope (Tokyo, Japan). For presentation purposes, images were pseudo-
colored as either red (protein of interest) or green (calnexin and EGFP-H-Ras), 
contrast enhanced and merged using ImageJ version 1.47 (http://rsbweb.nih.gov/ij 
[in the public domain]). All images presented are single sections in the z plane. 
Colocalizations were quantitated when required using ImageJ version 1.47 or fiji 
http://fiji.sc/Colocalization_Analysis [public domain] [204]. 
3.2.8 Protein extraction and immunoprecipitation  
Immunoprecipitation (IP) was used to isolate the expressed proteins from whole 
cell lysates of HEK293 cells or HEK293T. Forty eight hours following transfection, 
the cultured media was removed and cells were gently washed twice with ice cold 
PBS. After washing, 200 µl of ice cold lysis “MuSK extraction buffer” containing: 10 
mM HEPES, pH 7.9, 417 mM NaCl, 10mM KCL, 1% IGEPAL, 0.8mM EDTA and 2 
mM dithiothreitol (DTT) or radioimmunoprecipitation assay buffer (RIPA) containing 
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protease inhibitors was added to the dishes and incubated on ice for 10-15 minutes. 
Immediately after lysis, the NaCl concentration was adjusted and maintained at 400 
mM. The cell lysates were then centrifuged at 1000 xg for 15 minutes at 4 ˚C. The 
supernatants were then transferred to a new tube without disturbing the pellet. 
Proteins were quantified by a BCA kit according to the manufacturer’s instructions. A 
“MuSK extraction buffer” containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 1.5mM 
MgCl2, 1 mM EGTA, 1% Triton-X 100 and 10% glycerol was added to 0.5mg of cell 
lysate to a final volume of 400 µl. Two micrograms of rabbit anti-FLAG antibodies 
were added to the solution and incubated at 4 ˚C on a rotator for 1-3 hours then 30 
µl of pre-equilibrated protein Sepharose A/G with protease inhibitors was added and 
incubated at 4˚C for 2 hours to capture the immune complex. The tubes were 
centrifuged at 1000 xg for 1 minute at 4˚C and the supernatant was carefully 
removed. The Sepharose A/G beads were washed three times with PBS buffer, re-
centrifuged and the supernatant removed.  
3.2.9 Generation of HEK293 stable cell lines  
HEK 293 cells were stably transfected with MUSK-WT, P344R-MuSK constructs 
and an empty vector using a PCMV6-entry vector with a neomycin resistance 
cassette. Stable clones were selected for use with 700 µg/µl Geneticin® antibiotic 
(G418) for 4 weeks. Single clones for MUSK-WT and P344R-MuSK and the empty 
vector, as a control, were maintained at the same concentration.  
3.2.10 Deglycosylation assays 
Approximately 20 µg of the IP eluates were added to 5 µl of denaturation solution 
(containing 2% sodium dodecyl sulphate (SDS) and 1 M β-mercaptoethanol (BME)) 
and heated to 100 °C before the addition of 5 µl of sodium phosphate buffer (250 
mM, pH 5.5 for endo-β-N-acetylglucosaminidase H (Endo H) and buffer 7.4 for 
peptide-N(4)-(N-acetyl-beta-glucosaminyl) asparagine amidase (PNGase F). For 
Endo H; 2 µl of Endo H enzyme was added to each sample and incubated overnight 
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at 37 ˚C. For PNGase F, 2 units of enzyme were added and the samples incubated 
for 24 hours at 37 °C and then another 2 units of enzyme were added for a further 
24 hours. The treated samples were then subjected to SDS-PAGE and western 
blotting using anti-FLAG antibodies as described below.  
3.2.11 Western blot analysis  
Eluates of immunoprecipitation or whole cell lysates were treated with 6X 
Laemmli buffer. 30 µg of protein from control (untransfected cells), WT and mutant 
preparations were subjected to 8-15% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. After 1 
hour of blocking in 3% non-fat dry milk (NFM) in TRIS-buffered saline (TBS) PH 8; 
0.05% (w/v) Tween 20 (T), nitrocellulose blots were incubated for 1 hour with the 
appropriate primary antibodies in 3% NFM-TBS-T. Following washing with TBS-T, 
membranes were then incubated with rabbit anti-mouse IgG-peroxidase antibody or 
goat anti-rabbit IgG-peroxidase antibody in TBS-T containing 3% NFM for 1 hour 
and developed by Pierce ECL plus WB reagents (Thermo Scientific). All blots were 
viewed with Typhoon FLA 9500 ImageQuant TL software (GE Healthcare Sciences, 
Uppsala, Sweden). 
3.2.12 Glycine elution of immunoprecipitates 
Following immunoprecipitation, proteins were eluted from the Sepharose beads 
using 0.2 M glycine buffer at PH 2.6. 50 µl of glycine buffer was added to the beads 
and incubated for 10 minutes with frequent agitation before centrifugation. The 
eluates were pooled and neutralized by adding equal volumes of Tris pH 8.0. The 
beads were then neutralized by washing 2 times with 150 µl lysis buffer (without 
detergent) and pooled with eluates. 
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3.2.13 Cell-surface biotinylation  
HEK293 cells underwent cell surface biotinylation according to the 
manufacturer’s instructions. Briefly, cells were grown to a monolayer, serum-starved 
for 4 hours and then treated with chemical chaperones for 7 hours. Surface proteins 
were biotinylated by applying 0.5 ml of NHS-S-S-biotin in PBS for 30 minutes at 4°C 
on the apical side. After quenching, filters were excised and cells were lysed with 
0.5 ml lysis buffer containing protease and phosphatase inhibitors. Lysed samples 
were briefly sonicated, centrifuged at 13,000 rpm for 10 minutes at 4°C, and the 
supernatant was collected and used for protein assay and pull-down experiments. 
Biotinylated proteins were pulled down with streptavidin-agarose beads. Bound 
proteins were eluted by incubating the beads in a sample buffer containing urea, 
protease and phosphatase inhibitor cocktails at 100 °C for 5 minutes. The samples 
were centrifuged at 10,000 rpm for 5 minutes, and the supernatant was separated 
and mixed with 0.125 ml of trichloroacetic acid (TCA), incubated for 10 minutes on 
ice, and centrifuged at 14,000 rpm for 5 minutes. Supernatants were discarded and 
pellets washed three times with ice-cold acetone. The pellets were air-dried and 
protein quantified before it was processed for SDS-PAGE. For immunoblotting, 
proteins were separated by SDS-PAGE, followed by immunoblotting with anti-FLAG 
antibodies. The integrity of the plasma membrane and cell surface specific 
biotinylation and equal loading was confirmed using the IGF2R as a control. Blots 
were quantified as described above and normalized to the total plasma membrane 
receptor fraction.  
3.2.14 Cylcoheximide protein synthesis inhibition 
Half-life (t1/2) experiments employing cycloheximide (CHX) inhibition of protein 
synthesis were performed as described previously [205]. Cultures were treated with 
CHX (final concentration of 50 μg/ml) for the time periods indicated. In some cases 
the cultures were treated with inhibitors (45–60 minutes for proteasome inhibitors) 
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prior to harvesting, or the addition of CHX. The cells were lysed in lysis buffer plus 
inhibitors and lysates were run on a 8% SDS-PAGE gel. All t1/2 and MG132 plus 
CHX experiments were repeated three or more times. A 0.1% DMSO vehicle was 
used as a control. 
3.2.15 Proteasome inhibition 
Proteasome inhibitor MG132 at a concentration of 25 µM was added at the time 
periods indicated. The cell lysates were subjected to SDS-PAGE and 
immunoblotting with anti-FLAG antibodies. A 0.1% DMSO vehicle was used as a 
control.  
3.2.16 Anti-ubiquitin western blotting 
Following IP and SDS-fractionation on an 8% SDS-PAGE gel, the immunoblots 
were stripped by a stripping buffer, washed 3X with TBS-T and then autoclaved as 
previously described [206]. The blots were then blocked with 1% NFM in TBS-T 
(0.05% w/v Tween 20). TBS contained (per liter) 8g NaCl, 0.2g of KCL and 3g of 
Tris-base and was adjusted to a PH of 7.4. Anti-ubiquitin antibody was diluted 
1:1000 in 1% NFM in TBS-T and incubated overnight at 4 ˚C. The blots were 
washed 3X with TBS-T and incubated with secondary antibodies for 1 hour in 1% 
NFM-TBST and processed as described above. 
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3.2.17 Colocalization analysis 
Colocalization with calnexin and/or H-Ras was measured as a function using Fiji 
and then compared with WT on multiple CFM image sections of at least 30 cells in 
three independent experiments.  
Example 1: Merged protein colocalizes well with calnexin 
1. Merged images; split channels  
  
2. Choose parameters: e.g. Scatterplot with linear regression fit (white line) and 
correlation  
 
3. Results based on Pearsons coefficients (R) and Manders coefficients (M); 
 
4. Interpret results for colocalization  
Manders: 0 is no colocalization; 1 is perfect colocalization 
Pearsons: Rcoloc for whole image close to 1; very good colocalization 
R< threshold: <0 
Linear regression line: gradient (m) close to 1; intercept (b) close to 0 
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Example 2: Merged protein does not colocalize well with HRAS 
1. Merged images; split channels  
 
2. Choose parameters: e.g. Scatterplot with linear regression fit (white line) and 
correlation  
 
3. Results based on Pearsons coefficients (R) and Manders coefficients (M); 
 
4. Interpret results for colocalization  
Manders: 0 is no colocalization; 1 is perfect colocalization 
Pearsons: Rcoloc for whole image close to 1; very good colocalization 
R< threshold: <0 
Linear regression line: gradient (m) close to 1; intercept (b) close to 0 
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3.2.18 Quantification  
All blots were quatitified on both Typhoon FLA 9500 ImageQuant TL software 
and ImageJ version 1.47. An example of quantification using ImageJ version is 
shown below: 
1. The region of choice to be quantified is selected 
 
2. Calibration of the optical density (OD) 
  
3. Each lane is highlighted  
 
4. The protein is estimated in each lane and is plotted  
 
5. The output file can be used for normalization or expressed as a function  
 
3.2.19 Statistical analysis 
All statistical analyses were carried out on GraphPad (http://www.graphpad.com). 
Unpaired students t test was used for statistical comparisons. The mean ± standard 
error of each experiment with the N value. 
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Chapter 4: Results and Findings  
4.1 Frizzled Family Receptor 4 (FZD4) reported to cause 
Familial Exudative Vitreoretinopathy (FEVR) 
4.1.1 Introduction 
Familial Exudative Vitreoretinopathy (FEVR) (Online Mendelian Inheritance in 
Man 133780) is a developmental anomaly characterized by incomplete or no 
vascularization of the peripheral retina [207]. Patients with FEVR exhibit highly 
variable expressions of the disease, ranging from asymptomatic to complete 
blindness. FEVR is genetically heterogeneous and can be inherited in a dominant 
manner via frizzled class receptor 4 (FZD4), low-density lipoprotein receptor related 
protein 5 (LRP5), or tetraspanin 12 (TSPAN12) genes.  
This condition can also be inherited in a recessive manner via mutations in the 
LRP5 gene or in an X-linked fashion through mutations in the Norrin (NDP) gene 
[208]. However, the autosomal dominant inheritance is by far the most common 
cause of FEVR. Mutations in FZD4, a wingless-type mouse mammary tumor virus 
integration site family (Wnt) receptor, have been shown to cause premature arrest of 
retinal angiogenesis in patients with FEVR [209]. In addition, mutations in this 
protein have been linked to retinopathy of prematurity, a condition with phenotypic 
overlap with FEVR [210]. 
The seven-pass transmembrane FZD4 protein has a highly conserved 
extracellular frizzled cysteine-rich domain frizzled (Fz-CRD) (Figure ‎4.1.1). This N-
terminal extracellular CRD is conserved among Fz family members and determines 
binding specificity for Wnt ligands. The intracellular domains contain threonine-X-
valine PDZ-binding and lysine-threonine-X-X-X-tryptophan disheveled association 
sites [211]. The NDP/FZD4 proteins are involved in the wingless (Wnt) signaling 
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pathway controlling a transcriptional program that regulates endothelial growth and 
maturation throughout the course of retinal vascular development [212-214]. 
To date, 58 different FEVR pathogenic mutations have been reported for FZD4, 
of which 31 are missense changes scattered throughout the protein structure [215]. 
All the mutations except R417Q have been shown to cause the disease in the 
heterozygous state [216]. However, patients have been diagnosed as having more 
severe forms of FEVR when both alleles of FZD4 gene are mutated [210]. 
Studies on the cellular localization of FZD4 pathogenic mutations and their 
functional implications are scarce. A deletion of two nucleotides that led to a 
frameshift and created a stop codon at residue 533 (L501fsX533) resulted in a 
defective PDZ-binding motif and hence loss of FZD4 function in the 
calcium/calmodulin-dependent protein kinase II and protein kinase C signaling 
pathway [217]. A FZD4 haploinsufficiency effect was postulated to be the causative 
defect underlying FEVR in a patient hemizygous for FZD4 [218]. Due to the nature 
of the missense mutations and the importance of the CRD domains for proper 
protein folding [148]. It was hypothesized that some of the missense mutations in 
FZD4 might lead to protein misfolding and failure to pass the stringent endoplasmic 
reticulum (ER) quality control machinery. Proteins that fail this machinery are 
targeted for degradation by ER-associated protein degradation (ERAD). As detailed 
in the literature review chapter (chapter 2), protein misfolding is the underlying 
cause of numerous highly debilitating disorders, ranging from Alzheimer Disease to 
Cystic Fibrosis [1, 18, 148, 149]. 
I examined the trafficking of 15 FZD4 missense mutations causing FEVR, shown 
in Figure 4.1.1. I characterized these mutations for their cellular processing, 
subcellular localization, and polyubiquitination profiles and compared them with wild-
type (WT). I co-expressed the mutant constructs with WT construct to determine if a 
dominant-negative effect contributes to the disease pathology. I also evaluated 
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culturing the expressing cells at reduced temperatures or in the presence of 
chemical chaperones in an attempt to rescue trafficking defects of some mutants. 
My data suggest trafficking defects as the major disease mechanism underlying nine 
of the mutations studied, namely P33S [219], G36D [220], H69Y [221], M105V [210] 
M105T [220], C181R [221], C204Y [222], C204R [223], and G488D [210].  
4.1.2 Results 
4.1.2.1 Nine of 15 FZD4 mutants are predominantly localized to the 
ER 
Fifteen FEVR-causing missense mutations shown in Figure ‎4.1.1 were generated 
by site-directed mutagenesis, and their localization was assessed in both HeLa and 
COS-7 cell lines using IF and CFM following transient expression. The data for the 
COS-7 cell line are not shown but were always consistent with the HeLa cell line 
results. In both cell lines, the ER lectin chaperone calnexin was stained to establish 
colocalization with the ER network. In contrast to the WT-FZD4 construct, seven 
(P33S, G36D, H69Y, M105T, C204R, C204Y, and G488D) of the 15 tested mutants 
exhibited high degrees of colocalization with calnexin, suggesting mislocalization 
away from the plasma membrane in a perinuclear and reticular pattern, suggestive of 
the ER (Figure ‎4.1.2A [panels B–J are compared with panel A of WT-FZD4]). 
In addition, two mutants (M105V and C181R) showed partial ER localization with 
some residual protein localizing to the PM (Figure ‎4.1.2A [compare with panels F, 
G]). Figure ‎4.1.2B shows quantification of the degree of colocalization of mutants 
with calnexin compared with WT. The localization of the other six FEVR-causing 
mutants (W335C, R417P, R417Q, T445P, G492R, and S497P) resembled WT-
FZD4 on the plasma membrane (Figure ‎4.1.4).   
67 
 
 
Figure ‎4.1.1. Illustration of FZD4 protein domain structure. Frizzled family receptor 
4 is a seven-pass transmembrane protein with a signal peptide sequence found 
between amino acid positions 1 and 36/37, a Fz-CRD domain highlighted in green 
found at amino acid positions 42 through 167, a frizzled region spanning most of 
the protein within amino acid positions 210 through 514, a KTXXXW motif found at 
amino acid positions 499 through 504, and a PDZ motif located close to the C-
terminal at amino acid positions 535 through 537. The two potential N-glycosylation 
sites are indicated by arrows at amino acid positions 59 and 144. Missense FEVR-
causing mutations studied in this article are labeled across the protein. Missense 
mutations that traffic abnormally are shown with red stars (P33S, G36D, H69Y, 
M105T, M105V, C181R, C204R, C204Y, and G488D). 
To further assess the subcellular localization, WT-FZD4 and the 15 FZD4 FEVR-
causing mutant constructs were cotransfected in HeLa cells with EGFPHRAS 
plasmid, the latter acting as a plasma membrane marker. The same seven mutants 
(P33S, G36D, H69Y, M105T, C204R, C204Y, and G488D) exhibited a distinct 
perinuclear reticular pattern that is clearly different from the EGFP-H-Ras, 
establishing mislocalization away from the plasma membrane (Figure ‎4.1.3B–E, H–
J). A dual pattern of ER and PM localization for M105V and C181R mutants was 
once again observed (Figure ‎4.1.3F, 3G). The data in HeLa and COS-7 cell lines 
suggest that this mislocalization of the FEVR-causing FZD4 mutants is not cell-type 
specific. 
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Figure ‎4.1.2. Colocalization of several FZD4 missense mutants with the ER marker 
in HeLa cells. CFM images of WT-FZD4 and FZD4 mutants (P33S, G36D, H69Y, 
M105T, M105V, C181R, C204R, C204Y, and G488D) show the colocalization of 
these mutants with calnexin, an ER marker. A FLAG epitope expressed WT-FZD4 
protein, and mutants are seen in red on the left of each panel, and calnexin is shown 
in green in the middle image of each panel. The image on the right is the merging of 
the two signals. (A) Shown is WT-FZD4 localization to the plasma membrane, which 
is distinct from that of calnexin. In contrast, as shown in (B–J), these missense 
mutants are largely localized to an intracellular compartment that is perinuclear and 
reticular in nature and colocalizing with calnexin, suggestive of an ER localization. 
However, C181R and M105V seem to be partially localized to the ER, with some 
localization to the PM. Cells were transfected for 48 to 72 hours and then processed 
for IF as described in the Methods section. (B) Colocalization with calnexin was 
measured as a function and then compared with WT on multiple CFM image 
sections of at least 30 cells repeated for three independent experiments (mean [SE] 
of each experiment). Data (arbitrary units) are expressed as the mean (SE). ***P < 
0.001 compared with WT control. These images are representative images. No 
differences were found between the mutants’ phenotype (localization patterns). 
Scale bar: 25 µm. Magnification: 100X. 
 
4.1.2.2 N-glycosylation profiling of the nine mutants is consistent 
with imaging data confirming ER retention 
To further assess the subcellular localization of the ER-retained mutants, Endo H 
sensitivity and resistance in vitro assays on the expressed proteins were carried out. 
The FZD4 protein has two potential N-glycosylation sites in its extracellular domain 
(Figure ‎4.1.1, arrows). The principle of this assay is that the carbohydrate moieties 
of the ER-localized glycoproteins are cleavable by Endo H, whereas the post-ER 
species are resistant due to further remodeling of their N-glycans in the Golgi 
complex. Endo H cleaves after the first asparagine-linked N-acetylglucosamine (N-
glycan) of high-mannose and hybrid polysaccharides.  
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Figure ‎4.1.3. Exclusion of the seven missense FZD4 mutants from the plasma 
membrane in HeLa cells. The CFM images of WT-FZD4 and FZD4 mutants P33S, 
G36D, H69Y, M105T, M105V, C181R, C204R, C204Y, and G488D (red in the 
images on the left side of each panel) show their localization in HeLa cells relative to 
H-Ras, a plasma membrane marker (shown in the green image in the middle of 
each panel). The FLAG epitope-expressed WT-FZD4 protein in (A) indicates 
colocalization, with H-Ras indicating plasma membrane localization. However, (B–J) 
show that the mutants are largely excluded from the PM and localized to the 
perinuclear region, implying ER localization. C181R and M105V seem to be partially 
retained in the ER, with some PM localization, validating the data shown in Figure 2. 
Cells were transfected for 48 to 72 hours and then processed for IF. These images 
are representative images. No differences were found between the mutants’ 
phenotype (localization patterns). Scale bar: 25 µm. Magnification: 100 X. 
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Figure ‎4.1.4. Six of the fifteen mutants localized to PM resembling the WT protein. 
Confocal images of the missense disease causing mutants in a HeLa cell line. Far 
left: confocal images of FZD4 mutants: W335C, R417Q, R417P, T445P, G492R and 
S497P showing their localization in HeLa cells alongside calnexin, an endoplasmic 
reticulum marker. Flag epitope expressed protein is seen as red fluorescence (far 
left) under the confocal microscope and the ER resident protein calnexin as green 
fluorescence (middle panel). When the two images are merged together, merge (far 
right) localization can be viewed clearly. Panels J-O clearly localize on the plasma 
membrane. Cells were transfected for 48 hours and then processed for IF. Scale bar 
= 25 µm; 100X objective lens. Far right: Confocal images of FZD4 mutants: W335C, 
R417Q, R417P, T445P, G492R and S497P showing their localization in HeLa cells 
alongside H-Ras, a plasma membrane marker. Flag epitope expressed protein is 
seen as red fluorescence (far left) under the confocal microscope and the PM 
resident protein as green fluorescence (middle panel). When the two images are 
merged together, merge (far right) localization can be viewed clearly. Panels J-O 
clearly localize on the plasma membrane. Cells were transfected for 48 hours and 
then processed for IF. These images are representative images. No differences 
were found between the mutants’ phenotype (localization patterns). Scale bar = 25 
µm; 100X objective lens.  
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Therefore, one can expect that the mutants retained in the ER will have their N-
glycans cleaved when treated with Endo H. Proteins that have reached the Golgi 
complex would be resistant to Endo H treatment. Upon Endo H treatment, P33S, 
G36D, H69Y, M105V, M105T, C204Y, and C204R mutants showed complete 
conversion of the high-molecular-weight band into a lower-molecular-weight band, 
suggesting that these mutants are still in their immature states (Figure ‎4.1.5A). On 
the other hand, WT-FZD4 showed resistance to this treatment (Figure ‎4.1.5A). 
Interestingly, the C181R mutant gave two bands, one higher-molecular-weight 
band similar to the mature-form WT-FZD4 and a smaller-molecular-weight band 
that suggested incomplete ER retention of this protein (Figure ‎4.1.5A). 
Quantification of this is shown in Figure ‎4.1.5B. This observation may indicate that 
the change in amino acid may cause slow trafficking of this mutant to the PM. 
Interestingly, the M105V mutant, which previously appeared by IF to show a mixed 
localization between the ER and PM, resulted in one immature band. This may 
suggest that expression of the M105V mutant protein on the PM is somewhat 
minimal due to slow trafficking. It was notable that Endo H-treated and Endo H-
untreated P33S and G488D samples showed a higher molecular weight band 
which was presumed to be due to dimerization and possibly oligomerization 
(Figure ‎4.1.5A). This behavior in FZD4 has been observed previously by other 
researchers [20, 224, 225] and is shown in Figure ‎4.1.7.  
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Figure ‎4.1.5. N-glycosylation profiles for the ER-retained mutants and WT-FZD4. In 
whole-cell lysates (WCL), WT-FZD4 expressed protein has been seen as a 
monomer, dimer, and multimers at the top of an SDS-PAGE gel ( Figure ‎4.1.6). 
Wild-type FZD4 and mutants were pulled down with mouse anti-FLAG antibodies, 
followed by sepharose A/G bead sedimentation as described in the Methods 
section. Upon elution, 20 µg protein was treated and then digested with Endo H for 
5 hours with 60 mM DTT and 8 M urea (v/v) as described in the Methods section. 
P33S, M105T, and G488D mutants show an immature FZD4 protein, with lower-
molecular-weight bands compared with WT-FZD4 and its treated counterpart, 
suggestive of possible folding defects. The monomer’s molecular weight of FZD4 is 
approximately 60 kDa. Mutants P33S, G36D, H69Y, M105T, C204R, C204Y, and 
G488D were cleavable with Endo H, demonstrating their predominant localization in 
the ER. M105V and C181R were shown to have a dual pattern by CFM. However, 
when the M105V mutant was subjected to Endo H treatment, a single lower-
molecular-weight band was observed. On the other hand, two bands, one mature 
and one immature, were observed for C181R. Furthermore, P33S and G448D 
formed dimers and probably multimers on Endo H treatment at a temperature of 37 
ºC. Molecular mass standards are indicated in kDa. Quantification was carried out 
by Typhoon FLA 9500 ImageQuant TL software (GE Healthcare Life Sciences). 
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Figure ‎4.1.6. Percent of protein resistant and sensitive to Endo H. A bar chart in 
shows the percent of Endo H-resistant and Endo H-sensitive species for each 
sample in Figure ‎4.1.5. Wild-type is almost exclusively resistant to Endo H, whereas 
all the mutants (with the exception of C181R) are exclusively Endo H sensitive. 
 
 
Figure ‎4.1.7. Western blot analysis of whole cell lysate from HEK293 cells 
transfected with FZD4 wild type construct. FZD4 homo and hetero-oligomerizes to 
form higher order dimers and oligomers on an 8% SDS-PAGE gel. The size of 130 
kDa is consistent with the expected molecular mass of a Wnt dimer. A band at 78 
kDa has previously been observed as HSPA5/BiP associating with Wnt receptors 
[226]. The higher order oligomers are possibly comprised of FZD4 with or without 
the BiP chaperone protein or aggreagates of FZD4 protein.  
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4.1.2.3 The ER-retained mutants are highly polyubiquitinated 
 To determine if the ER-retained mutants are targeted for ERAD, HEK293T 
cells were transiently transfected with WT or mutant FZD4 plasmids. The expressed 
proteins underwent IP and were subjected to SDS-PAGE and probed with anti-
FLAG antibodies (Figure ‎4.1.8B), stripped, and re-probed with anti-Ub antibodies. 
Immunostaining by anti-Ub antibodies showed a striking smear of presumably 
multiple Ub-moieties attached to FZD4-mutant conjugates at the top of the resolving 
gel (Figure ‎4.1.8A). Conjugates with multiple Ub moieties in the form of branched 
chains appear to be associated with the seven FZD4 mutants to a much greater 
extent compared with WT (Figure ‎4.1.8C). These data suggest that the seven ER-
retained mutants are probably targeted for degradation by the proteasome via 
ERAD machinery. 
4.1.2.4 The effect of reducing temperature and incubation with 
different compounds directed at promoting folding and PM 
expression  
 Interestingly, ∆F508-CFTR mutants here shown to be mainly retained in the ER 
as a result of misfolding. However, when a small amount of the ∆F508-CFTR protein 
is expressed on the cell surface, it retains significant chloride channel conductance 
activity [29, 165]. Such results provided insight and proof of the principle that the 
molecular machinery directing folding and export could have an important role in 
both understanding the molecular basis for disease and developing novel 
therapeutic interventions [29, 227-229]. 
 In addition, it has been shown that cell membrane expression of functional 
∆F508-CFTR can be achieved by culturing the expressing cells at lower 
temperatures [30, 32]. Low-temperature incubation of affected tissues in CF is not a 
viable therapeutic option. However, incubation at lower temperatures may provide 
proof of the principle that the kinetic and/or thermodynamic aspects of secretory 
protein folding can be manipulated and therefore prevent targeting of the mutant 
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proteins to the ERAD machinery. Of the nine ER-retained mutants, M105T and 
C204Y showed partial rescue of trafficking to the PM by 57% and 46%, respectively, 
upon culturing the expressing cells at 27 °C (Figure ‎4.1.9). 
 
Figure ‎4.1.8. Polyubiquitination pattern of WT-FZD4 and ER-retained FZD4 mutants. 
(A) Immunoprecipitations of WT-FZD4, P33S, G36D, H69Y, M105T, C204Y, C204R, 
and G488D mutants were run on an 8% SDS-PAGE, blotted on nitrocellulose, and 
probed with anti-FLAG antibodies. The blots were then washed overnight with TBS-
T, stripped, autoclaved [171], and then reprobed with anti-Ub monoclonal antibodies 
as described in the Methods section. The samples of the seven ER-retained 
mutants show very-high-molecular-weight smears, suggesting polyubiquitination. 
Wild-type FZD4 also seems to be ubiquitinated, albeit to a much lesser extent. (B) 
Shown is an immunoblot of IP WT-FZD4, P33S, G36D, H69Y, M105T, C204Y, 
C204R, and G488D with anti-FLAG antibody before stripping for polyubiquitination 
studies. (C) Quantification of the polyubiquitination blot presented above is shown. 
Considerably higher levels of ubiquitination are observed for the mutants compared 
with WT. A negative IP is presented for comparison. Quantification was carried out 
by Typhoon FLA 9500 ImageQuant TL software (GE Healthcare Life Sciences). 
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 Different compounds have been shown to rescue folding of mutant proteins [35, 
157, 162]. The IF pattern of M105T and C204R mutants when cultured in the 
presence of 7.5% glycerol showed escape from ER retention by approximately 50% 
and 32%, respectively (Figure ‎4.1.9B–E). This observation indicates that glycerol 
enhances protein processing and exits mutant protein from the ER to the cell 
surface, although its trafficking is expected to be slower than WT.  
 In addition, M105T and C204Y mutants were treated with 0.1% DMSO 
(Figure ‎4.1.9C), 10 µM thapsigargin, or 1 µM curcumin (data not shown). The 
M105T mutant showed partial PM distribution when treated with 0.1% DMSO by 
approximately 32% (Figure ‎4.1.9D, E). C204Y showed a lower pattern of rescue to 
the PM compared with M105T (Figure ‎4.1.9D, E). Both M105T and C204Y showed 
no rescue at differing concentrations with either thapsigargin or curcumin. The other 
ER-retained mutants showed no rescue to the PM with any of the treatments 
examined.  
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Figure ‎4.1.9. Effect of low-temperature incubation and chemical chaperones on 
M105T and C204Y localization. (A) Shown are CFM images of reduced temperature 
and chemical compound incubation of WT-FZD4 acting as a control. In panels (B) 
and (C), the presented CFM images are of M105T and C204Y mutants across the 
three treatments (culturing at 27 oC, 7.5% glycerol, and 0.1% DMSO, respectively).  
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Figure ‎4.1.10. Quantification of colocalization, using ImageJ version 1.47, with the 
ER marker calnexin (above) and the PM marker H-Ras (below), expressed as a 
percent from the IF pattern of the expressed FZD4 proteins. At 27 oC, WT 
colocalized with the ER marker by approximately 3% only, whereas M105T and 
C204Y colocalized by 43% and C204Y by 54%. With 7.5% glycerol, M105T 
colocalized by 50% and C204Y by 85%. With 0.1% DMSO, M105T colocalized with 
calnexin by 32% and C204Y by 95%. Colocalization with calnexin was measured as 
a function of and then compared with WT on multiple CFM image sections of at least 
50 cells in three independent experiments (mean ± SE of each experiment). Shown 
is quantification of the amount of FZD4 proteins colocalizing with H-Ras, a PM 
marker. At 27 ºC, M105T and C204Y colocalized by 57% and 46%, respectively, 
whereas in the presence of 7.5% glycerol, M105T colocalized by 50% and C204Y 
by 32%. The M105T mutant showed partial plasma membrane distribution when 
treated with 0.1% DMSO by approximately 68% and C204Y by approximately 5%. 
One microgram WT-FZD4 or the mutant constructs was used for transfection 
experiments. For coexpression studies, 1 µg of each construct was cotransfected 
together. Colocalization with H-Ras was measured as a function of and then 
compared with WT on multiple CFM image sections of at least 50 cells in three 
independent experiments. Scale bar: 25 µm. Data (arbitrary units) are expressed as 
the mean (SE). ***P < 0.001. 
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4.1.2.5 Dominant-negative effect of FZD4 ER-retained mutants 
negated 
 FZD4 proteins have been shown to homodimerize in the ER. The ER-retained 
disease-causing mutants could possibly dimerize with the WT-FZD4 protein and trap 
it in the ER and hence cause a dominant negative effect. The disease is inherited as 
an autosomal dominant manner and this could be the underlying cellular mechanism 
of disease for at least some of these mutants as the Kaykas group had suggested 
[20]. 
 Therefore, I wanted to examine the possible dominant-negative effects of the 
mutant proteins on WT-FZD4. To be able to differentiate between the WT-FZD4 and 
the mutants, the WT-FZD4 was tagged with an HA epitope as described in the 
methodology section 3.3.1., whereas the different mutants are FLAG-tagged as 
described. The WT-FZD4 cDNA was co-expressed in 1:3 ratios with the following 
individual ER-retained mutants (P33S, G36D, H69Y, C181R, M105T, M105V, 
C204R, C204Y and G488D) and the localization of the WT-FZD4 was assessed by 
CFM.  
 Co-expression of WT-FZD4 with individual ER-retained mutants failed to show 
the retention of WT protein in the ER suggesting lack of dimerization with any of the 
mutants (Figure ‎4.1.11). Wild-type protein was expressed as usual on the plasma 
membrane when co-expressed with the mutants (Figure ‎4.1.11). Therefore, we can 
conclude that the ER-retained mutants studied do not trap WT within the ER and 
hence have no dominant-negative effects. In addition, IP of the mutant proteins 
failed to pull down WT-FZD4 (Figure ‎4.1.12). This implies that the mutant proteins 
may adopt conformations that do not allow dimerization with WT or that it is 
sequestered somehow away from WT. These data suggest that WT function might not 
be affected by the co-expression of the mutant alleles studied. 
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Figure ‎4.1.11. Absence of dominant negative effect of ER retained FZD4 mutants on 
WT-FZD4 protein. HeLa cells were co-transfected with WT-FZD4-HA and the 
individual ER retained FLAG-tagged mutants in a DNA amount ratio of 1:3 and 
cultured for 48 hours. The FZD4-WT was probed with polyclonal rabbit anti-HA 
antibodies (green) whereas the ER-retained mutants were probed with mouse anti-
FLAG polyclonal antibodies (red). The FZD4-WT localized normally to the plasma 
membrane in all panels B-J in similar fashion to the wild-type FZD4 shown in panel 
A. Colocalization function on multiple confocal sections of at least 30 cells in three 
independent experiments revealed that approximately 3% of the wild-type co-
localized with the mutants. All images were taken by a confocal microscope and 
overlayed using Image J 1.47v. All images presented are single sections in the z-
plane. Scale bar = 25 µm; 100X objective lens. 
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Figure ‎4.1.12. IP of the ER-retained mutants failed to co-IP the co-expressed WT 
protein. The wild-type FZD4 HA tagged and individually FLAG-tagged FZD4 mutants 
were co-expressed for 48 hours in HEK293T cells. The proteins were extracted and 
immunoprecipitated with anti-FLAG antibody. The samples were then run on an 8% 
SDS-PAGE gel and probed with anti-HA antibodies. Only the wild–type HA co-
expressed with the wild-type FZD4 Flag tagged protein. This implies that they were 
able to homodimerize together and consequently precipitated together. The blots 
were stripped and re-probed with anti-FLAG antibodies. All IP proteins showed up 
on the blot. B. Whole cell lysates of the protein used for the IP experiments was run 
on an 8% SDS gel and stained with anti-HA as a control.   
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4.1.3 Discussion 
Vascular diseases of the retina are a major cause of impaired vision and 
blindness. It has become evident that a large number of diseases with very different 
pathologies share a common framework of protein misfolding accompanied by 
degradation and/or aggregation of these misfolded proteins [1, 8]. Inherited diseases 
that harbor missense mutations may affect the folding or stability of proteins. For 
some of these types of mutant proteins, it might be possible to improve folding, 
stabilize the native structure, or suppress aggregation using chemical chaperones 
that mimic chaperone effects. 
I have shown how several FEVR-causing mutations lead to the retention of the 
mutant proteins by stringent ER quality control machinery. The ER chaperones have 
been shown to detect misfolded proteins, unmodified or orphaned subunits of 
protein complexes and target them for degradation by ERAD [56, 105, 110, 112, 
230]. My study shows that P33S, G36D, H69Y, M105T, C204R, C204Y, and G488D 
FZD4 mutants are exclusively retained in the ER. Interestingly, all these mutations 
are found in the extracellular portion of the protein except for the G488D mutation, 
which is found on the seventh transmembrane domain (Figure ‎4.1.1). 
A closer look at each mutation’s physicochemical properties and PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/ [in the public domain]) and SIFT 
(http://sift.jcvi.org/ [in the public domain]) server predictions sheds light on the predicted 
effects of some of the mutations on FZD4 protein (Table ‎4.1.1). For example, the 
P33S mutation is expected to cause inefficient or no cleavage of the signal peptide; 
therefore, the P33S mutant is likely to be stuck on the ER membrane. On the other 
hand, the C204R and C204Y mutations result in the disruption of a vital cysteine 
disulfide bonds. Smallwood et al. [214] have shown that the binding of Norrin to the 
CRD domain of FZD4 extends beyond the CRD’s 114 amino acids to include residue 
C204. Any effect beyond the CRD on Norrin binding is likely to represent just an effect 
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on FZD4 folding and not direct contact with Norrin. Zhang et al. [211] demonstrated 
how the C204R mutation fails to bind Norrin. The retention of both of these proteins in 
the ER may explain the inability of the protein to bind to its ligand. The glycine at 
position 488 is also highly conserved in orthologs and paralogs [210], and the change 
to an aspartic acid is expected to be deleterious. 
Table ‎4.1.1. Summary of the physicochemical properties of the FEVR-causing 
FZD4 mutations shown in this study to be mislocalized to the ER 
Mutation PolyPhen2 SIFT Charge Polarity Hydrophobicity Size Score 
P33S None 0.47, T Equal Increase Increase Decrease 23 
G36D 0.004, N 0.62, T Equal Increase Decrease Increase 32 
H69Y 0.029, N 0.08, T Decrease Equal Increase Equal 49 
M105T 0.997, D 0.47, T Equal Increase Decrease Decrease 32 
M105V 0.66, T 0.93, D Equal Equal Equal Decrease 16 
C181R 0.033, N 0.52, T Increase Increase Decrease Increase 77 
C204R 1, D 0.02, D Increase Increase Decrease Increase 77 
C204Y 1, D 0.04, D Equal Increase Equal Increase 85 
G488D 0.06, T 1, D Increase Increase Decrease Increase 28 
 
 
The modification score (INSTRUCT/CBI Knowledgebase; 
http://decrypthon.igbmc.fr/sm2ph/cgi-bin/home [in the public domain]) correlates 
with the severity of the change at the specified position. P33S is found within the 
signal peptide (SignalP 4.1 Server; http://www.cbs.dtu.dk/ services/SignalP/ [in the 
public domain]).[231] N, neutral; T, tolerated; D, deleterious change on the protein. 
Interestingly, the M105V and C181R mutations showed dual patterns of 
localization  (Figure ‎4.1.2F, G, Figure ‎4.1.3F, G). This partial ER retention behavior 
has been reported for other cysteine missense mutations [232]. The location of 
M105V and C181R is significant because they are within the CRD of the FZD4 
extracellular domain and are highly conserved in other species.  
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P33S and G488D show mainly dimers, multimers, and oligomers on an SDS-
PAGE gel, which has been previously observed with FZD4 protein (Figure ‎4.1.7 [20, 
224, 225]). In addition, heating of FZD4 protein has been reported to cause the 
formation of aggregates [224], which was observed in the current experiments. 
Interestingly, the mutations found to traffic abnormally are mainly found in the 
extracellular domain of FZD4, where the CRD region is located (Figure ‎4.1.1). The 
CRDs of frizzled proteins have been shown to form homo-oligomers and/or hetero-
oligomers within the ER [19, 20]. ERAD results in loss of function of the mutant 
protein as a result of being degraded before reaching its final destination. Frizzled 
family receptor 4 proteins dimerize in the ER, and Norrin dimers have been shown 
to interact with FZD4 dimers [234]. 
Therefore, I wanted to examine the possible dominant-negative effects of the 
mutant proteins on WT-FZD4. However, coexpression of WT-FZD4 with individual 
ER-retained mutants failed to show the retention of WT protein in the ER or its 
dimerization with any of the mutants (Figure ‎4.1.11). Wild-type protein was 
expressed as usual on the plasma membrane when coexpressed with the mutants 
(Figure ‎4.1.11). Therefore, I can conclude that the studied ER-retained mutants do 
not trap WT within the ER and hence have no dominant-negative effects. In addition, 
IP of the mutant proteins failed to pull down WT-FZD4 (Figure ‎4.1.12). This implies 
that the mutant protein may adopt conformations that do not allow dimerization with 
WT. This may also be due to aggregation of these proteins. These data suggest that 
WT function might not be affected by the coexpression of a mutant allele. A reported 
hemizygous mutation has shown haploinsufficiency and therefore loss-of-function of 
FZD4 as the underlying disease mechanism [218]. My data support the 
haploinsufficiency theory for this disease [218]. 
All but one mutation are found in the heterozygous state. It is likely that the 
phenotypic variability observed in heterozygous individuals within the same family 
86 
 
may result from the effects of modifier genes alongside an alteration in the gene 
dosage, resulting in allelic insufficiency. The ER retention for reported compound 
heterozygote patients carrying two different mutations (H69Y and G488D [210]) can 
explain why a more severe phenotype is observed compared with single 
heterozygous mutations. This data further illustrate the complexity of FEVR and 
provide a better understanding of the genotype-phenotype correlations for some 
mutants.  
M105V patients have been reported to show retinal folds, macular ectopia, 
peripheral non-perfusion, retinal exudates, retinal vascular tortuosity, retinal 
degeneration and holes [233]. Patients with the M105T had bilateral retinal 
detachment and partial and /or complete blindness at a very young age [220]. 
Therefore, the phenotype of the M105T mutation is more severe than the M105T 
and this may be due to the slow trafficking of the M105V to the cell surface. 
Interestingly, the M105T has an extreme phenotype  at a young age. Our results 
also show this mutation to be rescued to the cell-surface. This data needs to be 
further investigated to allow for therapeutic options for patients harboring this 
mutation in FZD4. However, the exact effects of the studied mutants on retinal 
vascularization and angiogenesis remain to be fully established. 
In addition, the non-ER-retained mutants could cause FEVR by forcing FZD4 to 
take up conformations that do not permit binding to its ligands or downstream 
targets. For example, Norrin, a cysteine knot protein and a ligand of FZD4, shows 
wide variation in the arrangement of monomers within the dimer and the surfaces 
that interact with receptors or other binding proteins [214, 234]. This may also affect 
ligand specificity. Interestingly, dimerization of frizzled is emerging as a possible 
mechanism for transduction specificity [235]. 
An essential outcome of ubiquitination is targeting to the 26S proteasome, a 
specific signal that is responsible for the degradation of many cellular proteins, 
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including numerous ER-retained proteins upon export from the ER to cytosol [110, 
111]. Most proteasome substrates are tagged not by a single Ub (monoUb) but by a 
polyubiquitin (polyUb) chain (PUC). It is generally thought that PUC’s longer than 
four Ub molecules are the preferred signal for efficient recognition and degradation 
by 26S proteasomes [236]. The FZD4 polyubiquitination pattern is that of a polyUb 
chain increasing the molecular weight of FZD4 to approximately 200 kDa 
(Figure ‎4.1.8). Once bound by proteasomes, substrate conjugates are 
deubiquitinated, unfolded, and subsequently degraded [8, 9]. Loss of function of 
FZD4 mutants caused by proteasomal degradation of the misfolded protein further 
reveals the mechanism of certain FZD4 mutations that cause retinal dysfunction. 
Interestingly, incubation at lower temperatures of 27 to 28°C [30] rescued the 
M105T mutant and partially rescued the C204Y mutant, as is observed with 
previous studies on CFTR [30, 32]. Glycerol, a small synthetic chemical that acts as 
an osmolyte, increases the hydration layer and the strength of the intramolecular 
hydrophobic bonding of the protein in the ER, which consequently allows the free 
movement of proteins, so as to prevent aggregation [28]. DMSO acts by probably 
increasing protein synthesis of the mutant or by overwhelming the quality control 
system. Thapsigargin, an inhibitor of the ER sarco(endo)plasmic reticulum calcium 
adenosine triphosphatase calcium pump, has been shown to increase cytosolic 
calcium, resulting in enhanced rescue of mutant proteins [160]. Curcumin, a 
nontoxic natural constituent of turmeric spice affects the calcium adenosine 
triphosphatases [167] found on the ER plasma membrane by inhibiting their ability to 
maintain a high ER calcium level. This, in turn, affects the ability of ER molecular 
chaperones to target the misfolded protein for ERAD, hence allowing the mutant 
protein to exit the ER. It would be interesting to look into more compounds that will 
inevitably provide the groundwork for designing a pharmacological chaperone to 
further salvage these mutations from their trafficking defect. 
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The present work represents an initial step in delineating the cellular mechanisms 
underlying some FEVR-causing missense mutations. It supports efforts for rescuing 
trafficking of other missense mutations that cause human diseases. It will be of great 
interest to determine whether modulating this pathway could represent a therapeutic 
approach to human retinal vascular disease.  
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4.2 Muscle, Skeletal, Receptor Tyrosine Kinase (MuSK) 
gene causing Congenital Myasthenic Syndrome (CMS) 
4.2.1 Introduction 
Congenital Myasthenic Syndromes (CMSs), OMIM: 601296, is a group of 
heterogeneous hereditary diseases characterized by reduced acetylcholine receptor 
(AChR) clustering at the neuromuscular junction (NMJ). CMSs can be classified into 
pre-synaptic, synaptic and postsynaptic defects which can lead to a dysfunctional 
neuromuscular signal where altered phenotypes are observed with varying degrees 
of muscle weakness [237]. AChR clustering and postsynaptic differentiation is 
orchestrated by interactions of the proteoglycan agrin (AGRN), the co-receptor low 
density lipoprotein receptor-related protein 4 (LRP4), and the muscle, specific 
receptor tyrosine kinase (MuSK), docking protein 7 (DOK7) and rapsyn (RAPSN) as 
illustrated in Figure ‎4.2.1A.  
Mutations in MUSK [238-241], among 18 known genes [242], have been 
identified to cause CMS. However, the cellular mechanism underlying MUSK-
mediated CMS is not well understood [237]. Furthermore, heterozygous and/or 
homozygous mutations in MUSK result in varied levels of impaired neuromuscular 
transmission. 
MuSK is a 97 kDA type 1, single pass tyrosine kinase receptor glycoprotein 
(Figure ‎4.2.1B) with an extracellular ectodomain containing three immunoglobulin 
(Ig)-like domains and a frizzled-like cysteine-rich domain (Fz-CRD) [243], a 
transmembrane-spanning region and an intracellular region including a 
juxtamembrane domain, a kinase domain and a short C-terminal tail [244]. The Fz-
CRD in proteins shows a pattern of 10 cysteine residues forming a five disulphide-
bridged domain and forms a well conserved and folded three dimensional structure 
[21, 245]. MuSK contains a Fz-like CRD (Fz-CRD) homologous to the domain on Fz 
receptors to which Wnt binds [246, 247]. In this regard, MuSK is related to orphan 
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receptor tyrosine kinase (RTK)-like proteins such as orphan receptor tyrosine 
kinases 1 and 2 [243, 245] and the Frizzled Family Wnt receptors [247]. 
 
Figure ‎4.2.1 (A). MuSK is the key player in synaptic differentiation. Neural agrin 
stimulates synaptic differentiation by activating MuSK. LRP4 is a functional and 
obligate receptor for agrin, forms a complex with MuSK and mediates agrin-
mediated MuSK activation. The N-terminal Ig-like domain in MuSK is essential for 
agrin to stimulate MuSK phosphorylation [21]. LRP4 self-associates and forms an 
agrin-independent complex with MuSK [248]. It has been proposed that agrin may 
alter the conformation of this preformed complex and MuSK is reoriented promoting 
trans-phosphorylation. However, the mechanism by which LRP4 transduces signals 
from neural agrin to MuSK remains unclear. DOK-7 binds to the intracellular portion 
of MuSK and AChR clustering at the NMJ. (B). Schematic representation of MuSK 
showing the position of missense mutations reported to date. Ig1-3, immunoglobulin-
like domains highlighted in blue boxes extracellularly; CRD, cysteine-rich domain 
highlighted in purple; tyrosine kinase domain highlighted in blue intracellularly. The 
activation loop is highlighted in yellow attached to tyrosine residues. The NPXY 
domain is the PTB-domain binding motif; the PDZ domain binding motif is 
highlighted in green at the C terminal. The P344R mutation is found after the N-
glycosylation sites: Asn222 and Asn338. 
So far, six MuSK missense mutations have been reported in patients with CMS 
(Figure ‎4.2.1B) including D38E [249], P344R [240], M605I, A727V [239], V790M 
[238] and M835V [241]. The P344R mutation is found in the Fz-CRD domain and 
therefore we hypothesize that this mutation will result in the misfolding of the 
receptor and its handling by the ER quality control machinery. MuSK is a potential 
ERAD substrate because it has structural similarities with previously identified 
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ERAD substrates of the receptor tyrosine kinases family of proteins [18, 148, 149]. 
There is a high degree of conservation of the tyrosine kinase motifs and several 
mutations in the frizzled-related proteins have been shown to be retained in the ER 
[148, 250].  
As detailed in the literature review chapter, the ER uses a stringent yet elaborate 
protein quality control system to ensure that only properly folded proteins are 
allowed to exit the ER to their final destinations [11, 126]. Remarkably, ER resident 
pro-molecular and molecular chaperones recognize misfolded polypeptides from 
their native counterparts [125]. A proportion of these ER-retained proteins are then 
targeted and dislodged from the ER, enter the cytosol where they get degraded by 
the ubiquitin/proteasome systems through ERAD [105].  
For this study, I utilized subcellular localization, N-glycosylation profiling, and 
ubiquitination status to implicate ER retention as the major cellular mechanisms 
underlying the P344R-MuSK mutation. However, this intracellular mistrafficking is 
correctable when cells were grown at 27 ˚C instead of 37 ˚C and in the presence of 
glycerol, dimethyl sulfoxide (DMSO), curcumin and thapsigargin.  
4.2.2 Results 
4.2.2.1 The P334R-MuSK mutant is largely localized within the ER in 
various cell lines 
HeLa cells transiently transfected with the wild-type (WT) C-terminally FLAG-
tagged MuSK cDNA show that the expressed protein is predominantly localized to 
the PM in contrast to calnexin, a well-established ER marker (Figure ‎4.2.2, panels 
A). Calnexin exhibits a typical perinuclear and reticular distribution suggestive of its 
ER distribution (Figure ‎4.2.2 middle Panels A). In contrast, the P344R-MuSK mutant 
was found to be predominantly localized to the ER as evidenced by its colocalization 
with calnexin (Figure ‎4.2.2, panels E). This mislocalization away from the plasma 
membrane in HeLa cells was further examined by its coexpression with EGFP-H-
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Ras which localizes to the plasma membrane (Figure ‎4.2.2, compare panels B and 
F). The perinuclear and reticular distribution of the P344R-MuSK mutant is clearly 
distinct from that of EGFP H-Ras and thus further suggests its mislocalization to the 
ER. In addition, the localization of this mutant is clearly different from that of the wild 
type MuSK protein (compare panels A-B with E-F in Figure ‎4.2.2). 
 
Figure ‎4.2.2. P344R-MuSK mutant localizes to the ER in HeLa, COS-7 and HEK293 
cell lines. FLAG-tagged wild-type MuSK protein is seen as red fluorescence 
whereas calnexin and GFP-Ras as green signals as indicated. Panels A, B, C and D 
show  WT-MuSK localizing to the plasma membrane away from calnexin (A) but 
with H-Ras (B, C and D) in HeLa (B), COS-7 (C) and HEK293T (D). On the other 
hand, the P344R-MuSK mutant localizes intracellularly with the ER marker 
(calnexin) in HeLa cells (F) and away from H-Ras in a HeLa cell line (F), COS-7 (G) 
and HEK293 (H) suggesting ER localization in all three cell lines. The scale bar 
represents 25µm and applies to all the panels.  
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Figure ‎4.2.3. Colocalization with calnexin and with H-Ras was measured as a 
function using Fiji [204]. Colocalization was compared with WT on multiple image 
sections of at least 30 cells in three independent experiments. The p- values were 
determined by two-tailed Student’s t-test when compared to the wild-type control. 
Statistical analysis by unpaired two-tailed Student’s t-test analysis of Pearson 
correlation data for P344R-MuSK versus wild-type MuSK, confirms that a significant 
difference exists between the localization. Data (arbitrary units) are expressed as 
mean ± S.E. ***, Differences were considered statistically significant as follows: * = 
0.01≤p<0.05; ** = 0.001≤p<0.01; *** = p<0.001 when compared to the wild-type 
control. Scale bar = 25 µm; 100X objective lens. 
This mislocalization was verified in two other cell lines using EGFP H-Ras as a 
plasma membrane marker. In both COS-7 and HEK293 cells, WT MuSK colocalizes 
with this marker (Figure ‎4.2.2 panels C and D, respectively) whereas the P344R-
MuSK mutant localized intracellularly away from EGFP H-Ras (Figure ‎4.2.2 panels 
G and H). These patterns of localization are suggestive of retention of the P344R-
MuSK mutant within the ER and that this mislocalization is not cell line specific. The 
other five C-terminally FLAG-tagged missense CMS-causing mutants (D38E, M605I, 
A727V, V790M and M835V) were found to be largely localized to the PM, similar to 
wild type MuSK (Figure ‎4.2.4).  
Quantification of the MuSK WT and / or the P344R-MuSK mutant colocalizing 
with either calnexin and or H-Ras in HeLa cells at 37 °C is shown in Figure ‎4.2.3. 
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This data shows that more than 85% of the mutant is colocalizing with the ER 
marker.  
4.2.2.2 Generation of HEK293 stable cell line for P344R-MuSK 
The localization of P344R-MuSK prompted me to make a stable cell line of 
MuSK-WT, P344R-MuSK and the empty vector as described in the methodology 
section 3.2.9: Generation of HEK293 stable cell lines using the G418 selection 
marker. The MuSK-WT served as a positive control for all experiments and the 
empty vector as a negative control. Henceforth, all experiments were carried out on 
these stable cell lines which provided a genetically homogenous and single clonal 
population of P344R-MuSK expression. This would provide a more accurate 
assessment to chemical compound treatment and other applications. Figure ‎4.2.5; 
panels A-C shows a single clonal population for the protein expression of MuSK-WT 
stable cell line alongside P344R-MuSK and empty vector respectively using IF and 
panel D, shows the expression by western blot using GAPDH (E) as an internal 
control.  
4.2.2.3 The N-glycosylation profile of P344R-MuSK shows absence of 
the mature N-glycans and hence confirms ER retention 
To further confirm the subcellular localization of P344R MuSK, PNGase and 
Endo H sensitivity and resistance in vitro assays of the expressed proteins were 
carried out. MuSK has two potential N-glycosylation sites in its extracellular domain 
[21] (Figure ‎4.2.1B). The principle of this assay is that the carbohydrate moieties of 
ER-localized glycoproteins are cleavable by Endo H whereas post-ER species are 
resistant due to further remodeling of their N-glycans in the Golgi complex. Endo H 
cleaves after the first asparagine-linked N-acetylglucosamine of high mannose and 
hybrid polysaccharides while PNGase removes both forms of the N-glycans. 
Therefore, one can expect that the ER-retained mutant will have its N-glycans 
cleavable when treated with the Endo H and PNGase enzymes suggesting its 
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presence within the ER. Upon this treatment, the P344R-MuSK mutant shows an 
exclusively Endo H susceptible protein with a lower molecular weight than the 
MuSK-WT and its untreated counterpart (Figure ‎4.2.6A) confirming its retention 
within the ER. It should be noted that the P344R-MuSK runs at a lower molecular 
weight compared to WT even before Endo H treatment implying an under-
glycosylated and immature protein. 
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Figure ‎4.2.4. Confocal images of the missense disease causing mutants in a HeLa 
cell line. Confocal images of MuSK mutants: D38E, M605I, A727V, V790M and 
M835V showing their localization in HeLa cells alongside H-Ras, a plasma 
membrane marker. Flag epitope expressed protein is seen as red fluorescence (far 
left) under the confocal microscope and the plasma membrane resident protein H-
Ras as green fluorescence (middle panel). When the two images are merged 
together, merge (far right) localization can be viewed clearly. Panels A-E clearly 
localize on the plasma membrane. Cells were transfected for 48 hours and then 
processed for IF. Scale bar = 25 μm; 40X objective lens.  
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Figure ‎4.2.5. Stable cell lines of the MuSK-WT, P344R-MuSK and empty vector in 
HEK293 cell lines. HEK293 (A) MuSK-WT, (B) P344R-MuSK and (C) a negative 
empty vector control stable cell lines were generated as described in the methods 
and observed by CFM for protein expression. The (A) panel shows the single clonal 
protein expression stained with the FLAG epitope (red); the (B) panel shows the 
calnexin staining in green and the C panel shows the overlay of both the protein and 
the calnexin staining. (D) To verify protein expression, the clones were then run on 
an 8% SDS-PAGE to observe the strength of protein expression. (E) GAPDH was 
run as a loading control and to observe that the integrity of the ER was normal. The 
expression of clone A for both MuSK-WT and P344R-MuSK were chosen for 
subsequent experiments. Scale bar = 25 µm; 40X objective lens. 
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Figure ‎4.2.6. The N-glycosylation status of MuSK WT and P344R-MuSK mutant. (A) 
MuSK WT and P344R-MuSK stably expressing cell lines were subjected to Endo H 
and PNGase F sensitivity and resistance assays as described in the methods 
section. Untreated P344R-MuSK mutant was seen to migrate faster on an 8% SDS-
PAGE gels compared to WT suggesting a folding defect or an immature protein 
(compare input in both cases). When treated with Endo H, the WT is resistant to this 
treatment whereas when treated with PNGase F, it migrated faster suggesting 
maturation of its N-glycans. In contrast the mutant migrated faster when treated with 
either Endo H or PNGase F suggesting immature N-glycans. (B). GAPDH blot was 
used as an internal loading control. This experiment was conducted in four times 
with similar results obtained in all instances. 
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4.2.2.4 The P344R mutant retained its autophosphorylation activity  
 MuSK has an autoregulatory mechanism by which it can control its enzymatic 
activity through autophosphorylation of the kinase activation loop (A loop) [251]. 
Upon autophosphorylation, the kinase A loop adopts a conformation that is 
optimized for substrate binding. Autophosphorylation can also occur through the 
tyrosine kinase domain. Autophosphorylation of two tyrosines, Tyr-553 (NPXY) and 
A loop Tyr-754[251] shown in Figure ‎4.2.1; within the juxtamembrane segment 
relieves autoinhibition resulting in a fully active kinase. This autophosphorylation is 
important for further downstream signaling.  
 To examine the phosphorylation status, P344R-MuSK and MuSK-WT stably 
expressing cell lines were homogenized in a mild buffer to preserve cellular kinases. 
In addition, phosphatase inhibitors were added to preserve the phosphorylation 
status of the protein. The whole cell lysates were then immunopreciptated and run 
on an SDS page (Figure ‎4.2.7A). In Figure ‎4.2.7A, the proteins were stained with 
anti-phosphotyrosine (α PY) antibodies. In Figure ‎4.2.7B, the blot was stripped and 
re-probed with α FLAG antibody. Like the wild type MuSK, the P344R mutant is 
shown to be phosphorylated. The mutant protein may have retained about 50% of 
its enzymatic activity (Figure ‎4.2.7C). A kinase dead mutant (K609A) was used as a 
control for this experiment. This demonstrates that the phosphorylation is 
autophosphorylation in nature. This also implies that the mutation did not affect the 
kinase domain of the protein and therefore it may still retain significant biological 
function. Therefore, if the protein is restored to the plasma membrane upon exiting 
the ER, it may be able to interact in neuromuscular synaptogenesis.  
4.2.2.5 The trafficking defect of the P344R mutant is correctable by 
varying culturing conditions 
 Interestingly, ΔF508-CFTR has been shown to be exclusively retained in the ER 
as a result of misfolding and retention by ERAD. However, it has been demonstrated 
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that culturing cells expressing this mutant at reduced temperatures results in the 
restoration of some cell surface mutant expression, but crucially restoring the 
chloride-channel conductance activity of the CFTR [29, 30, 32, 165]. This data and 
others provides encouraging evidence that the ER retention and degradation 
machineries can be manipulated and therefore are potential therapeutic targets.  
 I therefore, examined the effect of reducing the culturing temperature on the 
trafficking of the P344R-MuSK mutant. The WT and P344R-MuSK constructs were 
co-transfected with the PM marker, EGFP-HRAS and cultured at 27 ˚C, and 37 ˚C 
for 24 hours and 48 hours. This was followed by confocal microscopy to establish 
the subcellular localization of the proteins. The subcellular localization of the wild 
type MuSK was not affected by culturing at the reduced temperature 
(Figure ‎4.2.8A). The P344R-MuSK mutant protein’s localization to the plasma 
membrane was evident after 48 hours of culturing at 27 ºC (Figure ‎4.2.8B). 
4.2.2.6 Chemical chaperones rescued the trafficking defect of 
P344R-MuSK mutant 
 It has been established that some ER-retained temperature sensitive mutants 
can also be rescued when cells are cultured in the presence of chemical 
chaperones [28, 31]. Among these chemical chaperones are small synthetic 
chemicals such as glycerol, which act as osmolytes increasing the hydration layer, 
the strength of the intramolecular hydrophobic bonding of the protein, in the ER, 
which consequently allows the free movement of proteins, so as to prevent 
aggregation [28]. Quantification of the immunofluorescence pattern shows partial 
(~50%) rescue of the P344R mutant when treated with 2.5% glycerol (Figure ‎4.2.8; 
panels E and F). This observation indicates that glycerol allows the mutant to exit 
the ER and improves its appearance at the cell surface in a mature form (compare 
percent colocalization with calnexin compared to percent colocalization with H-Ras). 
P344R-MuSK mutant was also treated with 0.1% and 1% DMSO, 10 µm 
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thapsigargin or with 1 µM curcumin. P344R-MuSK mutant showed partial plasma 
membrane re-distribution when treated with these chemical chaperones especially 
with 10 µM thapsigargin (Figure ‎4.2.8A; MuSK WT and B; P344R). The MuSK WT 
was run as a control. Calnexin staining shown in Figure ‎4.2.8C with the vehicle 
alone and an empty vector with the vehicle is shown in Figure ‎4.2.8D.  
 
Figure ‎4.2.7. Effect of the P344R-MuSK mutation on MuSK autophosphorylation. 
HEK293 cells stably expressing WT MuSK or P344R-MuSK and empty vector 
constructs were subjected to IP and western blotting using anti-PY antibodies. 
Transiently transfected dead kinase K609A MuSK mutant (lane 2 and 4) and the 
empty vector construct (lane 5) were used as controls. Anti-PY antibodies were 
used for western blotting to detect the phosphorylated MUSK (A) then the blots were 
stripped and re-probed with anti-FLAG antibodies to determine levels of expression 
(B). Clearly, the MUSK WT (lane 1) is phosphorylated whereas the kinase dead 
mutants are not (lanes 2 and 4) suggesting autophosphorylation. The P344R seem 
to be also autophosphorylated by approximately 50% compared to the wild-type but 
not the double mutant P344R-K609A; lane 4. A representative experiment out of 
three realized is shown. MuSK amount and phosphorylation were then estimated 
with ImageQuantl J software. The introduction of the dead-kinase mutation in WT 
MuSK-K609A abolishes the autophosphorylation of MuSK WT and P344R seen in A 
(C) Phosphorylation is expressed as n-fold activation as compared to WT MuSK. 
Data are expressed as a percentage; and are the mean ± SE of three independent 
experiments. 
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Figure ‎4.2.8. Different culturing temperatures for MuSK-WT and P344R-MuSK in 
HeLa cells using an EGFP-H-Ras PM marker. (A). Using merged MuSK WT with 
PM marker H-Ras as a control panel A, culturing conditions were varied with a 
reduced temperature of 27 ˚C for 48 hours; 2.5 % glycerol; 0.1-1 % DMSO and 1 
µM-10 µM thapsigargin was not toxic to the cells and further modulated the P344R-
MuSK mutant’s rescue to the plasma membrane. (B). Merged P344R-MuSK with 
HRAS treated with 10 µM thapsigargin is represented. (C). P344R treated with 0.1% 
DMSO vehicle and (D). 0.1% DMSO with the empty vector. E. Colocalization with 
calnexin was measured as a function and then compared to the wild-type on 
multiple confocal images sections of at least 30 cells in three independent 
experiments. Data (arbitrary units) are expressed as mean ± S.E. when compared to 
the wild-type control. (F). Colocalization with H-Ras was measured as a function and 
then compared to the wild-type on multiple confocal images sections of at least 30 
cells in three independent experiments (mean ± S.E.).Scale bar = 25 µm; 100X 
objective lens. 
 A western blot analysis pattern for the chemical chaperone treatment effect is 
seen in Figure ‎4.2.9. Stable transfected cell lines of P344R-MuSK were incubated 
for 4 hours with serum-free media. The concentration of chemical chaperone 
required was then added to a reduced serum-free medium and the cells were 
incubated for 7 hours. Proteins were then run on an 8% SDS-PAGE with GAPDH as 
an internal control. The P344R-MuSK mutant shows an increase in protein stability 
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compared to the non-treated P344R-MuSK. The wild-type was used as an 
experimental control and was seemingly unaffected by the chemical compound 
treatment (Figure ‎4.2.9A); with GAPDH as an internal control. Quantification of 
these blots is shown in Figure ‎4.2.9B indicating an increase in the mutant signals by 
about two fold with these treatments. Cell surface biotinylation shown in Figure ‎4.2.9 
shows the amount of P344R-MuSK expressed on the cell surface compared to the 
untreated P344R-MuSK and MuSK-WT.  
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Figure ‎4.2.9. Effect of certain chemical chaperones on the maturation of P344R-
MuSK mutation. Stable cell lines of HEK 293 cells expressing MuSK-WT and the 
P344R-MuSK mutant were incubated with serum-free media for 4 hours and then 
with the appropriate chemical compound for 7 hours in reduced serum-free media. 
The immunoblot (IB) was stained with anti-FLAG were antibody. (A) The wild-type 
MuSK seems unaffected by this treatment. The treated P344R-MuSK protein 
extracts show enhanced protein expression compared to the untreated P344R-
MuSK counterpart. GAPDH is included as an internal control. 1% DMSO, 1 µM 
curcumin, 1 µM thapsigargin, 2.5% glycerol and 10 µM of thapsigargin show an 
enhanced protein processing compared to the untreated P344R-MuSK. (B) 
Quantification of the blots shows an increase in the stabilization of P344R-MuSK as 
compared to MuSK-WT under treatment. 
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Figure ‎4.2.10. Western blot analysis of cell surface biotinylated fraction. The blot 
was then stripped and re-probed for IGF2R which served as a loading control. 
Relative MuSK protein levels were determined by ImageQuant TL and were 
normalized to IGF2R and displayed in a bar-chart. All samples with and without 
treatment were normalized to their own control. This experiment was conducted in 
duplicate with similar results obtained in both instances. 
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4.2.2.7 MuSK protein degradation is mediated by the proteasome 
pathway 
To test whether P344R-MuSK is actively degraded in cells, the stable cell lines 
were treated with cycloheximide (CHX), an inhibitor of protein synthesis. It has been 
previously shown that the MuSK is a short-lived protein [238]. As shown in 
Figure ‎4.2.11, MuSK-WT and P344R-MuSK levels declined quickly at short-interval 
time periods, and P344R-MuSK displayed a much shorter half-life than the MuSK-
WT. Cells treated with the vehicle alone as a control (0.1% DMSO) were unaffected 
in both cell lines (Figure ‎4.2.14).  
To determine whether P344R-MuSK degradation is mediated by the proteasomal 
pathway, the stable cell lines expressing P344R-MuSK mutant and MuSK-WT were 
treated with the proteasome inhibitor MG132. It was found that 90 minutes of 
treatment resulted in about a two-fold increase in P344R-MuSK protein 
(Figure ‎4.2.12). These data suggest that P344R-MuSK degradation is mediated 
through the proteasome-dependent pathway. Since the MuSK-WT protein is a short 
lived protein it was expected to increase in protein expression with MG132 treatment 
but not as drastically as the P344R-MuSK (Figure ‎4.2.12; MG132 graph).  
It was then further investigated whether proteasome inhibition was indeed 
affecting the P344R-MuSK half-life. Stable cells were treated for different periods of 
time with CHX, in the presence of MG132 (Figure ‎4.2.13). In the presence of 
MG132, the P344R-MuSK mutant was as stabilized as the MuSK-WT 
(Figure ‎4.2.13; MG132 + CHX graph) confirming that P344R-MuSK is actively 
degraded by the proteasomal pathway in these cells. 
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Figure ‎4.2.11. MuSK is a short-lived protein. MuSK and P344R-MuSK are rapidly 
degraded in the cell. Stably transfected MuSK-WT and P344R-MuSK HEK293 cells 
were incubated with 50 mg/ml cycloheximide (CHX) for the indicated periods. 
Western blots were performed on whole cell lysates using anti-FLAG. Relative 
MuSK protein levels were determined by ImageQuantl and were normalized to that 
obtained in nontreated samples (0 h control, no CHX). In the graph, samples with 
and without treatment were normalized to their own control (0 h, 100%) at the 
indicated time points. The mean ± SE of three independent experiments is shown. 
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Figure ‎4.2.12. To observe the effects of the proteasomal inhibitor MG132 on MuSK 
and P344R-MuSK protein expression. Stably transfected MuSK-WT and P344R-
MuSK HEK293 cells were incubated with 25 µM MG132 for the indicated periods. 
Western blots were performed on whole cell lysates using anti-FLAG. Relative 
MuSK protein levels were determined by ImageQuantl and were normalized to that 
obtained in nontreated samples (0 h control, no MG132). In the graph, samples with 
and without treatment were normalized to their own control (0 h, 100%) at the 
indicated time points. The mean ± SE of three independent experiments is shown. 
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Figure ‎4.2.13. To observe the effects of both the proteasomal inhibitor MG132 and 
cycloheximide on MuSK and P344R-MuSK protein expression. Stably transfected 
MuSK-WT and P344R-MuSK HEK293 cells were incubated with 25 µM MG132 for 
one hour. CHX was then added at the indicated time points. Western blots were 
performed on whole cell lysates using anti-FLAG. Relative MuSK protein levels were 
determined by ImageQuantl and were normalized to that obtained in nontreated 
samples (0 h control, no MG132 + CHX). In the graph, samples with and without 
treatment were normalized to their own control (0 h, 100%) at the indicated time 
points. The mean ± SE of three independent experiments is shown. 
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Figure ‎4.2.14. Incubation with DMSO control vehicle had no effect on MuSK and 
P344R-MuSK protein expression. Stably transfected MuSK-WT and P344R-MuSK 
HEK293 cells were incubated with 0.1% DMSO for the indicated time points. 
Western blots were performed on whole cell lysates using anti-FLAG. Relative 
MuSK protein levels were determined by ImageQuantl and were normalized to that 
obtained in nontreated samples (0 h control, no DMSO). In the graph, samples with 
and without treatment were normalized to their own control (0 h, 100%) at the 
indicated time points. The mean ± SE of three independent experiments is shown. 
 
 
  
111 
 
4.2.2.8 The ER retained P344R-MuSK mutant is polyubiquitinated 
 To further verify if P344R-Musk is degraded by the proteasomal pathway. Stable 
cells of P344R-MuSK and MuSK-WT underwent separate treatments with MG132 
and CHX at the various time periods highlighted earlier. The proteins were subjected 
to IP, run on an 8% SDS-PAGE gels and probed with anti-FLAG antibodies 
(Figure ‎4.2.15 and Figure ‎4.2.16 respectively), stripped and re-probed for anti-
ubiquitin (Ub) as described in the methodology. Immunostaining by an anti-Ub 
antibody produced a striking accumulation of smears of multi-Ub-P344R-MuSK 
conjugates at the top of the resolving gel, in the presence of CHX (Figure ‎4.2.16) 
that was lower compared to MG132 treated samples (Figure ‎4.2.15).  
 These conjugates with multiple Ub moieties in the form of branched chains 
appear to be associated with the P344R-MuSK mutant very strongly compared to 
MuSK-WT. This is suggestive that the P344R-MuSK mutant is a target for 
degradation by the ERAD. To assess if the chemical compound treatments affected 
the ubiquitination of this mutant, the stable cell lines were treated with chemical 
chaperones and the proteins underwent IP (Figure ‎4.2.17), then were stripped and 
re-probed with anti-Ub. The blot shows higher level of conjugates of Ub-P344R-
MuSK with anti-Ubiquitin antibodies staining for the P344R-MuSK mutant compared 
to the wild-type. The Ub moieties have a lower intensity smear pattern under 
treatment with chemical chaperones compared to the non-treated P344R-MuSK 
mutant.  
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Figure ‎4.2.15. Polyubiquitination status of P344R MuSK mutant and MuSK 
wild-type under treatment. As a control for cycloheximide and MG132 
treatment, MuSK-WT and P344R-MuSK were treated with 25 µM MG132 and 
then immunoprecipitated. The nitrocellulose blot was washed overnight with 
TBS-T, then stripped and autoclaved. The blot was then re-probed for anti-
ubiquitin monoclonal antibody staining as described in the methods. The 
polyubiquitin smear is higher in P344R-MuSK compared to MuSK-WT under 
25 µM MG132 proteasomal inhibition. 
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Figure ‎4.2.16. Polyubiquitination status of P344R MuSK mutant and MuSK wild-
type under treatment. As a control for cycloheximide, MuSK-WT and P344R-MuSK 
were treated with 50 µg/ml CHX and then immunoprecipitated. The nitrocellulose 
blot was washed overnight with TBS-T, then stripped and autoclaved. The blot was 
then re-probed for anti-ubiquitin monoclonal antibody staining as described in the 
methods. The polyubiquitin status shows a decreasing smear compared in both 
MuSK-WT and P344R-MuSK indicating loss of protein translation. 
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Figure ‎4.2.17. P334R-MuSK mutant was treated with chemical compounds and 
without chemical compounds run on an SDS-PAGE and blotted. The nitrocellulose 
blot was washed overnight with TBS-T, then stripped and autoclaved. The blot was 
then re-probed for anti-ubiquitin monoclonal antibody staining as described in the 
methods. Formation of ubiquitin (Ub) conjugates of the untreated P344R-MuSK 
mutant are of very high molecular weights, greater than the 280kDa top marker, in 
fact just resting at the top of the 8% resolving gel and at the end of the stacking gel. 
However, with 10 μm thapsigargin treatment, 1 μM curcumin and 1% DMSO (lanes 
2-5), the poly-Ub conjugate “tree” smear is much less than the untreated P344R 
mutant counterpart. Quantification shows relative polyubiquitination of the 
polyubiquitin smear.  
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4.2.3 Discussion  
 Single point missense mutations in secretory proteins often produce molecules 
that are incapable of folding properly. These misfolded proteins may expose 
hydrophobic patches that are recognized by ER chaperones and so are deemed 
unsuitable to transit through the secretory pathway in this misfolded state. As a 
result they are initially retained in the ER then retrotranslocated back into the cytosol 
by the conserved ERAD machinery and passed on to the proteasome for disposal 
by degradation [8, 200, 252]. This ultimately results in the loss-of-function of the 
protein function at the cell surface and constitutes a cellular mechanism for many 
human monogenic diseases [148, 149, 151, 250]. 
 The M605I, A727V, V790M and M835V mutations in CMS patients are all found 
in the kinase domain of MuSK and their cellular pathogenesis has previously been 
partially characterized. A recently identified D38E is located in the extracellular 
domain of the protein and the affected aspartate residue at position 38, which is part 
of a beta-strand of Ig-like domain 1 (Ig1) of MuSK extracellular region, it is known to 
form an asymmetric homodimer mediated by a hydrophobic face [253] 
(Figure ‎4.2.18).  
 Thus, the missense mutation D38E-MuSK might interfere with the proper 
dimerization of MuSK and the subsequent association with LRP4 to form a 
functional LRP4-MuSK complex, or it may interfere with Wnt ligand binding. The 
M605I-MuSK mutation has been shown to result in moderate impairment of both 
phosphorylation and binding to Dok-7 while the A727V-MuSK mutation results in 
drastic impairment of phosphorylation and MuSK-Dok-7 interaction due to its 
location in the catalytic loop of the MuSK protein. The V790M-MuSK mutation 
impairs the binding of MuSK to Dok-7 thus preventing the interaction necessary for 
synaptogenesis [254] but it does not appear to alter MuSK autophosphorylation. The 
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M835V-MuSK mutation results in a constitutively active MuSK receptor with a 
decreased agrin and Dok-7-dependent phosphorylation.  
 The ER retention of P344R-MuSK, a possible result of misfolding due to a small 
conserved cyclic non-polar, proline (Pro) being replaced by arginine (Arg), a 
positively charged polar amino acid with a larger size within the well conserved CRD 
of MuSK is plausible. Prolines are particularly well conserved in these RTK-like 
proteins [245] and prolines often introduce a kink into the helical structure of proteins 
(Figure ‎4.2.18). Deleting proline residues can interfere with the cis-trans 
isomerization causing the folding polypeptide forcing a cis-conformation of peptide 
bonds affecting the rate of folding and the folding pathway itself [50]. Interestingly, 
the P344R-MuSK mutation is found between a negatively charged, conserved 
Aspartate (D) and Glutamate (E) following a disordered region in the MuSK-CRD. It 
has been shown that X-Pro cis to trans changes in prolines completely disrupt 
conformational folding in Ribonuclease A [255]. It is therefore, conceivable how a 
proline to arginine change in the CRD may disrupt conformational folding by altering 
a critical pattern of peptide-peptide hydrogen bonds responsible for the local 
secondary structure of MuSK, which is essential for the subsequent folding of the 
protein [50].  
 Interestingly, the CRD is glycosylated and the P344R mutation is found after the 
two N-linked glycosylation sites, Asn222 and Asn338 [21] (Figure ‎4.2.1). PolyPhen-
2, http://genetics.bwh.harvard.edu/pph2/ and SIFT, http://sift.jcvi.org/, have 
classified this mutation as probably damaging (0.985) and deleterious (0.05), 
respectively. Several strategies have been proposed to rescue the traffic of 
misfolded mutant proteins. The first approach is to manipulate the culturing 
temperature with the aim of observing if the misfolded protein is susceptible to 
therapeutic manipulation. Interestingly, the P344R-MuSK mutation trafficking defect 
is rescued upon culturing the cells at reduced culturing conditions of 27˚C, as was 
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also seen with the ΔF508-CFTR [256]. This suggests that the P344R-MuSK mutant 
might be a suitable ERAD candidate for therapeutic studies.  
 Chemical chaperones facilitate the escape of the P344R-MuSK mutation from the 
ER quality control system. They presumably shift the folding equilibrium of the 
mutant protein towards its native state, thus releasing it from its ER retention state. 
These chemical chaperones act more globally affecting the cellular proteostasis 
network, thereby leading to a more favorable folding and/or trafficking environment.  
 An essential outcome of ubiquitination is targeting to the 26S proteasome, a 
specific signal, which is responsible for the degradation of ER retained proteins 
[257]. The majority of proteasome substrates are tagged not by a single ubiquitin 
(monoUb), but by a polyubiquitin (polyUb) chain. It is generally thought that polyUb 
chains longer than four ubiquitin molecules are the preferred signal for efficient 
recognition and degradation by 26S proteasomes [236, 258]. The P344R-MuSK 
pattern is that of a polyUb chain increasing the molecular weight of P344R-MuSK to 
much more than 300 kDa. Once bound by proteasomes, substrate-conjugates are 
deubiquitinated, unfolded and subsequently degraded.  
 Taken together, my experiments demonstrate the potential for trafficking and the 
function of the P344R-MuSK mutant, to be rescued to the plasma membrane of 
HeLa, COS-7 and HEK293 cell lines. These findings suggest that extending the 
investigation to a larger number of chemical chaperones may identify chemicals that 
could potentially rescue trafficking and the function of this mutant. Although 
prescription of acetylcholinesterase inhibitors such as pyridostigmine, is so far the 
most cost effective therapeutic treatment for CMS, our study highlights that 
prospective alternative personalized treatments for patients suffering from the 
P344R-MuSK mutation causing CMS, can be developed to target the source of the 
disease, rather than its consequences. These findings also support efforts for 
rescuing trafficking of other missense mutations that cause disease. Treatments 
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suggest that the folding defect in P344R-MuSK can be improved. As a result, the 
P344R-MuSK mutant may be rescued however, a folding corrector or 
pharmacological chaperone has yet to be identified. 
 
Figure ‎4.2.18. Crystal Structure of the asymmetric frizzled-like cysteine-rich domain 
dimer of MuSK. The FZ-CRD of MuSK is shown as an asymmetric dimer taken from 
PDB: 3HKL and then was manipulated using RasMol 2.7 (www.RasMol.org) [21]. An 
Asymmetric dimer formation of the two copies of MuSK-CRD in the asymmetric unit 
are colored blue (copy A) and cyan blue (copy B). The CRD N-glycosylation site 
(Asn338) is shown in purple ball and stick representation. The N-glycan is shown as 
a green ball and stick representation above the Asn338. The P344R mutation 
highlighted in red ball and stick representation is found as the first amino acid of the 
alpha-helix sheet (a.a: 344-359) after the beta-strand (a.a: 335-338); 
http://www.rcsb.org/pdb. A proline (Pro); a small non-polar amino acid interacts with 
the protein backbone twice forming a five-membered ring, is substituted to an 
arginine (Arg); a basic larger amino acid with an electrically charged side chain that 
is hydrophilic. The positively charged arginine may interact with the negatively 
charged asparagine (Asn) forming salt bridges. Due to its position, it may mask the 
Asn from the N-glycan resulting in an immature under glycosylated protein. The 
P344R mutation is also in close proximity with Y341 shown as a yellow ball and stick 
representation, found at the dimer interface [21]. The Y341 is found to form 
hydrogen bonds with the Asn338 [21]. The P344R mutation is also close to A347 
(brown ball and stick representation) which is also involved in the dimer interface. 
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4.3 TEK Tyrosine Kinase, Endothelial (TEK) and 
autosomal dominantly inherited Cutaneomucosal 
Venous Malformation (VMCM) 
4.3.1 Introduction 
 Autosomal dominantly inherited Cutaneomucosal Venous Malformation (VMCM; 
OMIM 600195)] has been shown to be caused by mutations in the genes encoding 
for the angiopoietin receptor TEK Tyrosine Kinase, Endothelial (TEK), OMIM: 
600221 [259-261]. The vascular endothelial cell (EC)-specific receptor tyrosine 
kinase TEK plays a crucial role in angiogenesis and cardiovascular development 
[262, 263]. Germline substitutions in TEK cause a rare inherited form of venous 
anomalies where heterozygous TEK substitutions induce in vitro ligand-independent 
hyperphosphorylation [264, 265]. The lesions are characterized by multifocal small 
bluish cutaneous and mucosal lesions, composed of disorganized thin-walled 
vascular channels [260, 264]. VMCM is a rare disease that exhibits variable 
expressivity and high penetrance [266, 267].  
TEK can associate with p85, the regulatory subunit of phosphatidylinositol-4, 5-
bisphosphate 3-kinase, catalytic subunit alpha (PI3K), leading to activation of both 
PI3K and v-akt murine thymoma viral oncogene homolog 1 (Akt1) [268]. Tyrosine 
1101 of TEK is the major site of association of p85 and is required for activation of 
PI3K and Akt. This pathway is involved in cell survival and anti-apoptosis, which 
helps to explain the role of TEK in normal vascular maintenance. The details of the 
TEK signaling pathway are just beginning to emerge.   
There has been some controversy regarding the hyperphosphorylation status of 
the TEK receptor. Research has shown that overexpression of the mutants result in 
ligand-independent hyperphosphorylation of the receptor. However, Wouters et al., 
suggest this is a general feature of VMCM-causative TEK mutations [264]. 
Moreover, it has been shown that there is variation in the level of activation 
demonstrated by widely differing levels of chronic TEK hyperphosphorylation and 
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these are tolerated in the heterozygous state. This hyperphosphorylation is only 
observed in localized areas of lesions excised from the patients and is not found in 
the normal endothelial cells.  
 
Figure ‎4.3.1. Schematic representation of TEK. TEK is made up of an extracellular 
region. The latter of which is made up of three immunoglobulin-like loops (Ig1, 2, 3), 
three epidermal growth factor-like repeats (EGF), and three fibronectin type III-like 
repeats (FNIII). TEK also has an intracellular region made up of 2 tyrosine kinase 
domains (TK) separated by kinase insert domain (KID). Locations of missense 
substitutions identified in inherited VMCM are shown. A somatic mutation “Del” 
deletes part of the Ig2 found in the extracellular domain in the TEK-WT allele of one 
VMCM patient carrying the inherited R849W mutation. Taken from reference [260] 
 
Interestingly, Limaye et.al., identified a somatic, lesion-associated TIE2 “2nd-hit” 
alteration in one resected VMCM, from a patient carrying the germline R849W-TEK 
mutation. A cDNA screen revealed an in-frame deletion of 129-bp, corresponding to 
a loss of exon 3 and part of exon 4 (amino acids 122-165 of the extracellular Ig2 
ligand-binding domain; “Del” of TEK (Figure ‎4.3.1). They also showed that the “Del” 
allele is occurs on the wild-type and the deletion is part of an intragenic somatic 
DNA deletion. The lack of 43 amino acids resulted in the wild-type being retained in 
the ER and therefore loss of cell surface expression of the receptor, as well as its 
inability to bind Ang1, in contrast to WT [260].  
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Another somatic 2nd hit causing loss of function of the receptor in resected VMCM 
lesions showed a frequent L914F mutation and a series of double-mutations that 
occur in cis (on the same allele). The L914F mutation also resulted in retention of 
the TEK protein within the ER lumen.  
As a result, it was speculated that some of the eight reported inherited TEK 
missense mutations (R849W, Y897C, Y897S, R915H, R918C, V919L, A925S and 
K1100N) might traffic abnormally and get retained in the ER and eventually get 
degraded by the proteasome. I tested this hypothesis experimentally and it was 
shown to be incorrect as highlighted below.  
4.3.2 Results 
R849W, Y897C, Y897S, R915H, R918C, V919L, A925S and K1100N  mutations 
in TEK failed to affect the trafficking of the protein to PM. All the generated TEK 
missense mutants (R849W, Y897C, Y897S, R915H, R918C, V919L, A925S and 
K1100N) [264] were found to be largely localized to the plasma membrane in HeLa 
cells (Figure ‎4.3.2). HeLa cells transiently transfected with the wild-type C-terminally 
HA-tagged TEK cDNA show that the expressed protein is predominantly localized to 
the plasma membrane (PM) in contrast to calnexin, a well-established ER marker 
(middle panels). Calnexin exhibits a typical perinuclear and reticular distribution due 
to its well-established ER distribution (middle panels). In contrast, the TEK-WT and 
TEK mutants were found to be predominantly localized to the PM (merged panels). 
This localization on the plasma membrane in HeLa cells excluded the examined 
TEK missense mutants from being ERAD substrates and therefore the underlying 
cellular mechanisms of these disease-causing mutations remain unresolved. Further 
functional studies are recommended to elucidate their disease-causing 
mechanisms. 
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Figure ‎4.3.2. The localization of TEK-WT and the eight missense TEK disease-
causing mutants. The eight missense mutants clearly do not localize with the ER 
calnexin marker and localize in a similar pattern to the TEK-WT when the 
expressed HA epitope for each corresponding mutant is merged with the calnexin 
marker. ENG-WT is a positive control for HA epitope. 
4.3.3 Discussion  
ER-retention and abnormal trafficking does not contribute to the cellular 
mechanism of inherited cutaneomucosal venous malformation disease for the eight 
reported inherited TEK missense mutations (R849W, Y897C, Y897S, R915H, 
R918C, V919L, A925S and K1100N). Therefore, the question remains open as to 
how these mutations cause disease. Elucidation of the presence of double mutants 
in cis and 2nd hit somatic mutation effects may aid our understanding of how these 
hyperphosphorylating mutations lead to the development of the vascular lesions 
observed in VMCM.  
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4.4 Attempts on silencing ERAD components in a cell line 
stably expressing an ERAD substrate 
4.4.1 ERAD pathways 
 Recent evidence suggests that ERAD is composed of multiple pathways, is 
substrate specific and consequently caters for a range of different classes of 
substrates. The location of the misfolded lesion on a substrate relative to the ER 
membrane classifies the substrates into three types known as ERAD-cytoplasmic 
(ERAD-C); ERAD-luminal (ERAD-L) or ERAD-intramembrane (ERAD-M) substrates 
[7, 15, 16].  
 In ERAD-C, the misfolded domain lies at the cytoplasmic side of the membrane 
and are degraded by the ubiquitin ligase Doa10 complex. Proteins with luminal 
(ERAD-L) have the misfolded domain within the ER lumen are degraded by the 
SYVN1 complex alongside other proteins such as Derlin1, 2, 3 [17] which form a 
scaffold. This pathway also degrades soluble misfolded proteins of the ER lumen 
[18]. Since P344R-MuSK mutant is a type I integral protein, it is proposed that it has 
its lesion on the luminal side and I therefore assume that it follows the ERAD-L 
pathway. 
 OS-9 releases misfolded polypeptides with luminal or transmembrane folding 
defects (ERAD-L and ERAD-M substrates) to retro-translocation complexes built 
around the membrane-embedded E3 ubiquitin ligase, SYVN1. Misfolded 
polypeptides with cytosolic folding defects (ERAD-C substrates) also engage 
retrotranslocation complexes around E3 ubiquitin ligases. It has been observed that 
the location of misfolded domains(s) on ERAD substrates may determine which 
ERAD machinery complex is used for their degradation. This correlation between 
substrate class and choice of pathway is strongest in yeast and is found in 
mammalian cells to a much lesser extent [18].  
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 Several resident ER proteins on the ER membrane have been proposed to form 
retrotranslocation channels for the dislocation of misfolded proteins out of the ER for 
degradation by the proteasome system [140]. These proteins are briefly described in 
the following sub-sections. 
4.4.2 Synovial apoptosis inhibitor 1, synoviolin (SYVN1) 
 SYVN1 is an ER-localized membrane E3 ubiquitin ligase that polyubiquitinates 
ERAD substrates on the cytoplasmic face of the ER membrane (Figure ‎4.4.1). 
Ubiquitination of the protein substrate provides a critical step in protein dislocation 
[138]. The RING family constitutes the largest family of E3 ligases, with over 600 
human genes, including those involved in ERAD [132, 269]. The cytosolic RING-H2 
finger E3 domain creates a binding platform for the E2 conjugase and also interacts 
with the AAA ATPase [270]. Most ERAD E3 ligases are integral membrane proteins 
with a proportion of hydrophilic residues that result in a peptide-transporting pore 
[139, 140, 145, 271]. They form the core of the ERAD machinery, bringing together 
functionally distinct ERAD complexes. E3 ligases have been shown to ubiquitinate 
and deubiquitinate and also interact with deubuitinating enzymes before disposal 
[269]. SYVN1 has six transmembrane segments and is a very unstable protein, 
stabilized by the formation of a stoichiometric complex with SEL1L [272].  
4.4.3 Sel-1 suppressor of lin-12-like (C. elegans) (SEL1L) 
SEL1L is a type-I transmembrane protein with a large luminal domain containing 
SEL1 repeats [230]. SEL1L is an adapter membrane-associated glycoprotein that 
interacts with an assortment of ERAD regulators, including OS-9, ERLEC1/XTP3-B, 
EDEM1 and EDEM3, which facilitate substrate transfer from the protein-folding 
components to the ERAD complex [273]. SYVN1-SEL1L proteins interact with many 
proteins for example; OS9 [274], the Derlins, valosine-containing protein (VCP)/p97-
interacting membrane protein (VIMP) (VCP/p97), and Herp forming a large scaffold 
within the ER membrane [131, 275].  
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4.4.4 Osteosarcoma amplified 9, endoplasmic reticulum lectin  
(OS-9) 
OS-9 is found within the ER lumen and is an ER-resident glycosylated protein 
(Figure ‎4.4.1). It has a glucosidase type II domain involved in binding to misfolded 
proteins. OS-9 like ERLEC1/XTP3-B, another ER luminal protein, contain mannose-
6-phosphate receptor homology (MRH) domain. MRH domains specifically bind to 
terminal α-1,6-mannose residues to facilitate transfer of terminally misfolded 
glycoproteins to the scaffolded ERAD complex [130, 274, 276]. They can bind to 
glycosylated and non-glycosylated misfolded proteins.  
4.4.5 Derlin 1 (DERL1/DER1) 
Derlin contains four transmembrane regions. Mammals have three such 
homologues known as Derlin1, 2, and 3 [277]. These proteins may be part of the ER 
membrane retrotranslocation channel. VIMP is a small connecting protein for 
VCP/p97 to Derlins. As previously mentioned, VCP/p97, is an AAA ATPase involved 
in the extraction of ERAD clients. Der1 has been shown to initiate the export of 
misfolded polypeptides from the ER lumen by moving the substrates through the ER 
membrane and passing them on to SYVN1 for ubiquitination [278]. Der1 has also 
been shown to be important for the dislocation of other substrates, as part of other 
ERAD complexes [140, 141].  
In the ER of S. cerevisiae, a large complex made up Hrd1p-Hrd3p (SYVN1 and 
SEL1L in humans) alongside Der1p (DER1) has been observed. On the luminal 
side, Yos9p (OS9/OS-9) with other ER chaperones has been described.  
The importance of these proteins in ERAD-L prompted me to choose these 
members of the ERAD dislocation machinery as candidates for possible interactions 
with the P344R-MuSK mutant. siRNA knockdown of these candidates in isolation or 
in pairs, could rescue or stabilize the P344R-MuSK mutant from its ERAD fate.  
126 
 
 
Figure ‎4.4.1. The SYVN1/SEL1L complex of the mammalian ERAD machinery. OS-
9 is an ER lectin which recognizes misfolded substrates and passes them on to 
SYVN1, an E3-ligase. The SYVN1 ubiquitin ligase and SEL1L protein network and 
form a large scaffold embedded at the ER membrane. Other members of this 
scaffold include Derlin-1/2/3, VCP/p97, and Herp. The small membrane protein 
VIMP connects VCP/p97 to Derlins. SEL1L is a membrane-associated adapter 
glycoprotein which interacts with SYVN1 stabilizing it. SYVN1 is a very unstable 
protein with a short half-life. This E3 ligase polyubiquitinates the misfolded substrate 
on the cytoplasmic face of the ER membrane, while interacting with other 
components of the ERAD machinery forming this scaffold. Eventually the misfolded 
protein may or may not be unfolded before it reaches the VCP/P97 AAA ATPase 
which deubiquitinates the substrate and sends it off to the 26S proteasome for 
degradation. Redrawn from reference [272]. 
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4.4.6 Silencing of ERAD components by siRNA  
Small interfering RNA (siRNA) silencing has been used to dictate the difference 
between a deleterious mutation and a tolerated polymorphism as is seen with CF. 
As previously mentioned, partial siRNA silencing of the Hsp90 co-chaperone 
ATPase regulator (Aha1) [201] was able to rescue ΔF508-CFTR which has been 
shown to be functionally competent as a chloride ion transporter. Therefore, the goal 
of the majority of CF therapeutic treatments is overcoming folding and trafficking 
defects in the ER. 
The ability to control cell fate via the ER-folding, export and degradation 
pathways provides an exciting direction in future drug development within 
monogenic diseases. Identifying the cellular mechanism underlying genetic disease 
has offered hope to CF and other diseased patients. It remains to be determined if 
these disease causing mutations can be rescued or the ER milieu can be altered to 
allow these defective proteins to function as close as possible to their wild-type 
counterparts. This will provide the basis for designing specific drugs such as 
chemical and/or pharmacological chaperones that aid the transport of the disease-
causing mutant protein(s) to cellular membranes and eventually provide options for 
these patients. Likewise, tissue-specific chaperones can be therapeutic targets and 
have the capacity to provide important tools in biotechnology.  
As mentioned earlier, SEL1L and SYVN1 form a large ubiquitin ligase complex 
that interacts with SVIP. Silencing of this SYVN1-SEL1L complex has been shown 
to downregulate the degradation kinetics of some ERAD substrates [272] providing 
yet another ERAD target for rescuing misfolded proteins. OS-9 has been 
characterized extensively in yeast and it has been shown that N-glycans lacking the 
terminal mannose from the C branch are recognized by OS-9 and targeted for 
degradation [275]. Der1 was considered to provide the missing link between events 
on the lumenal side of the ER and the cytosolic extraction catalysed by p97 [277]. 
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4.4.7 Results 
4.4.7.1 Optimization of SYVN1, SEL1L, OS-9 and DER1 siRNA-
mediated knockdown  
 To assess the roles of SYVN1, SEL1L, OS-9 and DER1 in P344R-MuSK 
degradation they were knocked-down in HEK 293 cell line stably expressing this 
mutant. The siRNA transfection efficiency was optimized in non-expressing HEK 
cells to determine the optimal conditions that result in maximum gene silencing with 
minimal cytotoxicity. Proteins were extracted, run on SDS-PAGE gels and probed 
with the appropriate antibodies (Figure ‎4.4.2 and Figure ‎4.4.3). The four proteins 
(SYVN1, SEL1L, OS-9 and DER1) were effectively knocked down by a range of 85-
99% (Figure ‎4.4.3 line graph) when 200 pmol of the relevant siRNAs were used. 
The positive internal control, GAPDH, allowed the integrity of the cell line to be 
monitored and acts as a loading control. The scrambled sequence was used as a 
negative control for all experiments.  
4.4.7.2 Silencing of SYVN1, SEL1L, OS-9 and DER1 has no effect on 
the ER mislocalization of P344R-MuSK mutant 
 Endogenous SYVN1, SEL1L, OS-9 and DER1 were knocked down in HEK293 
cells stably expressing the P344R-MuSK mutant. The effect of this down regulation 
was assessed by confocal microscopy and biochemically by deglycosylation assays. 
The ERAD components were knocked down individually and in-paired combinations 
(e.g. SYVN1 and SEL1L) to observe any synergistic effect of combined silencing. 
The results are shown in Figure ‎4.4.4. In short, the silencing of the above proteins 
did not have a profound effect on P344R-MuSK mislocalization to the ER and no 
rescue to the PM was observed. This may be due to a limitation in the efficiency of 
silencing. Final concentrations of siRNA in culture media beyond 200 pmol resulted 
in massive cell death when silencing SEL1L, SYVN1, OS-9 and DER1. This could 
be due to the cells not being able to withstand complete silencing of these ERAD 
components which leads to apoptosis of the stable cell lines. It might be that this 
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residual amount of silencing may be needed for complete silencing of the ERAD 
machinery components and to rescue P344R-MuSK to the cell surface.  
 The effect of siRNA mers of DER1 and OS-9 together had a lesser effect on 
silencing of these proteins than when they were silenced on their own. This could be 
due to saturation of the Argoraute proteins found in the RNA-induced silencing 
complex (RISC). siRNA scrambled sequences and siRNA of GAPDH, used as a 
controls for the siRNA transfections, did not show any effect on the localization of 
P344R-MuSK mutant nor the integrity of the cell as seen with calnexin staining. For 
confirmation, I also examined the N-glycosylation profiles of the mutant protein 
under these silencing conditions as shown in Figure ‎4.4.6.  
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Figure ‎4.4.2. The effect of silencing of SYVN1 and SEL1L in HEK293 cells treated 
with targeted siRNA. The P344R-MuSK mutant HEK293 cell line was treated with 
increasing concentrations of silencing mers in triplicate. P344R-MuSK WCL 
untreated was taken as a control alongside scrambled mers at the highest 
concentration. The quantity of mers used ranged from 50-200 pmol. (A). WCL 
were run on a 10% SDS-PAGE and probed with anti-SYVN1 antibody. An 
untreated P344R-MuSK mutant stable cell line was used and the endogenous C 
terminus of the SYVN1 protein is shown. The 55 kDa is the expected size. The 
WCL was heated at 50 ºC to prevent aggregation and the upper bands may be 
smaller proteins still in complex with SYVN1 or the larger SYVN1 protein. (B) The 
blot was probed with anti-SEL1L and a band of approximately 100 kDa was 
detected. Scrambled siRNA was used as a non-specifc control alongside GAPDH 
as a loading control. Knockdown was most effective at 200 pmol.  
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Figure ‎4.4.3. The effect of silencing of OS-9 and DER1 in HEK293 cells treated with 
targeted siRNA. The P344R-MuSK mutant HEK293 cell line was treated with 
increasing concentrations of silencing mers in triplicate. P344R-MuSK WCL 
untreated was taken as a control alongside scrambled mers at the highest 
concentration. The quantity of mers used ranged from 50-200 pmol. (A). WCL were 
run on a 10% SDS-PAGE and probed with anti-OS-9. An untreated P344R-MuSK 
mutant stable cell line was used and the endogenous protein expression of OS-9 is 
shown as 3 bands. OS-9 has eight reported transcriptional variants with two main 
variants V1 at 95 kDa and V2 at 60 kDa. A band of 30 kDa has also been shown to 
probe with anti-OS-9 (www.abcam.com). Knockdown was effective at 200 pmol. (B) 
DER1 protein of 27 KDa was also knocked down at 200 pmol. The effect of silencing 
is shown in a line graph. The silencing of OS-9 and SEL1L was around 99%; 
SYVN1 band 55 kDa was silenced at around 90% and OS-9 V2, reported to interact 
with the SYVN1 and SEL1L complex [272] was at around 85%.  
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Figure ‎4.4.4. The effect of siRNA of ERAD components on stable HEK293 cell 
lines of P344R-MuSK mutant’s localization in the ER. FLAG-tagged P344R-MuSK 
protein is seen as red fluorescence whereas calnexin is seen as green signals. 
The ERAD components are shown as blue signals. Panel A-D shows four controls 
for each of the ERAD components SYVN1, SEL1L, OS-9 and DER1 respectively 
under non-silencing conditions. Panel E shows the effects of silencing SYVN1 
alone; panel F SYVN1 and SEL1L; panel G SYVN1 and DER1; panel H SYVN1 
and OS-9 pair. SYVN1 and OS-9 pair caused a portion of P344R-MuSK rescue to 
the plasma membrane. Panel I shows the effect of silencing SEL1L; Panel J 
SEL1L and DER1; Panel K SEL1L and OS-9 and the synergistic effect of DER1 
and OS-9. No rescue was seen in any of these panels. Panel M and N show the 
silencing of OS-9 and Der1 alone showing no rescue. Scrambled sequences were 
used as controls; panel o with staining of GAPDH in blue and panel P showing 
effect of siRNA GAPDH as a control. Objective lens 40X; Scale bar 25µm. 
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Figure ‎4.4.5. N-glycosylation profile of P344R-MuSK stable cell lines. P344R-
MuSK was subjected to Endo H treatment (section ‎3.4.10). After silencing the 
aforementioned ERAD components outlined in ‎4.4.7.2. The protein was run on a 
6% SDS-PAGE. (A) Untreated protein is shown in the far left first two lanes, (-) not 
treated with ENDO H and (+) means treated with ENDO H. The scrambled 
sequence of P344R-MuSK served as a control for the expression of MuSK and 
GAPDH a loading control. A representative result shown in blots A and B show that 
silencing of selected ERAD components alone or in-pairs had no effect on the 
maturation of P344R-MuSK. 
 
  
134 
 
4.4.7.3 The Immunoprecipitation of P344R-MuSK mutant failed to 
pull-down SYVN1, SEL1L, OS-9 or DER1  
I next examined whether there are interactions between SYVN1, SEL1L, OS-9 
and/or DER1 with P344R-MuSK mutant. The stably expressed P344R-MuSK mutant 
was immunoprecipitated with anti-FLAG antibody and the immunoprecipitates were 
probed with anti-SYVN1, anti-SEL1L, anti-OS-9 and anti-DER1 anti-bodies as 
shown in Figure ‎4.4.6. From this experiment it seems that there is no evidence of 
interaction between P344R-MuSK mutant and SYVN1, SEL1L, OS-9 and/or DER1. 
This negative result may be due to weak or transient interactions that did not 
withstand the nature of an IP.  
4.4.8 Discussion 
 Misfolded or unassembled proteins, retained in the ER, are eventually degraded 
by the proteasomes through ERAD [56]. Ubiquitin ligases embedded in the 
membrane of the ER ubiquitinate misfolded proteins by addition of PUCs during 
substrate retrotranslocation from the ER to the cytosol [230]. Hrd1p/Der3p ubiquitin-
ligase is shown to ubiquitinate ERAD substrates in S. cerevisiae. 
My results show that P344R-MuSK does not appear to interact with any of the 
following ERAD components. Endogenous SYVN1, SEL1L, OS-9 and DER1 in 
HEK293 cells. This was seen by immunoprecipitation and by confocal imaging. 
When silenced, the P344R-MuSK localization remained in the ER and P344R-MuSK 
did not traffic to the cell surface. This was further verified with endoglycosidase H 
digestion.  
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Figure ‎4.4.6. Immunoprecipitation of P344R-MuSK and SEL1L, SYVN1, OS-9 and 
Der1 interaction in vitro. P344R-MuSK protein was extracted and a proportion of the 
WCL was subjected to IP as described in the methods. Following IP, the protein was 
run on different gradients of SDS-PAGE as shown. MuSK-WT, P344R-MuSK and 
empty vector controls WCL were run as a control for the presence of the proteins 
SEL1L, SYVN1, OS9 and DER1 in the HEK293-P344R stable cell lines. Next, the IP 
of MuSK WT, P344R-MuSK and empty vector in duplicates using two different IP 
methods: SDS elution from the beads (far left), and glycine elution using low PH (far 
right) for comparison. The blots were probed with each of the antibodies: SEL1L, 
SYVN1, OS-9 and Der1. The blots were then stripped and re-probed with anti-FLAG 
to detect the presence of MuSK-WT, P344R-MuSK in WCL and in the IP product. 
The IP of both MuSK-WT, acting as a control, and the P344R-MuSK failed to pull 
down any of the four proteins SEL1L, SYVN1, OS-9 and Der1.  
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 Simply put, ERAD is a multifaceted pathway with many different players 
displaying substrate specificity. The complexity of ERAD is just beginning to emerge 
and its diversity has been contrasted to its yeast counterpart. The conformation of 
P344R-MuSK may require a different E3 ligase; as a range of misfolded 
conformations are possible in the ER [279]. E3 ligases have been shown to show 
preference for one substrate over others. A more subtle approach would be to 
isolate the ER organelle within this cell line and study all interacting partners or 
chaperones interacting with P344R-MuSK, “a P344R-MuSK interactome”. Silencing 
of these specific individual partners as with ∆F508-CFTR was able to rescue the 
∆F508-CFTR-functional mutant [201].  
 Carvalho et al. identified CPY, an ERAD-L substrate, crosslinking with a number 
of inter-bilayer residues of the SYVN1 transmembrane region [145]. SYVN1 was 
shown to be required for retrotranslocation however, their model was incomplete. 
Sato et al. devised a self-destructive ERAD substrate that self ubiquitinates 
independently of full-length SYVN1. They show that their substrate Hmg1 isozyme 
of yeast HMGR required only a built-in RING domain, correct E2 and the AAA 
ATPase complex only for retrotranslocation and degradation [139]. Since in vivo and 
in vitro retrotranslocation can occur in an ∆hrd1∆doa10 double null strain, this 
indicates that the dislocation channels may not be necessary [140]. 
 Substrate degradation is well characterized in S. cerevisiae. There are three 
distinct pathways with differing ubiquitin ligases involved. ERAD-C substrates with 
misfolded cytosolic domains are degraded by Doa10p; ERAD-L substrates with 
misfolded ER-luminal domains are recognized by Hrd1p while ERAD-M substrates 
with misfolded intramembrane domains also recognized by Hrd1p, however, the 
final scaffold for dislocation is different. In mammals, the substrate specificity 
required for E3-ubiquitin ligases remains to be elucidated.  
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 Recently, mammalian ERAD-LS substrates (soluble polypeptides with luminal 
lesions), were degraded by the HRD1-SEL1L scaffold with the OS-9 and 
ERLEC1/XTP3-B lectins. The mammalian system has been shown to be much more 
complex than yeast and has undergone an expansion of the ERAD E3 ligase family, 
with the Hrd1p homologs Hrd1 and Gp78, the Doa10p homolog membrane-
associated RING finger (C3HC4) 6, E3 ubiquitin protein ligase (MARCH6), RING 
finger protein 5, E3 ubiquitin protein ligase (RNF5), RING finger protein 139 
(RNF139), and STIP1 homology and U-box containing protein 1, E3 ubiquitin protein 
ligase (STUB1) and the Derlin-1/ (transmembrane protein 129, E3 ubiquitin protein 
ligase) TMEM129–dependent pathway [280]. There are approximately 600 E3 
ligases and their roles remain to be elucidated [273]. Similarities exist between yeast 
and mammalian ERAD systems. For example, the mammalian homologues of 
yeast; Yos9p (OS-9 and ERLEC1/XTP3-B) and the ubiquitin conjugating enzyme E2 
(UBC6e), have been shown to bind to the ERAD complex [272]. 
 How a luminal protein can cross the lipid bilayer is not known, and the existence 
of a proteinaceous pore has been suggested for certain substrates such as the class 
I major histocompatibility complex (MHC) products [277]. Interestingly, a model has 
been proposed for the involvement of lipid rearrangements in glycoprotein quality 
control [281]. Regardless, as mentioned earlier, this dislocation channel remains ill-
defined and identification of the channel would be a milestone that would unravel 
questions regarding this fascinating cellular pathway. 
 Silencing of the small VCP/p97-interacting protein (SVIP), identified it as an 
ERAD inhibitor that halts substrate ubiquitination and subsequent ERAD steps [282]. 
This finding has provided hope for misfolded proteins as overexpressing SVIP may 
allow misfolded proteins an escape to their final destination. Hence, overexpression 
of the SVIP alongside chemical chaperones may rescue misfolded proteins from 
their ERAD fate.   
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 Another protein, a heat shock protein like HSP70 (GRP78/BiP), which is an 
inhibitor of SVIP, and an ubiquitin ligase (E3) has been shown to target ΔF508-
CFTR for degradation [283]. HSPA5/BiP interacts with SYVN1, which counteracts its 
function. Silencing HSPA5/BiP or overexpressing SYVN1 can also result in 
promising results. Proteasomal inhibitors are currently being studied and have 
shown promise in certain cancers, however, these inhibitors had an adverse effect 
on wild-type CFTR and were consequently ineffective for CF treatment [6].  
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Chapter 5: Discussion and Conclusions 
5.1 Summary 
Inherited missense mutations altering amino acids in secretory proteins may lead 
to defective proteins which can not fold properly in the ER. The cell harbours a 
machinery which disposes of improperly folded proteins which disrupt the 
homeostasis of the cell and puts it in jeopardy. The cell maintains a high caliber of 
proteins by selecting glycoproteins that are fit for performing their intended function 
and are not deleterious to the cell. However, the high stringency of the ERQC 
system has considered mutant proteins that may be catalytically functional, as unfit 
to pass the QC standards, and as a consequence, these proteins are disposed of by 
ERAD. Developing novel therapeutic interventions for certain mutated proteins may 
allow proper trafficking, with the normal biological function of mutant proteins, 
alleviating symptoms for patients. 
ERAD has been shown to be a common mechanism for many debilitating genetic 
disorders ranging from cystic fibrosis to hypercholesterolemia [1, 8, 50]. Missense 
mutations in FZD4, a crucial Wnt receptor [155], disrupt the proper formation of 
blood vessels in the eye resulting in FEVR. Nine out of the fifteen examined 
missense mutations are retained by the ERQC and their localization was shown by 
confocal fluorescent microscopy to be perinuclear and reticular within the ER, in 
both HeLa and Cos-7 cell lines. In addition, these nine mutations show an immature 
N-glycosylation profile further supporting their ER-trafficking defects and lack of 
maturation to some degree. They were found to be tagged with PUCs indicating 
their interaction with the ubiquitin/proteasomal systems. In short, the mutated 
proteins are degraded by ERAD and lead to the loss-of-function of the proteins. 
These mutations cause disease in heterozygous states and my results suggest 
haploinsufficiency of the FZD4 wild-type allele as a consequence leading to FEVR.  
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A P344R-MuSK protein was shown to be immature, underglycosylated and 
localized to the ER in HeLa, Cos-7 and Hek293 cell lines. It was found to be tagged 
with PUCs and is degraded by the proteasome. Its half-life was shown to be 
reduced compared to MuSK-WT. It is a thermosensitve protein which is rescued by 
a range of chemical chaperones and retains its autophosphorylated state which 
implies that it may retain some biological activity if expressed at the cell-surface. 
M105T-FZD4, C204Y-FZD4 mutations were also thermosenstive and show 
maturation and exit out of the ER with chemical chaperone treatment to a lesser 
degree. Knockdown of prominent ERAD components did not rescue P344R-MuSK 
to the cell surface.  
5.2 Outlook and perspectives 
Fz-CRD missense mutations are emerging in the literature. However little is 
known about the importance of the Fz-CRD in disease development. Eight of the 
nine FZD4 mutations were found in the highly conserved Fz-CRD domain, vital for 
the folding and function of Wnt receptors. The main class of Wnt receptors is the 
seven-pass transmembrane frizzled receptors. The clustering of FEVR-causing 
mutations in the extracellular Fz-CRD of FZD4 suggests a stringent requirement for 
the correct folding of this domain prior to export of FZD4 from the ER to the plasma 
membrane. The positions of the missense mutations found within the Fz-CRD of 
FZD4 are highly conserved in homologs and orthologs alike [210, 221, 233]. 
 Two tyrosine kinase (TK) receptors, MuSK and ROR2 have been reported as 
non-conventional Wnt receptors. The P344R-MuSK mutation is also found at the 
heart of the CRD and shares the same Fz-CRD homology as the frizzled family of 
receptors (Fz1-Fz8) [21, 246]. Deletion studies of full-length MUSK lacking the Fz-
CRD was expressed in MUSK−/− myotubes. As a result, MuSK was unable to co-
cluster with rapsyn and AChRs [284]. The crystal structure of the MuSK Fz-CRD is 
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glycosylated and this contributes to a stabilized MuSK dimer [21] with the potential 
for MuSK oligomerization to elicit certain biological responses.  
 The RORs share significant domain similarity to MuSK receptor [285]. ROR2 
contains a Fz-CRD which binds Wnt5a for activation [148]. TK receptors are 
activated by ligand-induced homo- and/or hetero-dimerization [286] and therefore, it 
is plausible that Wnt5a activates Ror2 through dimerization via the CRD [22]. 
Missense mutations in the Fz-CRD domain of ROR2 were also found to traffic 
abnormally to the ER [148].  
 A recent study reported a S472G missense mutation located within the first Fz-
CRD of the corin protein. This missense mutation was shown to result in corin 
misfolding and ER-retention in preeclamptic patients [287].  
The cellular mechanism of the mutations in both FZD4 and MuSK Wnt receptors 
has not been previously characterized. Delineating the pathogenesis of disease may 
have profound values for patients and the research community. The understanding 
of how missense mutations cause changes in a proteins structure and its maturation 
and how this collectively contributes to disease; helps to further unravel what lies 
beneath the cell. It opens doors for genetic manipulation, as discussed below, with 
the aim of developing new drugs or technologies that aim at treating and/or 
alleviating the root cause of the disease symptoms not the consequences of the 
disease.  
Folding is a very precise process requiring fine tuning alongside chaperones in 
the ER. Missense mutations superimiposed on proteins change the amino acid 
residues which expose hydrophobic amino acid residues and therefore change the 
native structure of the protein as is seen with the FZD4-mutants (Table ‎4.1.1) and 
also affect the presence of a particular N-linked glycan causing misfolding or a 
misassembled protein as is seen with P344R-MuSK mutant. Inherited missense 
mutations in both FZD4 and MuSK show that there is more going on in the Fz-CRD 
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imposed by these missense mutations on the native structure of the protein, 
resulting in their mistrafficking to the ER and consequent proteasomal degradation.  
The therapeutic rescue of ER-trafficking mutants has been beneficial for some 
mutations. Efforts in understanding how the Fz-CRD folds as previously described 
with other proteins such as the low density lipoprotein receptor (LDLR) [288] may be 
necessary to understand how chemical chaperones can target this region and 
prevent misfolding. This may still be as starting point for therapy. However, since 
these proteins harbor a common Fz-CRD motif; it is plausible to research chemical 
chaperones or pharmacological chaperones that target the specific cysteine 
residues, to preserve the pattern and support the structural disulfide bonds and 
cysteine residues, so as to prevent misfolding altogether.  
It may be useful to adjust the reduction-oxidation potential within the ER to allow 
the cysteines in the Fz-CRD to fold more efficiently. The addition of an oxidizing 
agent in the microsomes of dogs was able to enter the ER lumen and act as 
cysteine reducing and oxidizing agent for influenza hemagglutinin (HA). Protein 
folding of HA was enhanced either by direct oxidation of disulfide bonds or by further 
assisting the oxidative enzymes such as the disulfide isomerase in the ER lumen 
[289].  
The adaptive UPR could be targeted with therapeutic agents to increase the 
transcriptional activation of chaperones that may further support folding of the 
protein. It can also transiently increase protein synthesis. This will inevitably open 
the door for treatment. It is important to understand further how genomic elements’ 
functional relationship has a role in phenotype formation and disease pathogenesis. 
In our post-genomic era, methods allowing genomic DNA sequences manipulation, 
visualization and regulation of gene expression are rapidly evolving. Genome editing 
such as TALEN (Transcription Activator-Like Effector Nucleases) [290-292] and 
CRISPR (Clustered Regulatory Interspaced Short Palindromic Repeats)/Cas9 
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systems [290, 292, 293] are reliable tools for genome engineering. They are useful 
for cell-based human hereditary disease modeling [290]. Here one could make a cell 
based model with the desired mutation incorporated in the appropriate cell lines. 
This would allow the visualization of the cellular processes such as chemical 
chaperone treatment and siRNA knowdown of ERAD components.  
The method used in this study could be useful for screening missense mutations 
to observe which mutants are thermosensitive and therefore can be engineered for 
further therapeutic purposes. It also provides the groundwork for supporting and 
developing the search for chemical chaperones that work in the cellular milieu to 
promote protein folding and maturation.  
5.3 Future work 
The next step would is a major challenge in cell biology. It would be to 
understand the role of protein energetics and chaperone function necessary in the 
folding of cargo for export from the ER. Complete or partial siRNA of co-chaperone 
partners is a novel way to rescue the ER-retained protein. Proteomics is a growing 
field and has been used to assess CFTR protein interactions also known as the 
CFTR interactome. Wang et al. proposed the reason that ΔF508-CFTR failed to fold 
correctly was because the mutant was unable to fold under the dynamics set forth 
by the ER-chaperone folding environment known as the “chaperome”. The steady-
state dynamics of the ER folding machinery were not in its favor. As a consequence, 
the Hsp90 co-chaperone which was shown to interact with CFTR’s protein folding in 
the ER was silenced to restore the energetically favorable environment for this 
mutant [201]. 
Academic laboratories are already coming together to collate and discuss the 
classic model for this group of trafficking conformational diseases, ∆F508-CFTR 
[27]. It is not enough to delineate a cellular pathogenic mechanism of disease let 
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alone find a novel mutation. It is more important to understand all aspects on how 
the mutant protein behaves in vivo; energetically with its chaperones, its 
thermodynamic properties and kinetics of folding, within its special environment. 
This in turn will enable researchers to fully understand how to therapeutically target 
the misfold or its interacting partners to promote its rescue and maturation offering a 
new paradigm with the aim of providing therapy for this class of proteins.  
Chemical chaperones that rescued ∆F508-CFTR mutant were a result of high-
throughput screening for drug discovery [294]. The extensive work carried out on the 
CFTR protein by researchers has made it possible to reach therapeutic targets 
faster than in other conformational diseases and consequently achieve greater 
results. This has been achieved by understanding the underlying cellular, molecular 
mechanisms and signaling pathways as an entity within the cell that governs ER-
retained inherited diseases.  
Insights from this basic research show how FEVR causing P33S, G36D, H69Y, 
M105T, M105V, C181R, C204R, C204Y, and G488D-FZD4 mutants and P344R-
MuSK mutant cause disease. The mechanism has been delineated however, further 
studies will be required to finish details. Testing of the FEVR-causing mutations in 
FZD4 deficient retinal cell lines and the P344R-MuSK on MuSK deficient 
myotubules are necessary to further understand how each mutant interacts in its 
own cellular milieu; to appreciate both the folding of Fz-CRD in the presence of the 
mutant and observe the stability of the mutant Fz-CRD with chemical chaperones. 
With the aid of current computer–based stimulations and bioinformatic tools, this is 
feasible. The importance of the proteins’ interplay with chaperones in the ER is vital 
for siRNA knockdown as a target for therapy. It is important to further study 
interacting partners and whether these mutants interact with general chaperones, 
such as Bip, or specific chaperones such as the CFTR’s Aha chaperone and the 
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Boca chaperone specific for the LRP5/6’s homologue arrow in Drosophila 
melanogaster; needed for wingless signal transduction [295]. 
From this work, it is envisioned that more molecular players in the FZD4 and 
MuSK pathway will be discovered and the folding of Fz-CRD will be sought after to 
design molecules for improving expression and stability of the mutant proteins at the 
cell surface. It could possibly pave the way for discovering new molecular 
chaperones, pharmacological chaperones and/or chemical correctors that 
specifically improve the mutant expression at the cell surface and consequently offer 
an alternative therapeutic measure for FEVR and CMS patients, the novelty of which 
is mutation specific which makes it personalized or alternatively targets disorders of 
Fz-CRD, allowing it to target more than one disease with one treatment.  
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